US20220281825A1 - Heterocyclic compounds for the treatment of arenavirus infection - Google Patents
Heterocyclic compounds for the treatment of arenavirus infection Download PDFInfo
- Publication number
- US20220281825A1 US20220281825A1 US17/726,096 US202217726096A US2022281825A1 US 20220281825 A1 US20220281825 A1 US 20220281825A1 US 202217726096 A US202217726096 A US 202217726096A US 2022281825 A1 US2022281825 A1 US 2022281825A1
- Authority
- US
- United States
- Prior art keywords
- heteroaryl
- aryl
- group
- cycloheteroalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005989 Arenaviridae Infections Diseases 0.000 title claims description 19
- 238000011282 treatment Methods 0.000 title description 22
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 451
- -1 5-indolyl Chemical group 0.000 claims abstract description 299
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 283
- 125000003118 aryl group Chemical group 0.000 claims abstract description 274
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 109
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 27
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims description 194
- 125000000217 alkyl group Chemical group 0.000 claims description 163
- 239000003085 diluting agent Substances 0.000 claims description 161
- 239000003937 drug carrier Substances 0.000 claims description 161
- 239000003981 vehicle Substances 0.000 claims description 161
- 125000003342 alkenyl group Chemical group 0.000 claims description 157
- 125000000304 alkynyl group Chemical group 0.000 claims description 155
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 155
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 155
- 238000000034 method Methods 0.000 claims description 155
- 229910052739 hydrogen Inorganic materials 0.000 claims description 103
- 125000003545 alkoxy group Chemical group 0.000 claims description 100
- 125000004104 aryloxy group Chemical group 0.000 claims description 99
- 239000001257 hydrogen Substances 0.000 claims description 94
- 239000000203 mixture Substances 0.000 claims description 64
- 150000002367 halogens Chemical class 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 31
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 18
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 17
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 16
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 16
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 11
- 108020004459 Small interfering RNA Proteins 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 8
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 7
- 229960000329 ribavirin Drugs 0.000 claims description 7
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 5
- 239000002955 immunomodulating agent Substances 0.000 claims description 5
- 229940121354 immunomodulator Drugs 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108700011259 MicroRNAs Proteins 0.000 claims description 3
- 108020000999 Viral RNA Proteins 0.000 claims description 3
- 239000003730 rna directed rna polymerase inhibitor Substances 0.000 claims description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 2
- IDVQGNMSSHPZSJ-UHFFFAOYSA-N 7-methylsulfanyl-3-nitro-6h-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one Chemical compound N1=C([N+]([O-])=O)C(=O)N2NC(SC)=NC2=N1 IDVQGNMSSHPZSJ-UHFFFAOYSA-N 0.000 claims 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 160
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 118
- 241000124008 Mammalia Species 0.000 description 113
- 238000004113 cell culture Methods 0.000 description 108
- 241000282412 Homo Species 0.000 description 104
- 239000012472 biological sample Substances 0.000 description 101
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 85
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 70
- 241000712891 Arenavirus Species 0.000 description 63
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 60
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 52
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 50
- 239000002585 base Substances 0.000 description 49
- 235000019439 ethyl acetate Nutrition 0.000 description 48
- 239000002904 solvent Substances 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 39
- 230000000694 effects Effects 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 36
- 229910000027 potassium carbonate Inorganic materials 0.000 description 35
- 229910052794 bromium Inorganic materials 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 32
- 241000700605 Viruses Species 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 30
- 239000007787 solid Substances 0.000 description 30
- 239000000460 chlorine Substances 0.000 description 29
- 229910052938 sodium sulfate Inorganic materials 0.000 description 29
- 229910052801 chlorine Inorganic materials 0.000 description 28
- 239000003054 catalyst Substances 0.000 description 27
- 239000007832 Na2SO4 Substances 0.000 description 26
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 26
- 150000002148 esters Chemical group 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- CJUHQADBFQRIMC-UHFFFAOYSA-N (4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=C1 CJUHQADBFQRIMC-UHFFFAOYSA-N 0.000 description 23
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000000377 silicon dioxide Substances 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 22
- 229910052681 coesite Inorganic materials 0.000 description 21
- 229910052906 cristobalite Inorganic materials 0.000 description 21
- 229910052682 stishovite Inorganic materials 0.000 description 21
- 229910052905 tridymite Inorganic materials 0.000 description 21
- VIWCOGHNVAGBPG-UHFFFAOYSA-N 1,6-bis(4-propan-2-yloxyphenyl)indazole Chemical compound CC(C)OC1=CC=C(C=C1)N1N=CC2=CC=C(C=C12)C1=CC=C(C=C1)OC(C)C VIWCOGHNVAGBPG-UHFFFAOYSA-N 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 16
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 16
- VHADYSUJZAPXOW-UHFFFAOYSA-N 1h-indol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2NC=CC2=C1 VHADYSUJZAPXOW-UHFFFAOYSA-N 0.000 description 15
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 15
- 241000711975 Vesicular stomatitis virus Species 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 229910052740 iodine Inorganic materials 0.000 description 13
- 239000012453 solvate Substances 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- 108090000288 Glycoproteins Proteins 0.000 description 12
- 102000003886 Glycoproteins Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 description 12
- 239000000969 carrier Substances 0.000 description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- ODPYYNLRURJCGN-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine Chemical compound CC(C)OC1=CC=C(C=C1)C1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C ODPYYNLRURJCGN-UHFFFAOYSA-N 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- BUCHWYCTPHHPJS-UHFFFAOYSA-N 6-bromo-1-(4-propan-2-yloxyphenyl)benzimidazole Chemical compound BrC=1C=CC2=C(N(C=N2)C2=CC=C(C=C2)OC(C)C)C=1 BUCHWYCTPHHPJS-UHFFFAOYSA-N 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- AXGBHQRIAOMLDX-UHFFFAOYSA-N 5-bromo-2-nitro-N-(4-propan-2-yloxyphenyl)aniline Chemical compound CC(C)Oc1ccc(Nc2cc(Br)ccc2[N+]([O-])=O)cc1 AXGBHQRIAOMLDX-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 206010061192 Haemorrhagic fever Diseases 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 239000006184 cosolvent Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- MLNFMFAMNBGAQT-UHFFFAOYSA-N 4-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC=C(N)C=C1 MLNFMFAMNBGAQT-UHFFFAOYSA-N 0.000 description 7
- SVNWPUVHHHICPW-UHFFFAOYSA-N 6-bromo-3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine Chemical compound BrC=1C=CC=2N(C=1)C(=CN=2)C1=CC=C(C=C1)OC(C)C SVNWPUVHHHICPW-UHFFFAOYSA-N 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- DNNABDNURCJMHF-UHFFFAOYSA-N 3-bromo-6-(4-propan-2-yloxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine Chemical compound BrC1=NN=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C DNNABDNURCJMHF-UHFFFAOYSA-N 0.000 description 6
- VQCWSOYHHXXWSP-UHFFFAOYSA-N 4-bromo-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1F VQCWSOYHHXXWSP-UHFFFAOYSA-N 0.000 description 6
- LWAVFLMXSGFCHY-UHFFFAOYSA-N 6-bromo-3-iodo-7-methylimidazo[1,2-a]pyridine Chemical compound C1=C(Br)C(C)=CC2=NC=C(I)N21 LWAVFLMXSGFCHY-UHFFFAOYSA-N 0.000 description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- XTUVHPDHPJSFRN-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl]oxysilane Chemical compound C(C)(C)(C)[Si](OC1(CC1)C1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C)(C)C XTUVHPDHPJSFRN-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- DISOQYRUKBUGRN-UHFFFAOYSA-N 1-[4-[3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]cyclopropan-1-ol Chemical compound CC(C)OC1=CC=C(C=C1)C1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)C1(CC1)O DISOQYRUKBUGRN-UHFFFAOYSA-N 0.000 description 5
- YOZDPHQFKGEIOU-UHFFFAOYSA-N 2-[4-[3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]propan-2-ol Chemical compound CC(C)OC1=CC=C(C=C1)C1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)C(C)(C)O YOZDPHQFKGEIOU-UHFFFAOYSA-N 0.000 description 5
- RPNSJNIBPQQHHW-UHFFFAOYSA-N 3-(4-cyclopropylphenyl)-6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine Chemical compound C1(CC1)C1=CC=C(C=C1)C1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C RPNSJNIBPQQHHW-UHFFFAOYSA-N 0.000 description 5
- ZCLHZGVRTDACDV-UHFFFAOYSA-N 3-bromo-6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine Chemical compound BrC1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C ZCLHZGVRTDACDV-UHFFFAOYSA-N 0.000 description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
- GUAOESFJOBMVDK-UHFFFAOYSA-N 4-bromo-5-methyl-2-N-(4-propan-2-yloxyphenyl)benzene-1,2-diamine Chemical compound CC(C)Oc1ccc(Nc2cc(Br)c(C)cc2N)cc1 GUAOESFJOBMVDK-UHFFFAOYSA-N 0.000 description 5
- CTPLSNAPMRULFK-UHFFFAOYSA-N 6-bromo-1-(4-propan-2-yloxyphenyl)indazole Chemical compound BrC1=CC=C2C=NN(C2=C1)C1=CC=C(C=C1)OC(C)C CTPLSNAPMRULFK-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 108060004795 Methyltransferase Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 241001112090 Pseudovirus Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 229910052727 yttrium Inorganic materials 0.000 description 5
- OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 4
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- YKFSINHLIBHTTF-UHFFFAOYSA-N 3-bromo-6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrazine Chemical compound BrC1=CN=C2N1C=C(N=C2)C1=CC=C(C=C1)OC(C)C YKFSINHLIBHTTF-UHFFFAOYSA-N 0.000 description 4
- VADGFPDSVWQCHR-UHFFFAOYSA-N 6-bromo-3-iodoimidazo[1,2-a]pyridine Chemical compound C1=C(Br)C=CC2=NC=C(I)N21 VADGFPDSVWQCHR-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- QNKNOGXQPRRBNE-UHFFFAOYSA-N BrC1=CC=C(C=C1)C1(CC1)O[Si](C)(C)C(C)(C)C Chemical compound BrC1=CC=C(C=C1)C1(CC1)O[Si](C)(C)C(C)(C)C QNKNOGXQPRRBNE-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001502 aryl halides Chemical class 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 4
- 229950008454 favipiravir Drugs 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- IZOOGQYKHWNGOK-UHFFFAOYSA-N (4-cyclopropyloxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1CC1 IZOOGQYKHWNGOK-UHFFFAOYSA-N 0.000 description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 3
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 3
- AAEHUPYJNIKIPE-UHFFFAOYSA-N 5-bromo-3-(4-propan-2-yloxyphenyl)-1-benzofuran Chemical compound BrC=1C=CC2=C(C(=CO2)C2=CC=C(C=C2)OC(C)C)C=1 AAEHUPYJNIKIPE-UHFFFAOYSA-N 0.000 description 3
- VARHKNWSPWIPHV-UHFFFAOYSA-N 5-bromo-3-(4-propan-2-yloxyphenyl)imidazo[4,5-b]pyridine Chemical compound CC(C)Oc1ccc(cc1)-n1cnc2ccc(Br)nc12 VARHKNWSPWIPHV-UHFFFAOYSA-N 0.000 description 3
- SDSOFFITDDUFPP-UHFFFAOYSA-N 6-bromo-1-(4-methoxyphenyl)benzimidazole Chemical compound C1=CC(OC)=CC=C1N1C2=CC(Br)=CC=C2N=C1 SDSOFFITDDUFPP-UHFFFAOYSA-N 0.000 description 3
- COPKZDUGFVHUSY-UHFFFAOYSA-N 6-bromo-1-(4-propan-2-yloxyphenyl)benzotriazole Chemical compound BrC=1C=CC2=C(N(N=N2)C2=CC=C(C=C2)OC(C)C)C=1 COPKZDUGFVHUSY-UHFFFAOYSA-N 0.000 description 3
- MEZJGYCBKLQCDC-UHFFFAOYSA-N 6-bromo-1-(4-propan-2-yloxyphenyl)indole Chemical compound BrC1=CC=C2C=CN(C2=C1)C1=CC=C(C=C1)OC(C)C MEZJGYCBKLQCDC-UHFFFAOYSA-N 0.000 description 3
- SCLGXRQKFWFMPJ-UHFFFAOYSA-N 6-bromo-3-iodo-7-methoxyimidazo[1,2-a]pyridine Chemical compound BrC=1C(=CC=2N(C=1)C(=CN=2)I)OC SCLGXRQKFWFMPJ-UHFFFAOYSA-N 0.000 description 3
- WHNSLGYHTRIPTB-UHFFFAOYSA-N 6-bromo-3-iodo-8-methylimidazo[1,2-a]pyridine Chemical compound CC1=CC(Br)=CN2C(I)=CN=C12 WHNSLGYHTRIPTB-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 3
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 3
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 3
- 208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 3
- 201000010424 Brazilian hemorrhagic fever Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 201000010423 Chapare hemorrhagic fever Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010023927 Lassa fever Diseases 0.000 description 3
- 201000010755 Lujo hemorrhagic fever Diseases 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 244000308495 Potentilla anserina Species 0.000 description 3
- 235000016594 Potentilla anserina Nutrition 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 201000009693 Venezuelan hemorrhagic fever Diseases 0.000 description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- OLKSGNATJCUAGX-UHFFFAOYSA-N ethyl 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine-2-carboxylate Chemical compound CC(C)OC1=CC=C(C=C1)C1=C(N=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C)C(=O)OCC OLKSGNATJCUAGX-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SGEOBUJTURUUJE-UHFFFAOYSA-N (6-propan-2-yloxypyridin-3-yl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=N1 SGEOBUJTURUUJE-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- YNJMEMFHKOOQNV-UHFFFAOYSA-N 1,6-bis(4-propan-2-yloxyphenyl)indole Chemical compound CC(C)OC1=CC=C(C=C1)N1C=CC2=CC=C(C=C12)C1=CC=C(C=C1)OC(C)C YNJMEMFHKOOQNV-UHFFFAOYSA-N 0.000 description 2
- MQUDFGCLRUWQDW-UHFFFAOYSA-N 1,7-bis(4-propan-2-yloxyphenyl)imidazo[1,5-a]pyridine Chemical compound CC(C)OC1=CC=C(C=C1)C=1N=CN2C=1C=C(C=C2)C1=CC=C(C=C1)OC(C)C MQUDFGCLRUWQDW-UHFFFAOYSA-N 0.000 description 2
- WEXJIRLGBLTWKS-UHFFFAOYSA-N 1-(4-methoxyphenyl)-6-(3-propan-2-ylphenyl)benzimidazole Chemical compound COC1=CC=C(C=C1)N1C=NC2=C1C=C(C=C2)C1=CC(=CC=C1)C(C)C WEXJIRLGBLTWKS-UHFFFAOYSA-N 0.000 description 2
- QVENRFXQAONJGI-UHFFFAOYSA-N 1-[4-[6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-3-yl]phenyl]cyclopropan-1-ol Chemical compound CC(C)OC1=CC=C(C=C1)C=1C=CC=2N(C=1)C(=CN=2)C1=CC=C(C=C1)C1(CC1)O QVENRFXQAONJGI-UHFFFAOYSA-N 0.000 description 2
- NULYQBMKXDZCNQ-UHFFFAOYSA-N 1-iodo-4-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=C(I)C=C1 NULYQBMKXDZCNQ-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XSRPONSCJROWRN-UHFFFAOYSA-N 2-[4-[3-(4-propan-2-yloxyphenyl)imidazo[4,5-b]pyridin-5-yl]phenyl]propan-2-ol Chemical compound CC(C)Oc1ccc(cc1)-n1cnc2ccc(nc12)-c1ccc(cc1)C(C)(C)O XSRPONSCJROWRN-UHFFFAOYSA-N 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- NKTDTMONXHODTI-UHFFFAOYSA-N 2-pentyne Chemical compound CCC#CC NKTDTMONXHODTI-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- ATYUJQFEIXRZAN-UHFFFAOYSA-N 3,5-bis(4-propan-2-yloxyphenyl)-1-benzofuran Chemical compound CC(C)OC1=CC=C(C=C1)C1=COC2=C1C=C(C=C2)C1=CC=C(C=C1)OC(C)C ATYUJQFEIXRZAN-UHFFFAOYSA-N 0.000 description 2
- SEOACUMDNJVDTB-UHFFFAOYSA-N 3,5-bis(4-propan-2-yloxyphenyl)-2,1-benzoxazole Chemical compound CC(C)OC1=CC=C(C=C1)C=1ON=C2C=1C=C(C=C2)C1=CC=C(C=C1)OC(C)C SEOACUMDNJVDTB-UHFFFAOYSA-N 0.000 description 2
- NLNRHPDJTJECFA-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine Chemical compound CC(C)OC1=CC=C(C=C1)C1=NN=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C NLNRHPDJTJECFA-UHFFFAOYSA-N 0.000 description 2
- XIPTUNAVWVSJLB-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrazine Chemical compound CC(C)OC1=CC=C(C=C1)C1=CN=C2N1C=C(N=C2)C1=CC=C(C=C1)OC(C)C XIPTUNAVWVSJLB-UHFFFAOYSA-N 0.000 description 2
- UFLSAFLDZSGHIY-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine-2-carbonitrile Chemical compound CC(C)OC1=CC=C(C=C1)C1=C(N=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C)C#N UFLSAFLDZSGHIY-UHFFFAOYSA-N 0.000 description 2
- RRFXTDMQQCLCKK-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound CC(C)OC1=CC=C(C=C1)C1=C(N=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C)C(=O)O RRFXTDMQQCLCKK-UHFFFAOYSA-N 0.000 description 2
- RTIDRXNVEIDIIT-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrimidine Chemical compound CC(C)OC1=CC=C(C=C1)C1=CN=C2N1C=C(C=N2)C1=CC=C(C=C1)OC(C)C RTIDRXNVEIDIIT-UHFFFAOYSA-N 0.000 description 2
- KMKRHBSPYFQDKY-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-b]pyridazine Chemical compound CC(C)Oc1ccc(cc1)-c1cnc2ccc(nn12)-c1ccc(OC(C)C)cc1 KMKRHBSPYFQDKY-UHFFFAOYSA-N 0.000 description 2
- SBXNQELLNZWZKS-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,5-a]pyridine Chemical compound CC(C)OC1=CC=C(C=C1)C1=NC=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C SBXNQELLNZWZKS-UHFFFAOYSA-N 0.000 description 2
- PGUCFPALUISPQJ-UHFFFAOYSA-N 3,6-dibromoimidazo[1,2-a]pyridine-2-carbonitrile Chemical compound BrC1=C(N=C2N1C=C(C=C2)Br)C#N PGUCFPALUISPQJ-UHFFFAOYSA-N 0.000 description 2
- HAZWVIURIAKNAR-UHFFFAOYSA-N 3-[4-[3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]azetidin-3-ol Chemical compound CC(C)OC1=CC=C(C=C1)C1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)C1(CNC1)O HAZWVIURIAKNAR-UHFFFAOYSA-N 0.000 description 2
- DXULXEZUNDXULP-UHFFFAOYSA-N 3-bromo-6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrimidine Chemical compound BrC1=CN=C2N1C=C(C=N2)C1=CC=C(C=C1)OC(C)C DXULXEZUNDXULP-UHFFFAOYSA-N 0.000 description 2
- JRYMLXAOKOSRNC-UHFFFAOYSA-N 3-bromo-N-(4-methoxyphenyl)-2-nitroaniline Chemical compound COc1ccc(Nc2cccc(Br)c2[N+]([O-])=O)cc1 JRYMLXAOKOSRNC-UHFFFAOYSA-N 0.000 description 2
- FDCIPSYXPOQRPQ-UHFFFAOYSA-N 3-iodo-6-(4-propan-2-yloxyphenyl)imidazo[1,5-a]pyridine Chemical compound IC1=NC=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C FDCIPSYXPOQRPQ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- SFDYRFJGFWPCKJ-UHFFFAOYSA-N 4-[6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-3-yl]benzoic acid Chemical compound CC(C)OC1=CC=C(C=C1)C=1C=CC=2N(C=1)C(=CN=2)C1=CC=C(C(=O)O)C=C1 SFDYRFJGFWPCKJ-UHFFFAOYSA-N 0.000 description 2
- HRNVKPBHONZJOR-UHFFFAOYSA-N 4-bromo-2-N-(1H-indol-5-yl)benzene-1,2-diamine Chemical compound Nc1ccc(Br)cc1Nc1ccc2[nH]ccc2c1 HRNVKPBHONZJOR-UHFFFAOYSA-N 0.000 description 2
- QFUBIHBCKPEKOR-UHFFFAOYSA-N 4-bromo-2-n-(4-propan-2-yloxyphenyl)benzene-1,2-diamine Chemical compound C1=CC(OC(C)C)=CC=C1NC1=CC(Br)=CC=C1N QFUBIHBCKPEKOR-UHFFFAOYSA-N 0.000 description 2
- YOUOMGJCXLDRQP-UHFFFAOYSA-N 5-bromo-3-(4-propan-2-yloxyphenyl)-2,1-benzoxazole Chemical compound BrC=1C=CC=2C(=C(ON=2)C2=CC=C(C=C2)OC(C)C)C=1 YOUOMGJCXLDRQP-UHFFFAOYSA-N 0.000 description 2
- QCYFJDVWMQSTOH-UHFFFAOYSA-N 5-bromo-4-methoxy-2-nitro-N-(4-propan-2-yloxyphenyl)aniline Chemical compound BrC=1C(=CC(=C(NC2=CC=C(C=C2)OC(C)C)C=1)[N+](=O)[O-])OC QCYFJDVWMQSTOH-UHFFFAOYSA-N 0.000 description 2
- VUFIOXHNTZIKAM-UHFFFAOYSA-N 5-bromo-N-(3-methoxyphenyl)-2-nitroaniline Chemical compound COc1cccc(Nc2cc(Br)ccc2[N+]([O-])=O)c1 VUFIOXHNTZIKAM-UHFFFAOYSA-N 0.000 description 2
- QXFSFCKXPSCPGN-UHFFFAOYSA-N 5-bromo-n-(2-methoxyphenyl)-2-nitroaniline Chemical compound COC1=CC=CC=C1NC1=CC(Br)=CC=C1[N+]([O-])=O QXFSFCKXPSCPGN-UHFFFAOYSA-N 0.000 description 2
- MCKPBMOIKJYEAX-UHFFFAOYSA-N 5-bromo-n-(4-methoxyphenyl)-2-nitroaniline Chemical compound C1=CC(OC)=CC=C1NC1=CC(Br)=CC=C1[N+]([O-])=O MCKPBMOIKJYEAX-UHFFFAOYSA-N 0.000 description 2
- LWYVDJMXIIPESS-UHFFFAOYSA-N 5-methyl-3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine Chemical compound CC1=C(C=CC=2N1C(=CN=2)C1=CC=C(C=C1)OC(C)C)C1=CC=C(C=C1)OC(C)C LWYVDJMXIIPESS-UHFFFAOYSA-N 0.000 description 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 2
- HOENDKINJYDDFI-UHFFFAOYSA-N 6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrimidine Chemical compound C(C)(C)OC1=CC=C(C=C1)C=1C=NC=2N(C=1)C=CN=2 HOENDKINJYDDFI-UHFFFAOYSA-N 0.000 description 2
- LHYLQXQCFUTYCH-UHFFFAOYSA-N 6-(4-propan-2-yloxyphenyl)imidazo[1,5-a]pyridine Chemical compound C(C)(C)OC1=CC=C(C=C1)C=1C=CC=2N(C=1)C=NC=2 LHYLQXQCFUTYCH-UHFFFAOYSA-N 0.000 description 2
- YFTKESCBIKQXLI-UHFFFAOYSA-N 6-bromo-1-(1H-indol-5-yl)benzimidazole Chemical compound BrC=1C=CC2=C(N(C=N2)C=2C=C3C=CNC3=CC=2)C=1 YFTKESCBIKQXLI-UHFFFAOYSA-N 0.000 description 2
- DUYYKXLGDPNYKC-UHFFFAOYSA-N 6-bromo-1-(4-propan-2-yloxyphenyl)imidazo[4,5-c]pyridine Chemical compound CC(C)Oc1ccc(cc1)-n1cnc2cnc(Br)cc12 DUYYKXLGDPNYKC-UHFFFAOYSA-N 0.000 description 2
- SMRASBPZVDVCPX-UHFFFAOYSA-N 6-bromo-3-nitro-N-(4-propan-2-yloxyphenyl)pyridin-2-amine Chemical compound CC(C)Oc1ccc(Nc2nc(Br)ccc2[N+]([O-])=O)cc1 SMRASBPZVDVCPX-UHFFFAOYSA-N 0.000 description 2
- XGPWODGVQVBZLR-UHFFFAOYSA-N 6-bromo-5-methyl-1-(4-propan-2-yloxyphenyl)benzimidazole Chemical compound BrC=1C(=CC2=C(N(C=N2)C2=CC=C(C=C2)OC(C)C)C=1)C XGPWODGVQVBZLR-UHFFFAOYSA-N 0.000 description 2
- TYDYYXQQGZNATK-UHFFFAOYSA-N 6-bromo-7-methylimidazo[1,2-a]pyridine Chemical compound C1=C(Br)C(C)=CC2=NC=CN21 TYDYYXQQGZNATK-UHFFFAOYSA-N 0.000 description 2
- YXCVVPDRPSSFRF-UHFFFAOYSA-N 6-bromoimidazo[1,2-a]pyridine-2-carbonitrile Chemical compound C1=C(Br)C=CC2=NC(C#N)=CN21 YXCVVPDRPSSFRF-UHFFFAOYSA-N 0.000 description 2
- PHDBFLVZUIZGJI-UHFFFAOYSA-N 6-chloro-3-(4-propan-2-yloxyphenyl)imidazo[1,2-b]pyridazine Chemical compound CC(C)Oc1ccc(cc1)-c1cnc2ccc(Cl)nn12 PHDBFLVZUIZGJI-UHFFFAOYSA-N 0.000 description 2
- UPSLXWGPAJCRLF-UHFFFAOYSA-N 7-bromo-1-iodoimidazo[1,5-a]pyridine Chemical compound BrC1=CC=2N(C=C1)C=NC=2I UPSLXWGPAJCRLF-UHFFFAOYSA-N 0.000 description 2
- NVXQPZAIBYFHEX-UHFFFAOYSA-N 7-methoxy-3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine Chemical compound COC1=CC=2N(C=C1C1=CC=C(C=C1)OC(C)C)C(=CN=2)C1=CC=C(C=C1)OC(C)C NVXQPZAIBYFHEX-UHFFFAOYSA-N 0.000 description 2
- MJQQLLCMNOALHJ-UHFFFAOYSA-N 7-methyl-3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine Chemical compound CC1=CC=2N(C=C1C1=CC=C(C=C1)OC(C)C)C(=CN=2)C1=CC=C(C=C1)OC(C)C MJQQLLCMNOALHJ-UHFFFAOYSA-N 0.000 description 2
- YCCMWVSKUZBERI-UHFFFAOYSA-N 8-methyl-3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine Chemical compound CC=1C=2N(C=C(C=1)C1=CC=C(C=C1)OC(C)C)C(=CN=2)C1=CC=C(C=C1)OC(C)C YCCMWVSKUZBERI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101710170439 Glycoprotein 2a Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000190708 Guanarito mammarenavirus Species 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101800000461 Stable signal peptide Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 229940118555 Viral entry inhibitor Drugs 0.000 description 2
- GVZKTTKKEWDYQO-UHFFFAOYSA-N [4-(1-hydroxycyclobutyl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1(O)CCC1 GVZKTTKKEWDYQO-UHFFFAOYSA-N 0.000 description 2
- DPIDNFWCDMXMDY-UHFFFAOYSA-N [4-(2-hydroxypropan-2-yl)phenyl]boronic acid Chemical compound CC(C)(O)C1=CC=C(B(O)O)C=C1 DPIDNFWCDMXMDY-UHFFFAOYSA-N 0.000 description 2
- RCUWZKVTDDDVET-UHFFFAOYSA-N [4-(2-morpholin-4-ylethoxy)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCCN1CCOCC1 RCUWZKVTDDDVET-UHFFFAOYSA-N 0.000 description 2
- MFZNJRNTHPKCFY-UHFFFAOYSA-N [4-(difluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)F)C=C1 MFZNJRNTHPKCFY-UHFFFAOYSA-N 0.000 description 2
- BKHBDGFRIWAUKK-UHFFFAOYSA-N [4-(difluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)F)C=C1 BKHBDGFRIWAUKK-UHFFFAOYSA-N 0.000 description 2
- OKHCKPPOCZWHRN-UHFFFAOYSA-N [4-[(2-methylpropan-2-yl)oxy]phenyl]boronic acid Chemical compound CC(C)(C)OC1=CC=C(B(O)O)C=C1 OKHCKPPOCZWHRN-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002832 anti-viral assay Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- BIFZUIRJJWFGNV-UHFFFAOYSA-N ethyl 3,6-dibromoimidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC(Br)=CN2C(Br)=C(C(=O)OCC)N=C21 BIFZUIRJJWFGNV-UHFFFAOYSA-N 0.000 description 2
- VABDCFNYXYPEPZ-UHFFFAOYSA-N ethyl 4-[6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-3-yl]benzoate Chemical compound CC(C)OC1=CC=C(C=C1)C=1C=CC=2N(C=1)C(=CN=2)C1=CC=C(C(=O)OCC)C=C1 VABDCFNYXYPEPZ-UHFFFAOYSA-N 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000002905 orthoesters Chemical class 0.000 description 2
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 239000013641 positive control Chemical class 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- GDVSBVWTWGUDAW-UHFFFAOYSA-M sodium 7-methylsulfanyl-3-nitro-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-olate dihydrate Chemical compound O.O.[Na+].N1=NC([N+]([O-])=O)=C([O-])N2N=C(SC)N=C21 GDVSBVWTWGUDAW-UHFFFAOYSA-M 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- NFTFFSJYASXDIW-UHFFFAOYSA-N tert-butyl 3-(4-bromophenyl)-3-[tert-butyl(dimethyl)silyl]oxyazetidine-1-carboxylate Chemical compound BrC1=CC=C(C=C1)C1(CN(C1)C(=O)OC(C)(C)C)O[Si](C)(C)C(C)(C)C NFTFFSJYASXDIW-UHFFFAOYSA-N 0.000 description 2
- NRKUHBKJYXFLGN-UHFFFAOYSA-N tert-butyl 3-[tert-butyl(dimethyl)silyl]oxy-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]azetidine-1-carboxylate Chemical compound [Si](C)(C)(C(C)(C)C)OC1(CN(C1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C NRKUHBKJYXFLGN-UHFFFAOYSA-N 0.000 description 2
- HZBBXGQUISLBNG-UHFFFAOYSA-N tert-butyl 3-[tert-butyl(dimethyl)silyl]oxy-3-[4-[3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]azetidine-1-carboxylate Chemical compound [Si](C)(C)(C(C)(C)C)OC1(CN(C1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)C=1C=CC=2N(C=1)C(=CN=2)C1=CC=C(C=C1)OC(C)C HZBBXGQUISLBNG-UHFFFAOYSA-N 0.000 description 2
- WSJUFZJCRXOHRN-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[4-[3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]cyclopropyl]oxysilane Chemical compound [Si](C)(C)(C(C)(C)C)OC1(CC1)C1=CC=C(C=C1)C=1C=CC=2N(C=1)C(=CN=2)C1=CC=C(C=C1)OC(C)C WSJUFZJCRXOHRN-UHFFFAOYSA-N 0.000 description 2
- VEKJLWPUNBJCLQ-UHFFFAOYSA-N tert-butyl-dimethyl-[1-[4-[6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-3-yl]phenyl]cyclopropyl]oxysilane Chemical compound [Si](C)(C)(C(C)(C)C)OC1(CC1)C1=CC=C(C=C1)C1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C VEKJLWPUNBJCLQ-UHFFFAOYSA-N 0.000 description 2
- ZWWVRMRNVOCKMD-UHFFFAOYSA-N tert-butyl-dimethyl-[3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]oxetan-3-yl]oxysilane Chemical compound C(C)(C)(C)[Si](OC1(COC1)C1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C)(C)C ZWWVRMRNVOCKMD-UHFFFAOYSA-N 0.000 description 2
- CDDLBXZFQDPDCS-UHFFFAOYSA-N tert-butyl-dimethyl-[3-[4-[3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]azetidin-3-yl]oxysilane Chemical compound [Si](C)(C)(C(C)(C)C)OC1(CNC1)C1=CC=C(C=C1)C=1C=CC=2N(C=1)C(=CN=2)C1=CC=C(C=C1)OC(C)C CDDLBXZFQDPDCS-UHFFFAOYSA-N 0.000 description 2
- GLYIVAAPBJPIIA-UHFFFAOYSA-N tert-butyl-dimethyl-[3-[4-[3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]oxetan-3-yl]oxysilane Chemical compound [Si](C)(C)(C(C)(C)C)OC1(COC1)C1=CC=C(C=C1)C=1C=CC=2N(C=1)C(=CN=2)C1=CC=C(C=C1)OC(C)C GLYIVAAPBJPIIA-UHFFFAOYSA-N 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SYWDZJWBRYIJJB-UHFFFAOYSA-N (1-methylindol-5-yl)boronic acid Chemical compound OB(O)C1=CC=C2N(C)C=CC2=C1 SYWDZJWBRYIJJB-UHFFFAOYSA-N 0.000 description 1
- JRHPOFJADXHYBR-YUMQZZPRSA-N (1s,2s)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@H]1CCCC[C@@H]1NC JRHPOFJADXHYBR-YUMQZZPRSA-N 0.000 description 1
- UFYDUWGUTFJYHC-UHFFFAOYSA-N (2-fluoro-4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C(F)=C1 UFYDUWGUTFJYHC-UHFFFAOYSA-N 0.000 description 1
- OEBXBUNQDNBWRP-UHFFFAOYSA-N (2-methyl-4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C(C)=C1 OEBXBUNQDNBWRP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XZQQJUVWZYJYPN-UHFFFAOYSA-N (3-fluoro-4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=C1F XZQQJUVWZYJYPN-UHFFFAOYSA-N 0.000 description 1
- XRGBZDZYYQVOJZ-UHFFFAOYSA-N (3-methyl-4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=C1C XRGBZDZYYQVOJZ-UHFFFAOYSA-N 0.000 description 1
- UKZVUHVNTYDSOP-UHFFFAOYSA-N (3-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=CC(B(O)O)=C1 UKZVUHVNTYDSOP-UHFFFAOYSA-N 0.000 description 1
- QSWLFBMVIGQONC-UHFFFAOYSA-N (3-propan-2-ylphenyl)boronic acid Chemical compound CC(C)C1=CC=CC(B(O)O)=C1 QSWLFBMVIGQONC-UHFFFAOYSA-N 0.000 description 1
- GNRHNKBJNUVWFZ-UHFFFAOYSA-N (4-carbamoylphenyl)boronic acid Chemical compound NC(=O)C1=CC=C(B(O)O)C=C1 GNRHNKBJNUVWFZ-UHFFFAOYSA-N 0.000 description 1
- ZLNFACCFYUFTLD-UHFFFAOYSA-N (4-ethoxycarbonylphenyl)boronic acid Chemical compound CCOC(=O)C1=CC=C(B(O)O)C=C1 ZLNFACCFYUFTLD-UHFFFAOYSA-N 0.000 description 1
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 1
- NIQHFKWRHJZMQU-UHFFFAOYSA-N (4-propan-2-yloxycarbonylphenyl)boronic acid Chemical compound CC(C)OC(=O)C1=CC=C(B(O)O)C=C1 NIQHFKWRHJZMQU-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- OHOTUZDQPKBUJB-UHFFFAOYSA-N 1,6-bis(4-methoxyphenyl)benzimidazole Chemical compound COc1ccc(cc1)-c1ccc2ncn(-c3ccc(OC)cc3)c2c1 OHOTUZDQPKBUJB-UHFFFAOYSA-N 0.000 description 1
- BDRNXXWLNZTHNA-UHFFFAOYSA-N 1,6-bis(4-propan-2-yloxyphenyl)benzimidazole Chemical compound CC(C)Oc1ccc(cc1)-c1ccc2ncn(-c3ccc(OC(C)C)cc3)c2c1 BDRNXXWLNZTHNA-UHFFFAOYSA-N 0.000 description 1
- CKWRAYGCDLYUSQ-UHFFFAOYSA-N 1-(4-bromophenyl)cyclopropan-1-ol Chemical compound C=1C=C(Br)C=CC=1C1(O)CC1 CKWRAYGCDLYUSQ-UHFFFAOYSA-N 0.000 description 1
- PUKVCMQNDSNSPR-UHFFFAOYSA-N 1-[4-[1-(4-propan-2-yloxyphenyl)indazol-6-yl]phenyl]ethanone Chemical compound CC(C)Oc1ccc(cc1)-n1ncc2ccc(cc12)-c1ccc(cc1)C(C)=O PUKVCMQNDSNSPR-UHFFFAOYSA-N 0.000 description 1
- NWRFNSKITTUWFZ-UHFFFAOYSA-N 1-[4-[3-[4-(1-hydroxycyclobutyl)phenyl]imidazo[1,2-a]pyridin-6-yl]phenyl]cyclobutan-1-ol Chemical compound OC1(CCC1)c1ccc(cc1)-c1cnc2ccc(cn12)-c1ccc(cc1)C1(O)CCC1 NWRFNSKITTUWFZ-UHFFFAOYSA-N 0.000 description 1
- NCOBKKZWPNUPRF-UHFFFAOYSA-N 1-[4-[6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrazin-3-yl]phenyl]ethanone Chemical compound CC(C)OC1=CC=C(C=C1)C=1N=CC=2N(C=1)C(=CN=2)C1=CC=C(C=C1)C(C)=O NCOBKKZWPNUPRF-UHFFFAOYSA-N 0.000 description 1
- VFPAOFBPEYCAAZ-UHFFFAOYSA-N 1-bromo-3-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1Br VFPAOFBPEYCAAZ-UHFFFAOYSA-N 0.000 description 1
- ZDFBKZUDCQQKAC-UHFFFAOYSA-N 1-bromo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1 ZDFBKZUDCQQKAC-UHFFFAOYSA-N 0.000 description 1
- SBKUWMSVXMRVFM-UHFFFAOYSA-N 1-bromo-5-fluoro-2-methoxy-4-nitrobenzene Chemical compound COC1=CC([N+]([O-])=O)=C(F)C=C1Br SBKUWMSVXMRVFM-UHFFFAOYSA-N 0.000 description 1
- RYWJXYWJUJFEMD-UHFFFAOYSA-N 1-bromo-5-fluoro-2-methyl-4-nitrobenzene Chemical compound CC1=CC([N+]([O-])=O)=C(F)C=C1Br RYWJXYWJUJFEMD-UHFFFAOYSA-N 0.000 description 1
- NLWYVKHISUTBMY-UHFFFAOYSA-N 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C2CC2)N=C1 NLWYVKHISUTBMY-UHFFFAOYSA-N 0.000 description 1
- CGHIBGNXEGJPQZ-UHFFFAOYSA-N 1-hexyne Chemical compound CCCCC#C CGHIBGNXEGJPQZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ZCBIFHNDZBSCEP-UHFFFAOYSA-N 1H-indol-5-amine Chemical compound NC1=CC=C2NC=CC2=C1 ZCBIFHNDZBSCEP-UHFFFAOYSA-N 0.000 description 1
- CLVPGJWAMIADSY-UHFFFAOYSA-N 1h-indazol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2NN=CC2=C1 CLVPGJWAMIADSY-UHFFFAOYSA-N 0.000 description 1
- ZVMHOIWRCCZGPZ-UHFFFAOYSA-N 1h-indol-6-ylboronic acid Chemical compound OB(O)C1=CC=C2C=CNC2=C1 ZVMHOIWRCCZGPZ-UHFFFAOYSA-N 0.000 description 1
- ZIXLJHSFAMVHPC-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OCCC2=C1 ZIXLJHSFAMVHPC-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- RZZGFCFQBVRQSX-UHFFFAOYSA-N 2,4-dibromo-5-nitropyridine Chemical compound [O-][N+](=O)C1=CN=C(Br)C=C1Br RZZGFCFQBVRQSX-UHFFFAOYSA-N 0.000 description 1
- INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 1
- FFRFTURYWWFKIC-UHFFFAOYSA-N 2,6-dibromo-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Br)N=C1Br FFRFTURYWWFKIC-UHFFFAOYSA-N 0.000 description 1
- ZGNJBDFDJLZYDM-UHFFFAOYSA-N 2,9-bis(4-propan-2-yloxyphenyl)purine Chemical compound CC(C)Oc1ccc(cc1)-c1ncc2ncn(-c3ccc(OC(C)C)cc3)c2n1 ZGNJBDFDJLZYDM-UHFFFAOYSA-N 0.000 description 1
- DBTSXHMNKXXNDV-UHFFFAOYSA-N 2-(4-propan-2-yloxyphenyl)acetonitrile Chemical compound CC(C)OC1=CC=C(CC#N)C=C1 DBTSXHMNKXXNDV-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- UOEGCVFXAKQTNI-UHFFFAOYSA-N 2-bromo-1-(4-propan-2-yloxyphenyl)ethanone Chemical compound CC(C)OC1=CC=C(C(=O)CBr)C=C1 UOEGCVFXAKQTNI-UHFFFAOYSA-N 0.000 description 1
- IPWWIXMFLXNCOX-UHFFFAOYSA-N 2-chloro-9-(4-propan-2-yloxyphenyl)purine Chemical compound CC(C)Oc1ccc(cc1)-n1cnc2cnc(Cl)nc12 IPWWIXMFLXNCOX-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- NSSUALWGSAOJJV-UHFFFAOYSA-N 3,5-bis(4-propan-2-yloxyphenyl)-1H-indazole Chemical compound CC(C)OC1=CC=C(C=C1)C1=NNC2=CC=C(C=C12)C1=CC=C(C=C1)OC(C)C NSSUALWGSAOJJV-UHFFFAOYSA-N 0.000 description 1
- DVRKXGGQASOCER-UHFFFAOYSA-N 3,5-dipyridin-2-ylimidazo[4,5-b]pyridine Chemical compound C1=NC2=CC=C(C=3N=CC=CC=3)N=C2N1C1=CC=CC=N1 DVRKXGGQASOCER-UHFFFAOYSA-N 0.000 description 1
- ZQZOPUGANRDRCQ-UHFFFAOYSA-N 3,6-bis(4-cyclopropyloxyphenyl)imidazo[1,2-a]pyridine Chemical compound C1(CC1)OC1=CC=C(C=C1)C1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)OC1CC1 ZQZOPUGANRDRCQ-UHFFFAOYSA-N 0.000 description 1
- JRDMOLPRJZUOJF-UHFFFAOYSA-N 3,6-bis(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridine-2-carboxamide Chemical compound CC(C)OC1=CC=C(C=C1)C1=C(N=C2N1C=C(C=C2)C1=CC=C(C=C1)OC(C)C)C(=O)N JRDMOLPRJZUOJF-UHFFFAOYSA-N 0.000 description 1
- XCQLBMLVMWAIJL-UHFFFAOYSA-N 3-(1H-indol-5-yl)-6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrazine Chemical compound CC(C)Oc1ccc(cc1)-c1cn2c(cnc2cn1)-c1ccc2[nH]ccc2c1 XCQLBMLVMWAIJL-UHFFFAOYSA-N 0.000 description 1
- DKYPGFLZMVBMEK-UHFFFAOYSA-N 3-(1H-indol-5-yl)-6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrimidine Chemical compound CC(C)Oc1ccc(cc1)-c1cnc2ncc(-c3ccc4[nH]ccc4c3)n2c1 DKYPGFLZMVBMEK-UHFFFAOYSA-N 0.000 description 1
- FPTOVMWPBXAKSQ-UHFFFAOYSA-N 3-[4-[3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]oxetan-3-ol Chemical compound CC(C)OC1=CC=C(C=C1)C1=CN=C2N1C=C(C=C2)C1=CC=C(C=C1)C1(COC1)O FPTOVMWPBXAKSQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LZAXVCBLZXZVCK-UHFFFAOYSA-N 3-bromo-6-iodoimidazo[1,2-a]pyridine Chemical compound C1=CC(I)=CN2C(Br)=CN=C21 LZAXVCBLZXZVCK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- DQQNMIPXXNPGCV-UHFFFAOYSA-N 3-hexyne Chemical compound CCC#CCC DQQNMIPXXNPGCV-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 1
- XRBGFEHBCNWZDR-UHFFFAOYSA-N 4-bromo-1-(4-methoxyphenyl)benzimidazole Chemical compound BrC1=CC=CC=2N(C=NC=21)C1=CC=C(C=C1)OC XRBGFEHBCNWZDR-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- YFTAUNOLAHRUIE-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)N=C1 YFTAUNOLAHRUIE-UHFFFAOYSA-N 0.000 description 1
- DKKGUGAWBOHTDU-UHFFFAOYSA-N 5-[3-(4-propan-2-yloxyphenyl)-1-benzofuran-5-yl]-1H-indole Chemical compound CC(C)Oc1ccc(cc1)-c1coc2ccc(cc12)-c1ccc2[nH]ccc2c1 DKKGUGAWBOHTDU-UHFFFAOYSA-N 0.000 description 1
- UMQHFGBQHPXZET-UHFFFAOYSA-N 6-(1H-indol-5-yl)-1-(4-propan-2-yloxyphenyl)indazole Chemical compound N1C=CC2=CC(=CC=C12)C1=CC=C2C=NN(C2=C1)C1=CC=C(C=C1)OC(C)C UMQHFGBQHPXZET-UHFFFAOYSA-N 0.000 description 1
- LSNJDAQPIBBFEF-UHFFFAOYSA-N 6-(1H-indol-5-yl)-1-(4-propan-2-yloxyphenyl)indole Chemical compound CC(C)Oc1ccc(cc1)-n1ccc2ccc(cc12)-c1ccc2[nH]ccc2c1 LSNJDAQPIBBFEF-UHFFFAOYSA-N 0.000 description 1
- OUKMCZZUEJSWDU-UHFFFAOYSA-N 6-(1H-indol-5-yl)-3-(4-propan-2-yloxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine Chemical compound CC(C)Oc1ccc(cc1)-c1nnc2ccc(cn12)-c1ccc2[nH]ccc2c1 OUKMCZZUEJSWDU-UHFFFAOYSA-N 0.000 description 1
- YKQLNFLJHKEDLM-UHFFFAOYSA-N 6-(4-propan-2-yloxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine Chemical compound C(C)(C)OC1=CC=C(C=C1)C=1C=CC=2N(C=1)C=NN=2 YKQLNFLJHKEDLM-UHFFFAOYSA-N 0.000 description 1
- QTJQUEOVMNZKRW-UHFFFAOYSA-N 6-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrazine Chemical compound C(C)(C)OC1=CC=C(C=C1)C=1N=CC=2N(C=1)C=CN=2 QTJQUEOVMNZKRW-UHFFFAOYSA-N 0.000 description 1
- IATGFCWTHBMFGO-UHFFFAOYSA-N 6-bromo-1-(2-methoxyphenyl)benzimidazole Chemical compound BrC=1C=CC2=C(N(C=N2)C2=C(C=CC=C2)OC)C=1 IATGFCWTHBMFGO-UHFFFAOYSA-N 0.000 description 1
- SXXSQGXCTUCJFG-UHFFFAOYSA-N 6-bromo-1-(3-methoxyphenyl)benzimidazole Chemical compound BrC=1C=CC2=C(N(C=N2)C2=CC(=CC=C2)OC)C=1 SXXSQGXCTUCJFG-UHFFFAOYSA-N 0.000 description 1
- WMKDUJVLNZANRN-UHFFFAOYSA-N 6-bromo-1h-indazole Chemical compound BrC1=CC=C2C=NNC2=C1 WMKDUJVLNZANRN-UHFFFAOYSA-N 0.000 description 1
- MAWGHOPSCKCTPA-UHFFFAOYSA-N 6-bromo-1h-indole Chemical compound BrC1=CC=C2C=CNC2=C1 MAWGHOPSCKCTPA-UHFFFAOYSA-N 0.000 description 1
- NQQMDOVHQGHIJR-UHFFFAOYSA-N 6-bromo-3-(4-propan-2-yloxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine Chemical compound BrC=1C=CC=2N(C=1)C(=NN=2)C1=CC=C(C=C1)OC(C)C NQQMDOVHQGHIJR-UHFFFAOYSA-N 0.000 description 1
- TWVGLGIBWNJERF-UHFFFAOYSA-N 6-bromo-3-(4-propan-2-yloxyphenyl)imidazo[1,2-a]pyrimidine Chemical compound BrC=1C=NC=2N(C=1)C(=CN=2)C1=CC=C(C=C1)OC(C)C TWVGLGIBWNJERF-UHFFFAOYSA-N 0.000 description 1
- ZSTIVBYZPKCEDM-UHFFFAOYSA-N 6-bromo-3-iodo-5-methylimidazo[1,2-a]pyridine Chemical compound BrC=1C=CC=2N(C=1C)C(=CN=2)I ZSTIVBYZPKCEDM-UHFFFAOYSA-N 0.000 description 1
- ANXNYNYSSAQZLV-UHFFFAOYSA-N 6-bromo-5-methoxy-1-(4-propan-2-yloxyphenyl)benzimidazole Chemical compound BrC=1C(=CC2=C(N(C=N2)C2=CC=C(C=C2)OC(C)C)C=1)OC ANXNYNYSSAQZLV-UHFFFAOYSA-N 0.000 description 1
- RUXDLXVEJBFDMW-UHFFFAOYSA-N 6-bromo-5-methyl-1-(4-propan-2-yloxyphenyl)benzotriazole Chemical compound BrC=1C(=CC2=C(N(N=N2)C2=CC=C(C=C2)OC(C)C)C=1)C RUXDLXVEJBFDMW-UHFFFAOYSA-N 0.000 description 1
- FUGACMZCEQHBIU-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyridine Chemical compound CC1=CC(Br)=CN2C=CN=C12 FUGACMZCEQHBIU-UHFFFAOYSA-N 0.000 description 1
- KKMWDXNBIKMCEH-UHFFFAOYSA-N 6-bromoimidazo[1,2-a]pyrazine Chemical compound C1=NC(Br)=CN2C=CN=C21 KKMWDXNBIKMCEH-UHFFFAOYSA-N 0.000 description 1
- DMNOTJNQPFQCNE-UHFFFAOYSA-N 6-bromoimidazo[1,2-a]pyridine-2-carbaldehyde Chemical compound C1=C(Br)C=CC2=NC(C=O)=CN21 DMNOTJNQPFQCNE-UHFFFAOYSA-N 0.000 description 1
- YLWZYCSSUYSOAW-UHFFFAOYSA-N 6-bromoimidazo[1,5-a]pyridine Chemical compound C1=C(Br)C=CC2=CN=CN21 YLWZYCSSUYSOAW-UHFFFAOYSA-N 0.000 description 1
- IWHCPHZAMFSDFM-UHFFFAOYSA-N 6-chloro-3-iodoimidazo[1,2-b]pyridazine Chemical compound N1=C(Cl)C=CC2=NC=C(I)N21 IWHCPHZAMFSDFM-UHFFFAOYSA-N 0.000 description 1
- MMDCOOMHHPUECK-UHFFFAOYSA-N 7-bromoimidazo[1,5-a]pyridine Chemical compound C1=C(Br)C=CN2C=NC=C21 MMDCOOMHHPUECK-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102400000310 Alpha-dystroglycan Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- QWYPPWSJICTEMU-UHFFFAOYSA-N BrC=1C(=CC=2N(C=1)C=CN=2)OC Chemical compound BrC=1C(=CC=2N(C=1)C=CN=2)OC QWYPPWSJICTEMU-UHFFFAOYSA-N 0.000 description 1
- KHXZYRKATOPIDK-UHFFFAOYSA-N C(C)(C)OC1=CC=C(C=C1)B(O)O.BrC=1C=CC2=C(N(N=N2)C2=CC=C(C=C2)OC(C)C)C=1 Chemical compound C(C)(C)OC1=CC=C(C=C1)B(O)O.BrC=1C=CC2=C(N(N=N2)C2=CC=C(C=C2)OC(C)C)C=1 KHXZYRKATOPIDK-UHFFFAOYSA-N 0.000 description 1
- KGCVJFPYYVPEKA-UHFFFAOYSA-N C1(CCCC1)OC1=C(C#N)C=C(C=C1)C1=CC=C(C=C1)N1C=NC2=C1C=C(C=C2)C=1NOC(N=1)=O Chemical compound C1(CCCC1)OC1=C(C#N)C=C(C=C1)C1=CC=C(C=C1)N1C=NC2=C1C=C(C=C2)C=1NOC(N=1)=O KGCVJFPYYVPEKA-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 108010071885 Dystroglycans Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 101000900206 Hantaan virus (strain 76-118) Envelopment polyprotein Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000712890 Junin mammarenavirus Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000555271 Mobala mammarenavirus Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001244466 New world arenaviruses Species 0.000 description 1
- 108700018419 Niemann-Pick C1 Proteins 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- UTKNUPLTWVCBHU-UHFFFAOYSA-N OBO.CC(C)(O)C(C)(C)O Chemical class OBO.CC(C)(O)C(C)(C)O UTKNUPLTWVCBHU-UHFFFAOYSA-N 0.000 description 1
- 241001244462 Old world arenaviruses Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101710119090 RING finger protein Z Proteins 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 125000005631 S-sulfonamido group Chemical group 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 241000736032 Sabia <angiosperm> Species 0.000 description 1
- 241000150278 Seoul orthohantavirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000712908 Tacaribe mammarenavirus Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- XFDVDBZKAWJLFA-UHFFFAOYSA-N [3-(4-bromophenyl)oxetan-3-yl]oxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC1(COC1)c1ccc(Br)cc1 XFDVDBZKAWJLFA-UHFFFAOYSA-N 0.000 description 1
- NAUAVKHPAOUUAP-UHFFFAOYSA-N [4-(1-aminocyclopropyl)phenyl]boronic acid Chemical compound C=1C=C(B(O)O)C=CC=1C1(N)CC1 NAUAVKHPAOUUAP-UHFFFAOYSA-N 0.000 description 1
- ODKMFCPXFMQWHA-UHFFFAOYSA-N [4-(2-methoxyethoxy)phenyl]boronic acid Chemical compound COCCOC1=CC=C(B(O)O)C=C1 ODKMFCPXFMQWHA-UHFFFAOYSA-N 0.000 description 1
- AYJVDOMUBHORKK-UHFFFAOYSA-N [4-(cyclopropylmethoxy)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCC1CC1 AYJVDOMUBHORKK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000001506 calcium phosphate Chemical class 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000006210 cyclodehydration reaction Methods 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- MWDCKDQQAFZDOH-UHFFFAOYSA-N ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=C(Br)C=CC2=NC(C(=O)OCC)=CN21 MWDCKDQQAFZDOH-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005283 haloketone group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- MELUCTCJOARQQG-UHFFFAOYSA-N hex-2-yne Chemical compound CCCC#CC MELUCTCJOARQQG-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- KUQCOTSTUVAICI-UHFFFAOYSA-N n-propan-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound C1=CC(NC(C)C)=CC=C1B1OC(C)(C)C(C)(C)O1 KUQCOTSTUVAICI-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000005499 phosphonyl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- IWDANOJGJIFBEL-UHFFFAOYSA-N spiro[3.4]octane Chemical compound C1CCC21CCCC2 IWDANOJGJIFBEL-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- XRLOWKAACZKDBK-UHFFFAOYSA-N tert-butyl 3-(4-bromophenyl)-3-hydroxyazetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1(O)C1=CC=C(Br)C=C1 XRLOWKAACZKDBK-UHFFFAOYSA-N 0.000 description 1
- RUXGCTDRNQBDSV-UHFFFAOYSA-N tert-butyl 5-bromo-3-iodoindazole-1-carboxylate Chemical compound BrC1=CC=C2N(C(=O)OC(C)(C)C)N=C(I)C2=C1 RUXGCTDRNQBDSV-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000006169 tetracyclic group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000005423 trihalomethanesulfonamido group Chemical group 0.000 description 1
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to the use of heterocyclic compounds for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Venezuelan, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.
- arenavirus infection such as Lassa, Venezuelan, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers
- Arenaviridae comprise a diverse family of 29 (and growing) negative stranded enveloped RNA viruses. Arenaviruses are divided into two groups, Old and New World complex, based on serological, genetic and geographical data. Old World viruses are found primarily throughout South and West Africa and include the prototypic lymphocytic choriomeningitis virus (LCMV), along with Lassa (LASV), Lujo (LUJV), Mopeia (MOPV), Ippy and Mobala (MOBV) viruses. Both LASV and LUJV can cause lethal hemorrhagic fever (HF), while LCMV infection is associated with aseptic meningitis.
- LCMV prototypic lymphocytic choriomeningitis virus
- LASV Lassa
- LJV Lujo
- MOPV Mopeia
- Ippy and Mobala MOBV
- Lassa alone is estimated to cause over 300,000 disease cases each year in West Africa of which 15-20% of hospitalized patients die and survivors often suffer sequelae, including permanent bilateral hearing damage.
- Clade B HF viruses include, Junin (JUNV), Machupo (MACV), Guanarito (GTOV), Sabia (SABV) and Chapare, along with non-HF viruses such as Tacaribe (TCRV) and Amapari (AMPV).
- Arenaviruses consist of a nucleocapsid (NP) surrounded by an envelope membrane, and the NP contains two ambisense RNA genome segments L and S that direct the synthesis of two polypeptides.
- the L segment encodes the RNA-dependent-RNA polymerase (RdRp) and a small Ring Finger protein Z.
- the S segment encodes for nucleoprotein and a glycoprotein precursor GPC that is cleaved by host proteases and undergoes post-translational modification into a mature complex composed of glycoproteins GP1 (binds host protein at the cell surface), GP2 (directs pH dependent membrane fusion and release ofgenomic material in the cytoplasm) and a stable signal peptide (SSP1).
- GP1 binds host protein at the cell surface
- GP2 directs pH dependent membrane fusion and release ofgenomic material in the cytoplasm
- SSP1 stable signal peptide
- the mature glycoprotein complex (GP) is formed in the viral envelope and is responsible for mediating viral entry.
- the Old World arenaviruses bind to host ⁇ -dystroglycan while New World arenaviruses bind to transferrin receptor 1 for entry/endocytosis into cells.
- the virus Upon binding to cell surface receptors, the virus is endocytosed and directed to acidic late endosomes whereby GP2 mediates pH dependent membrane fusion and release of genomic material into the cytoplasm for viral replication and transcription. Therefore, viral entry inhibitors (e.g., small molecules) that target virus GP complex or host factors are a potential therapeutic/prophylactic approach in treating patients infected with arenavirus infection.
- VSV vesicular stomatitis virus
- GP pseudotype VSV viruses The cell entry and infectivity properties of GP pseudotype VSV viruses have been shown for multiple viruses including HIV, Hepatitis B and C, Ebola, Lassa, Hanta and others [Ogino, M., et al. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test . Clin. Diagn. Lab. Immunol. (2003) 10(1):154-60; Saha, M. N., et al. Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus . J. Virol.
- a reporter gene such as green fluorescent protein (GFP) or luciferase can be engineered into the pseudovirus genome, and virus infectivity in mammalian cell lines (e.g.
- Vero or Hek293 can be monitored using optical detection methods (e.g. plate reader) [Cote, M.; Misasi, J.; Ren, T.; Bruchez, A., Lee, K., Filone, C. M.; Hensley, L.; Li, Q.; Ory, D.; Chandran, K.; Cunningham, J., Small molecule inhibitors reveal Niemann - Pick C 1 is essential for Ebola virus infection , Nature (2011) 477: 344-348, Elshabrawy, H. A., et al.
- the “pseudoviruses” may therefore be used to screen chemical compound libraries to identify inhibitors of arenavirus cell entry while avoiding the complications of working with highly pathogenic BSL-4 agents.
- entry inhibitors described were identified using an arenavirus GP pseudovirus screen and selected compounds were tested against native non-HF virus TCRV to confirm activity against replicative arenavirus. Selected top compounds were then tested against native HF viruses including LASV and JUNV to confirm activity against the native highly pathogenic human (HF) arenaviruses.
- the present invention relates to the use of heterocyclic compounds for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Venezuelan, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.
- arenavirus infection such as Lassa, Venezuelan, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I
- A, D, and E are independently N or C—R 3 ;
- G, H, and J are independently N or C;
- K and L are independently N, O, S, N—R 3 , or C—R 3 ;
- R 1 is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- R 2 is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 3 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —C(O)NR 6a R 6b , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —(CH 2 ) n C(O)OR 5 , —(
- R 4 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —C(O)NR 6a R 6b , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —(CH 2 ) n C(O)OR 5 , —(CH 2
- each of the R 5 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 6a , R 6b , and R 6c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl,
- R 6a and R 6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R 7 group;
- R 7 is independently selected from hydrogen, halogen, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, cyano, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 8 , —C(O)NR 9a R 9b , —NR 9a R 9b , —S(O) m R 8 , —S(O) m NR 9a R 9b , —NR 9a S(O) m R 8 , —(CH 2 ) n C(O)ORB, —(CH 2 )
- each of the R 8 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 9a , R 9b , and R 9c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl,
- R 9a and R 9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted
- R 10 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- the present invention relates to the use of heterocyclic compounds for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Venezuelan, Argentine, Venezuelan, Brazilian, Chapare, and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.
- arenavirus infection such as Lassa, Venezuelan, Argentine, Venezuelan, Brazilian, Chapare, and Lujo hemorrhagic fevers
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I
- A, D, and E are independently N or C—R 3 ;
- G, H, and J are independently N or C;
- K and L are independently N, O, S, N—R 3 , or C—R 3 ;
- R 1 is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- R 2 is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 3 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —C(O)NR 6a R 6b , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —(CH 2 ) n C(O)OR 5 , —(
- R 4 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —C(O)NR 6a R 6b , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —(CH 2 ) n C(O)OR 5 , —(CH 2
- each of the R 5 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 6a , R 6b , and R 6c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl,
- R 6a and R 6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R 7 group;
- R 7 is independently selected from hydrogen, halogen, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, cyano, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 8 , —C(O)NR 9a R 9b , —NR 9a R 9b , —S(O) m R 8 , —S(O) m NR 9a R 9b , —NR 9a S(O) m R 8 , —(CH 2 ) n C(O)ORB, —(CH 2 )
- each of the R 8 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 9a , R 9b , and R 9c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl,
- R 9a and R 9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted
- R 10 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- n 0, 1, or 2;
- n 0, 1, 2, 3, 4, 5, or 6.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- G, H, and J are independently N or C;
- K and L are independently N, O, S, N—R 3 , or C—R 3 ;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein R 3 and R 4 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are independently N or C—R 3 ;
- G, H, and J are independently N or C;
- L is N, N—R 3 , or C—R 3 ;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , R 2 , and R 3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , R 2 , and R 3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy, surprisingly providing improved metabolic stability in multi-species microsomal assays.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein R 3 is defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- K is C—R 3 ;
- R 1 is selected from (C 1 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , R 2 , and R 3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein G and H are C, J and L are N, A, D, E, and K are independently C—R 3 , and R 1 is defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein G and H are C, A, J, and L are N, and D, E, and K are independently C—R 3 , or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R 1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein G and H are C, D, J and L are N, and A, E, and K are independently C—R 3 , or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R 1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein G and H are C, A, D, J, and L are N, and E and K are independently C—R 3 , or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R 1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, and E are independently N or C—R 3 , G and H are C, J is N, and K and L are independently CR 3 , or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, and E are independently N or C—R 3 , G and H are C, J and K are N, and L is CR 3 , or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, and E are independently N or C—R 3 , G, H and J are C, K and L are independently N or NR 3 , or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- H and L are N;
- K is C—R 3 ;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R 1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, and E are independently C—R 3 , G and J are C, H and L are N, K is C—R 3 , and R 1 is define as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein D and E are independently C—R 3 , G and J are C, A, H, and L are N, K is C—R 3 , and R 1 is defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein D and E are independently C—R 3 , G and J are C, A, H, and L are N, K is C—R 3 , and R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A and D are independently C—R 3 , G and J are C, E, H, and L are N, and K is C—R 3 , or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 :
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R 1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R 3 ;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R 1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R 3 ;
- H, K, and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group, and wherein (C 2 to C 9 ) heteroaryl is C-attached;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R 1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 2 is selected from the group consisting of
- R 4b is selected from (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and —C(O)R 5 , wherein
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- K is C—R 3 .
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are independently C—R 3 ;
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R 3 ;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are C—H
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are independently C—R 3 ;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-alkoxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are C—H
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-alkoxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R 3 ;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-isopropyloxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are C—H
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-isopropyloxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are independently C—R 3 ;
- A, J and L are N.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are independently C—R 3 ;
- A, J and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are C—H
- A, J and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are independently C—R 3 ;
- A, J and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-alkoxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are C—H
- A, J and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-alkoxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are independently C—R 3 ;
- A, J and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-isopropyloxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, J and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-isopropyloxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- K and L are independently C—R 3 .
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- K is C—R 3 ;
- L is N—R 3 .
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- L is C—R 3 .
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- L is N—R 3 .
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- H and L are N;
- K is C—R 3 .
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R 3 ;
- H and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are C—H
- H and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R 3 ;
- H and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-alkoxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are C—H
- H and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-alkoxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R 3 ;
- H and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-isopropyloxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are C—H
- H and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4 group;
- R 2 is 4-isopropyloxyphenyl.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- H and K are N;
- L is CR 3 .
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- G and K are N;
- L is C—R 3 .
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- H, K, and L are N.
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- K is C—R 3 ;
- the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- the invention relates to compounds of Structural Formula I
- A, D, and E are independently N or C—R 3 ;
- G, H, and J are independently N or C;
- K is N or C—H
- L is N, N—R 3 , or C—R 3 ;
- R 1 is selected from (C 1 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, and 5-indolyl, wherein
- each of the said (C 1 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is substituted with at least one R 4a group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached;
- R 1 is not selected from the group consisting of substituted 3-carbamoyl-2-phenyl-1-benzofuran-5-yl, substituted 1,3,4-oxadiazolyl, substituted 1,3,4-triazolyl, substituted 1,3,4-thiadiazolyl, substituted oxazoyl, substituted thiazoyl, substituted 1H-pyrazol-4-yl, substituted 1H-pyrazol-5-yl, optionally substituted 1-phenyl-1H-imidazol-5-yl, 4- ⁇ [(2-aminoethyl)amino]methyl ⁇ phenyl, (2-amino-1,3-benzoxazol)-5-yl; (2-amino-1,3-benzoxazol)-4-yl, 2-chloropyridyl-3-yl, 2-methylpyridinyl-4-yl, 2-fluoropyridyl-4-yl, 6-aminopyridyl-3-yl
- R 2 is selected from the group consisting of
- each of the R 3 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —C(O)NR 6a R 6b , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —(CH 2 ) n C(O)OR 5 , —(
- R 4a is independently selected from halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —OC(O)R 5 , —NR 6a C(O)R 5 , and —NR 6c C(O)NR 6a R 6
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of
- each of the R 5 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 6a , R 6b , and R 6c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl,
- R 6a and R 6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R 7 group;
- R 7 is independently selected from hydrogen, halogen, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, cyano, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 8 , —C(O)NR 9a R 9b , —NR 9a R 9b , —S(O) m R 8 , —S(O) m NR 9a R 9b , —NR 9a S(O) m R 8 , —(CH 2 ) n C(O)ORB, —(CH 2 )
- each of the R 8 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 9a , R 9b , and R 9c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl,
- R 9a and R 9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted
- R 10 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- n 0, 1, or 2;
- n 1, 2, 3, 4, 5, or 6.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R 3 is hydrogen
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- K is C—H.
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein G and H are C, J and L are N, K is C—H, and R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R 3 .
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D and E are independently C—R 3 ;
- A, J, and L are N;
- K is C—H.
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- a and E are independently C—R 3 ;
- K is C—H.
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- E is C—R 3 ;
- K is C—H
- A, D, J, and L are N.
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- K is C—H
- L is C—R 3 .
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- L is C—R 3 .
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- L is N—R 3 .
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- H and L are N;
- K is C—H.
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein G and J are C; H and L are N, K is C—H, and R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R 3 .
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D and E are independently C—R 3 ;
- A, H, and L are N;
- K is C—H
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- a and D are independently C—R 3 ;
- K is C—H
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein G and H are C, J, K, and L are N, and R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R 3 .
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R 3 ,
- H, K, and L are N.
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 , and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 3 is hydrogen
- the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R 4b is isopropoxy.
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R 3 ;
- G and K are N;
- L is C—R 3 .
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- A, D, and E are independently N or C—R 3 ;
- K is C—H
- the invention relates to compounds of Structural Formula I, wherein R 1 and R 2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- A, D, and E are independently N or C—R 3 ;
- the invention relates to compounds of Structural Formula I
- A, D, E, and K are C—H
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4a group
- R 1 is not selected from the group consisting of optionally substituted 3-carbamoyl-2-phenyl-1-benzofuran-5-yl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted 1H-pyrazol-4-yl, optionally substituted 1-phenyl-1H-pyrazol-5-yl, optionally substituted 1-phenyl-1H-imidazol-5-yl, 4- ⁇ [(2-aminoethyl)amino]methyl ⁇ phenyl, and (2-amino-1,3-benzoxazol)-5-yl;
- R 4a is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —OC(O)R 5 , —NR 6a C(O)R 5 , and —NR 6c C(O)NR 6a
- R 4b is selected from halogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —C(O)NR 6a R 6b , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —(CH 2 ) n C(O)OR 5 , —(CH 2 ) n C(O)NR 6a R 6b
- each of the R 5 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- R 6a and R 6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R 7 group;
- R 7 is independently selected from hydrogen, halogen, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, cyano, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 8 , —C(O)NR 9a R 9b , —NR 9a R 9b , —S(O) m R 8 , —S(O) m NR 9a R 9b , —NR 9a S(O) m R 8 , —(CH 2 ) n C(O)ORB, —(CH 2 )
- each of the R 8 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 9a , R 9b , and R 9c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl,
- R 9a and R 9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted
- R 10 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- n 0, 1, or 2;
- n 1, 2, 3, 4, 5, or 6;
- the invention relates to compounds of Structural Formula I
- A, J and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4a group
- R 1 is not selected from the group consisting of optionally substituted 3-carbamoyl-2-phenyl-1-benzofuran-5-yl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted 1H-pyrazol-4-yl, optionally substituted 1-phenyl-1H-pyrazol-5-yl, optionally substituted 1-phenyl-1H-imidazol-5-yl, and (2-amino-1,3-benzoxazol)-5-yl;
- R 2 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4b group,
- R 4a is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —OC(O)R 5 , —NR 6a C(O)R 5 , and —NR 6c C(O)NR 6a
- R 4b is independently selected from halogen, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —C(O)NR 6a R 6b , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —(CH 2 ) n C(O)OR 5 , —(CH 2 ) n C(O)NR
- each of the R 5 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 6a , R 6b , and R 6c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl,
- R 6a and R 6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R 7 group;
- R 7 is independently selected from hydrogen, halogen, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, cyano, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 8 , —C(O)NR 9a R 9b , —NR 9a R 9b , —S(O) m R 8 , —S(O) m NR 9a R 9b , —NR 9a S(O) m R 8 , —(CH 2 ) n C(O)ORB, —(CH 2 )
- each of the R 8 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 9a , R 9b , and R 9c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl,
- R 9a and R 9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted
- R 10 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- n 0, 1, or 2;
- n 1, 2, 3, 4, 5, or 6;
- the invention relates to compounds of Structural Formula I
- A, D, E, and K are CH;
- H and L are N;
- R 1 is selected from (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl, wherein
- each of the said (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl is optionally substituted with at least one R 4a group with the proviso that
- R 1 is not selected from the group consisting of optionally substituted 3-carbamoyl-2-phenyl-1-benzofuran-5-yl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted 1H-pyrazol-4-yl, optionally substituted 1-phenyl-1H-pyrrol-2-yl, optionally substituted 1-phenyl-1H-pyrazol-5-yl, optionally substituted 1-phenyl-1H-imidazol-5-yl, 2-(4-fluoro-3-methylphenyl)pyridin-3-yl, and (2-amino-1,3-benzoxazol)-5-yl;
- R 4a is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 5 , —NR 6a R 6b , —S(O) m R 5 , —S(O) m NR 6a R 6b , —NR 6a S(O) m R 5 , —OC(O)R 5 , —NR 6a C(O)R 5 , and —NR 6c C(O)NR 6a
- R 4b is selected from the group consisting of
- R 4b is selected from the group consisting of isopropylthio, morpholin-4-yl, thiomorpholine-1,1-dione-4-yl, and amino,
- R 1 is not selected from the group consisting of
- R 4b is selected from the group consisting of 2-hydroxyethoxy, 2-(oxan-2-yloxy)ethoxy, 2-(oxan-4-yloxy)ethoxy, and 2-(oxan-4-yloxy)ethylamino,
- R 1 is not selected from the group consisting of 1H-pyrrol-3-yl, 1H-pyrazol-1yl, 1H-imidazol-1-yl, 4-pyridin-1-yl, 1-methyl-1H-methyl-pyrazol-4-yl, and 1,3-oxazol-2-yl;
- each of the R 5 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 6a , R 6b , and R 6C are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl,
- R 6a and R 6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R 7 group;
- R 7 is independently selected from hydrogen, halogen, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, cyano, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, —C(O)R 8 , —C(O)NR 9a R 9b , —NR 9a R 9b , —S(O) m R 8 , —S(O) m NR 9a R 9b , —NR 9a S(O) m R 8 , —(CH 2 ) n C(O)ORB, —(CH 2 )
- each of the R 8 is independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- each of the R 9a , R 9b , and R 9c are independently selected from hydrogen, (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl,
- R 9a and R 9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted
- R 10 is independently selected from hydrogen, halogen, cyano, OH, CF 3 , (C 1 to C 6 ) alkyl, (C 2 to C 6 ) alkenyl, (C 2 to C 6 ) alkynyl, (C 1 to C 6 ) alkoxy, aryloxy, (C 3 to C 10 ) cycloalkyl, (C 5 to C 10 ) cycloalkenyl, (C 2 to C 9 ) cycloheteroalkyl, (C 6 to C 10 ) aryl, and (C 2 to C 9 ) heteroaryl, wherein
- n 0, 1, or 2;
- n 1, 2, 3, 4, 5, or 6.
- the invention relates to compounds, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, selected from the group consisting of the compounds described as examples A1 to A31, B1 to B15, C1 to C51, and D1 to D23 in the method of preparation section.
- a therapeutically effective amount of a therapeutic agent selected from the group consisting of Ribavirin, polymerase inhibitors, T-705 (favipiravir), Triazavirin, small interfering RNAs (siRNAs), vaccines, and immunomodulators can be administered with the compound of the invention.
- halo and/or “halogen” refer to fluorine, chlorine, bromine or iodine.
- (C 1 to C 6 )” alkyl refers to a saturated aliphatic hydrocarbon radical including straight chain and branched chain groups of 1 to 6 carbon atoms.
- Examples of (C 1 to C 6 ) alkyl groups include methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and the like.
- Et and “ethyl,” as used herein, mean a —C 2 H 5 group.
- (C 2 to C 8 ) alkenyl means an alkyl moiety comprising 2 to 8 carbons having at least one carbon-carbon double bond.
- the carbon-carbon double bond in such a group may be anywhere along the 2 to 8 carbon chain that will result in a stable compound.
- Such groups include both the E and Z isomers of said alkenyl moiety. Examples of such groups include, but are not limited to, ethenyl, propenyl, butenyl, allyl, and pentenyl.
- allyl means a —CH 2 CH ⁇ CH 2 group.
- C(R) ⁇ C(R), represents a carbon-carbon double bond in which each carbon is substituted by an R group, and includes E and Z isomers.
- (C 2 to C 8 ) alkynyl means an alkyl moiety comprising from 2 to 8 carbon atoms and having at least one carbon-carbon triple bond.
- the carbon-carbon triple bond in such a group may be anywhere along the 2 to 8 carbon chain that will result in a stable compound. Examples of such groups include, but are not limited to, ethyne, propyne, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 1-hexyne, 2-hexyne, and 3-hexyne.
- (C 1 to C 8 ) alkoxy means an O-alkyl group wherein said alkyl group contains from 1 to 8 carbon atoms and is straight, branched, or cyclic.
- alkyl group contains from 1 to 8 carbon atoms and is straight, branched, or cyclic.
- examples of such groups include, but are not limited to, methoxy, ethoxy, n-propyloxy, iso-propyloxy, n-butoxy, iso-butoxy, tert-butoxy, cyclopentyloxy, and cyclohexyloxy.
- (C to C 10 ) aryl means a group derived from an aromatic hydrocarbon containing from 6 to 10 carbon atoms. Examples of such groups include, but are not limited to, phenyl or naphthyl.
- (C 2 to C 9 ) heteroaryl means an aromatic heterocyclic group having a total of from 5 to 10 atoms in its ring, and containing from 2 to 9 carbon atoms and from one to four heteroatoms each independently selected from O, S and N, and with the proviso that the ring of said group does not contain two adjacent O atoms or two adjacent S atoms.
- the heterocyclic groups include benzo-fused ring systems.
- aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
- the (C 2 to C 9 ) heteroaryl groups may be C-attached or N-attached where such is possible.
- a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
- a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).
- (C 2 to C 9 ) cycloheteroalkyl means a non-aromatic, monocyclic, bicyclic, tricyclic, spirocyclic, or tetracyclic group having a total of from 4 to 13 atoms in its ring system, and containing from 2 to 9 carbon atoms and from 1 to 4 heteroatoms each independently selected from O, S and N, and with the proviso that the ring of said group does not contain two adjacent O atoms or two adjacent S atoms.
- such C 2 to C 9 cycloheteroalkyl groups may contain an oxo substituent at any available atom that will result in a stable compound.
- such a group may contain an oxo atom at an available carbon or nitrogen atom. Such a group may contain more than one oxo substituent if chemically feasible.
- a C 2 to C 9 cycloheteroalkyl group contains a sulfur atom, said sulfur atom may be oxidized with one or two oxygen atoms to afford either a sulfoxide or sulfone.
- An example of a 4 membered cycloheteroalkyl group is azetidinyl (derived from azetidine).
- An example of a 5 membered cycloheteroalkyl group is pyrrolidinyl.
- An example of a 6 membered cycloheteroalkyl group is piperidinyl.
- An example of a 9 membered cycloheteroalkyl group is indolinyl.
- An example of a 10 membered cycloheteroalkyl group is 4H-quinolizinyl.
- C 2 to C 9 cycloheteroalkyl groups include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyra
- (C 3 to C 10 ) cycloalkyl group means a saturated, monocyclic, fused, spirocyclic, or polycyclic ring structure having a total of from 3 to 10 carbon ring atoms.
- groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, and adamantyl.
- spirocyclic as used herein has its conventional meaning, that is, any compound containing two or more rings wherein two of the rings have one ring carbon in common.
- Non-limiting examples of a spirocyclic compound include spiro[3.3]heptane, spiro[3.4]octane, and spiro[4.5]decane.
- (C 1 to C 8 ) cycloalkenyl means an unsaturated, monocyclic, fused, spirocyclic ring structures having a total of from 5 to 8 carbon ring atoms. Examples of such groups include, but are not limited to, cyclopentenyl, cyclohexenyl.
- cyano refers to a —C ⁇ N group.
- aldehyde refers to a carbonyl group, where R is hydrogen.
- alkoxy refers to both an —O-alkyl and an —O-cycloalkyl group, as defined herein.
- alkoxycarbonyl refers to a —C(O)OR.
- alkylaminoalkyl refers to an -alkyl-NR-alkyl group.
- alkylsulfonyl refer to a —SO 2 -alkyl.
- amino refers to an —NH 2 or an —NRR′ group.
- aminoalkyl refers to an -alkyl-NRR′ group.
- aminocarbonyl refers to a —C(O)NRR′.
- arylalkyl refers to -alkyl-aryl, where alkyl and aryl are defined herein.
- aryloxy refers to both an —O-aryl and an —O-heteroaryl group, as defined herein.
- aryloxycarbonyl refers to —C(O)O-aryl.
- arylsulfonyl refers to a —SO 2 -aryl.
- a “C-amido” group refers to a —C(O)NRR′ group.
- a “carbonyl” group refers to a —C(O)R.
- a “C-carboxyl” group refers to a —C(O)OR group.
- a “carboxylic acid” group refers to a C-carboxyl group in which R is hydrogen.
- dialkylaminoalkyl refers to an -(alkyl)N(alkyl) 2 group.
- halo or “halogen” group refers to fluorine, chlorine, bromine or iodine.
- haloalkyl group refers to an alkyl group substituted with one or more halogen atoms.
- heteroalicycloxy refers to a heteroalicyclic-O group with heteroalicyclic as defined herein.
- heteroaryloxy refers to a heteroaryl-O— group with heteroaryl as defined herein.
- a “hydroxy” group refers to an —OH group.
- N-amido refers to a —R′C(O)NR— group.
- N-carbamyl refers to a —ROC(O)NR— group.
- a “nitro” group refers to a —NO 2 group.
- N-Sulfonamido refers to a —NR—S(O) 2 R group.
- N-thiocarbamyl refers to a —ROC(S)NR′— group.
- An “O-carbamyl” group refers to a —OC(O)NRR′ group.
- An “O-carboxyl” group refers to a —RC(O)O— group.
- An “O-thiocarbamyl” group refers to a —OC(S)NRR′ group.
- oxo refers to a carbonyl moiety such that alkyl substituted by oxo refers to a ketone group.
- a “perfluoroalkyl group” refers to an alkyl group where all of the hydrogen atoms have been replaced with fluorine atoms.
- a “phosphonyl” group refers to a —P(O)(OR) 2 group.
- a “silyl” group refers to a —SiR 3 group.
- S-sulfonamido refers to a —S(O) 2 NR— group.
- a “sulfinyl” group refers to a —S(O)R group.
- a “sulfonyl” group refers to a —S(O) 2 R group.
- a “thiocarbonyl” group refers to a —C( ⁇ S)—R group.
- a “trihalomethanecarbonyl” group refers to a Z 3 CC(O)— group, where Z is halogen.
- a “trihalomethanesulfonamido” group refers to a Z 3 CS(O) 2 NR— group, where Z is halogen.
- a “trihalomethanesulfonyl” group refers to a Z 3 CS(O) 2 — group, where Z is halogen.
- a “trihalomethyl” group refers to a —CZ 3 group, where Z is halogen.
- substituted means that the specified group or moiety bears one or more substituents.
- unsubstituted means that the specified group bears no substituents.
- optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents. It is to be understood that in the compounds of the present invention when a group is said to be “unsubstituted,” or is “substituted” with fewer groups than would fill the valencies of all the atoms in the compound, the remaining valencies on such a group are filled by hydrogen.
- a C 6 aryl group also called “phenyl” herein
- phenyl is substituted with one additional substituent
- one of ordinary skill in the art would understand that such a group has 4 open positions left on carbon atoms of the C 6 aryl ring (6 initial positions, minus one to which the remainder of the compound of the present invention is bonded, minus an additional substituent, to leave 4). In such cases, the remaining 4 carbon atoms are each bound to one hydrogen atom to fill their valencies.
- a C 6 aryl group in the present compounds is said to be “disubstituted,” one of ordinary skill in the art would understand it to mean that the C 6 aryl has 3 carbon atoms remaining that are unsubstituted. Those three unsubstituted carbon atoms are each bound to one hydrogen atom to fill their valencies.
- solvate is used to describe a molecular complex between compounds of the present invention and solvent molecules.
- examples of solvates include, but are not limited to, compounds of the invention in combination with water, isopropanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof.
- DMSO dimethylsulfoxide
- hydrate can be used when said solvent is water. It is specifically contemplated that in the present invention one solvent molecule can be associated with one molecule of the compounds of the present invention, such as a hydrate. Furthermore, it is specifically contemplated that in the present invention, more than one solvent molecule may be associated with one molecule of the compounds of the present invention, such as a dihydrate.
- solvates of the present invention are contemplated as solvates of compounds of the present invention that retain the biological effectiveness of the non-hydrate form of the compounds.
- pharmaceutically acceptable salt means a salt of a compound of the present invention that retains the biological effectiveness of the free acids and bases of the specified derivative and that is not biologically or otherwise undesirable.
- pharmaceutically acceptable formulation means a combination of a compound of the invention, or a salt or solvate thereof, and a carrier, diluent, and/or excipient(s) that are compatible with a compound of the present invention, and is not deleterious to the recipient thereof.
- Pharmaceutical formulations can be prepared by procedures known to those of ordinary skill in the art.
- the compounds of the present invention can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, and the like.
- excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as povidone, sodium starch glycolate, sodium carboxymethylcellulose, agar, calcium carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate and solid polyethylene glycols.
- Final pharmaceutical forms may be pills, tablets, powders, lozenges, saches, cachets, or sterile packaged powder
- compositions of the present invention can contain more than one active ingredient.
- such formulations may contain more than one compound according to the present invention.
- such formulations may contain one or more compounds of the present invention and one or more additional agents that reduce abnormal cell growth.
- Arenavirus GP-inhibiting amount refers to the amount of a compound of the present invention, or a salt or solvate thereof, required to inhibit the cell entry of Arenaviruses in vivo, such as in a mammal, birds or in vitro.
- the amount of such compounds required to cause such inhibition can be determined without undue experimentation using methods described herein and those known to those of ordinary skill in the art.
- a therapeutically effective amount means an amount of a compound of the present invention, or a salt thereof, that, when administered to a mammal in need of such treatment, is sufficient to effect treatment, as defined herein.
- a therapeutically effective amount of a compound of the present invention, or a salt thereof is a quantity sufficient to modulate or inhibit the activity of the Arenavirus GP protein such that cell entry and replication of arenaviruses that is mediated by activity of the Arenavirus GP protein is reduced or alleviated.
- treat with reference to arenavirus infection, in mammals, particularly a human, include: (i) preventing the disease or condition from occurring in a subject which may be predisposed to the condition, such that the treatment constitutes prophylactic treatment for the pathologic condition; (ii) modulating or inhibiting the disease or condition, i.e., arresting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or (iv) relieving and/or alleviating the disease or condition or the symptoms resulting from the disease or condition.
- references herein to the inventive compounds include references to salts, solvates, and complexes thereof, including polymorphs, stereoisomers, tautomers, and isotopically labeled versions thereof.
- compounds of the present invention can be pharmaceutically acceptable salts and/or pharmaceutically acceptable solvates.
- stereoisomers refers to compounds that have identical chemical constitution, but differ with regard to the arrangement of their atoms or groups in space.
- enantiomers refers to two stereoisomers of a compound that are non-superimposable mirror images of one another. A pure enantiomer can be contaminated with up to 2% of the opposite enantiomer.
- racemic or “racemic mixture,” as used herein, refer to a 1:1 mixture of enantiomers of a particular compound.
- diastereomers refers to the relationship between a pair of stereoisomers that comprise two or more asymmetric centers and are not mirror images of one another.
- the symbol is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.
- the carbon atoms and their bound hydrogen atoms are not explicitly depicted, e.g.,
- the compounds of the present invention may have asymmetric carbon atoms.
- the carbon-carbon bonds of the compounds of the present invention may be depicted herein using a solid line (-), a solid wedge ( ), or a dotted wedge ( ).
- the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g., specific enantiomers, racemic mixtures, etc.) at that carbon atom are included.
- the use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom.
- a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included.
- the compounds of the present invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof.
- the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
- a substituent “R” may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.
- enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the reacemate using, for example, chiral high pressure liquid chromatography (HPLC).
- HPLC high pressure liquid chromatography
- the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine.
- a suitable optically active compound for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine.
- the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art.
- Chiral compounds of the invention may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.
- Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art. See, e.g., “Stereochemistry of Organic Compounds” by E L Eliel (Wiley, New York, 1994), the disclosure of which is incorporated herein by reference in its entirety.
- a compound of the invention contains an alkenyl or alkenylene group
- geometric cis/trans (or Z/E) isomers are possible.
- the compound contains, for example, a keto or oxime group or an aromatic moiety
- tautomeric isomerism (‘tautomerism’) can occur.
- tautomerism include keto and enol tautomers.
- a single compound may exhibit more than one type of isomerism. Included within the scope of the invention are all stereoisomers, geometric isomers and tautomeric forms of the inventive compounds, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof.
- Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallization.
- the compounds of the present invention may be administered as prodrugs.
- certain derivatives of compounds of Formula I which may have little or no pharmacological activity themselves can, when administered to a mammal, be converted into a compound of Formula (I) having the desired activity, for example, by hydrolytic cleavage.
- Such derivatives are referred to as “prodrugs”.
- Prodrugs can, for example, be produced by replacing appropriate functionalities present in the compounds of Formula I with certain moieties known to those skilled in the art. See, e.g., “Prodrugs as Novel Delivery Systems”, Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987 (ed.
- prodrugs include: an ester moiety in the place of a carboxylic acid functional group; an ether moiety or an amide moiety in place of an alcohol functional group; and an amide moiety in place of a primary or secondary amino functional group.
- replacement groups are known to those of skill in the art. See, e.g., “Design of Prodrugs” by H Bundgaard (Elsevier, 1985), the disclosure of which is incorporated herein by reference in its entirety. It is also possible that certain compounds of Formula I may themselves act as prodrugs of other compounds of Formula I.
- Salts of the present invention can be prepared according to methods known to those of skill in the art.
- Examples of salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, and methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, heptanoate, hex
- the compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
- the acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially equivalent amount of the selected mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon evaporation of the solvent, the desired solid salt is obtained.
- the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding an appropriate mineral or organic acid to the solution.
- Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
- such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
- the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention.
- Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc.
- salts can be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
- they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
- stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
- the desired salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalicacid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
- an inorganic acid such as hydrochloric acid, hydrobro
- the desired salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
- an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
- suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
- the invention also includes isotopically-labeled compounds of the invention, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulfur, such as 35 S.
- isotopically-labeled compounds of the invention for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
- the radioactive isotopes tritium, ( 3 H) and carbon-14, ( 14 C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Substitution with heavier isotopes such as deuterium, 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, for example, 35 S increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
- compositions of the invention comprise a therapeutically effective amount of at least one compound of the present invention and an inert, pharmaceutically acceptable carrier or diluent.
- a pharmaceutical composition of the invention is administered in a suitable formulation prepared by combining a therapeutically effective amount (i.e., an arenavirus GP modulating, regulating, or inhibiting amount effective to achieve therapeutic efficacy) of at least one compound of the present invention (as an active ingredient) with one or more pharmaceutically suitable carriers, which may be selected, for example, from diluents, excipients and auxiliaries that facilitate processing of the active compounds into the final pharmaceutical preparations.
- a therapeutically effective amount i.e., an arenavirus GP modulating, regulating, or inhibiting amount effective to achieve therapeutic efficacy
- one compound of the present invention as an active ingredient
- pharmaceutically suitable carriers which may be selected, for example, from diluents, excipients and auxiliaries that facilitate processing of the active compounds into the final pharmaceutical preparations.
- the pharmaceutical carriers employed may be either solid or liquid.
- Exemplary solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
- Exemplary liquid carriers are syrup, peanut oil, olive oil, water and the like.
- the inventive compositions may include time-delay or time-release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like. Further additives or excipients may be added to achieve the desired formulation properties.
- a bioavailability enhancer such as Labrasol, Gelucire or the like, or formulator, such as CMC (carboxymethyl cellulose), PG (propyleneglycol), or PEG (polyethyleneglycol), may be added.
- CMC carboxymethyl cellulose
- PG propyleneglycol
- PEG polyethyleneglycol
- Gelucire® a semi-solid vehicle that protects active ingredients from light, moisture and oxidation, may be added, e.g., when preparing a capsule formulation.
- the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or formed into a troche or lozenge.
- the amount of solid carrier may vary, but generally, will be from about 25 mg to about 1 g.
- the preparation may be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampoule or vial or non-aqueous liquid suspension.
- a semi-solid carrier is used, the preparation may be in the form of hard and soft gelatin capsule formulations.
- the inventive compositions are prepared in unit-dosage form appropriate for the mode of administration, e.g., parenteral or oral administration.
- a salt of a compound of the present invention may be dissolved in an aqueous solution of an organic or inorganic acid, such as a 0.3 M solution of succinic acid or citric acid.
- the agent may be dissolved in a suitable co-solvent or combinations of co-solvents.
- suitable co-solvents include alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in concentrations ranging from 0 to 60% of the total volume.
- a compound of the present invention is dissolved in DMSO and diluted with water.
- the composition may also be in the form of a solution of a salt form of the active ingredient in an appropriate aqueous vehicle such as water or isotonic saline or dextrose solution.
- the agents of the compounds of the present invention may be formulated into aqueous solutions, preferably in physiologically compatible buffers such as Hanks solution, Ringer's solution, or physiological saline buffer.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art.
- the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers known in the art.
- Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
- Pharmaceutical preparations for oral use can be obtained using a solid excipient in admixture with the active ingredient (agent), optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, or polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as crosslinked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- concentrated sugar solutions may be used, which may optionally contain gum arabic, polyvinylpyrrolidone, Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agents.
- compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and, optionally, stabilizers.
- the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
- the compositions may take the form of tablets or lozenges formulated in conventional manner.
- the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of gelatin for use in an inhaler or insufflator and the like may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit-dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- a suitable vehicle e.g., sterile pyrogen-free water
- the compounds of the present invention may also be formulated as a depot preparation.
- Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- a pharmaceutical carrier for hydrophobic compounds is a co-solvent system comprising benzyl alcohol, a non-polar surfactant, a water-miscible organic polymer, and an aqueous phase.
- the co-solvent system may be a VPD co-solvent system.
- VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the non-polar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
- the VPD co-solvent system (VPD: 5W) contains VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration.
- the proportions of a co-solvent system may be suitably varied without destroying its solubility and toxicity characteristics.
- co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinylpyrrolidone; and other sugars or polysaccharides may be substituted for dextrose.
- hydrophobic pharmaceutical compounds may be employed.
- Liposomes and emulsions are known examples of delivery vehicles or carriers for hydrophobic drugs.
- Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity due to the toxic nature of DMSO.
- the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
- sustained-release materials have been established and are known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.
- additional strategies for protein stabilization may be employed.
- the pharmaceutical compositions also may comprise suitable solid- or gel-phase carriers or excipients.
- These carriers and excipients may provide marked improvement in the bioavailability of poorly soluble drugs.
- Examples of such carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- additives or excipients such as Gelucire®, Capryol®, Labrafil®, Labrasol®, Lauroglycol®, Plurol®, Peceol®, Transcutol® and the like may be used.
- the pharmaceutical composition may be incorporated into a skin patch for delivery of the drug directly onto the skin.
- an exemplary daily dose generally employed will be from about 0.001 to about 1000 mg/kg of body weight, with courses of treatment repeated at appropriate intervals.
- the pharmaceutically acceptable formulations of the present invention may contain a compound of the present invention, or a salt or solvate thereof, in an amount of about 10 mg to about 2000 mg, or from about 10 mg to about 1500 mg, or from about 10 mg to about 1000 mg, or from about 10 mg to about 750 mg, or from about 10 mg to about 500 mg, or from about 25 mg to about 500 mg, or from about 50 to about 500 mg, or from about 100 mg to about 500 mg.
- the pharmaceutically acceptable formulations of the present invention may contain a compound of the present invention, or a salt or solvate thereof, in an amount from about 0.5 w/w % to about 95 w/w %, or from about 1 w/w % to about 95 w/w %, or from about 1 w/w % to about 75 w/w %, or from about 5 w/w % to about 75 w/w %, or from about 10 w/w % to about 75 w/w %, or from about 10 w/w % to about 50 w/w %.
- the compounds of the present invention may be administered to a mammal, such as a human, suffering from a condition or disease mediated by arenavirus, either alone or as part of a pharmaceutically acceptable formulation, once a day, twice a day, three times a day, four times a day, or even more frequently.
- the compounds of the present invention may be administered to a mammal, such as a human, suffering from a condition or disease mediated by arenavirus in combination with at least one other agent used for treatment of arenavirus selected from the group consisting of Ribavirin, viral RNA-dependent-RNA-polymerase inhibitors as shown by Ng K K, Arnold J J and Cameron C E, Structure - Function Relationships Among RNA - Dependent RNA Polymerases , Curr Top Microbiol Immunol, 2008; 320: 137-156, incorporated herein by reference in its entirety, Favipiravir, a broad-spectrum inhibitor of viral RNA-Dependent RNA Polymerases, Triazavirin, a broad-spectrum inhibitor of viral RNA-Dependent RNA Polymerases, small interfering RNAs (siRNAs) and microRNAs as shown by Carthew R W and Sontheimer E J, Origins and Mechanisms of miRNAs and si
- the compounds of the present invention are useful for modulating or inhibiting arenavirus GP.
- these compounds are useful for the prevention and/or treatment of disease states associated with arenavirus infection.
- This invention also relates to a method for the treatment of arenavirus infection including a human comprising administering to said mammal an amount of a compound of the Formula I, as defined above, or a salt or solvate thereof, that is effective in treating disease states associated with Arenavirus infection.
- Scheme 1 shows a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, J and L are N, and K is C—R 3 .
- Reduction of the nitro group using a reducing agent such as Fe or SnCl 2 in a solvent such as THE or methanol can provide aniline 1-3 which can be reacted with ester R 3 CO 2 R or orthoester R 3 C(OR) 3 to form 1-4.
- Coupling of 1-4 with a boronic acid or boronic ester R 1 B(OR) 2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K 2 CO 3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 2 shows a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, E, J and L are N, and K is C—R 3 .
- a palladium catalyst such as Pd(dba) 3 [A. Rosenberg, J. Zhao, D. A. Clark, Org. Lett. 14, 2012, 1764-1767].
- Coupling of 2-5 with a boronic acid or boronic ester R 1 B(OR) 2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K 2 CO 3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 3 depicts an alternative method useful for the synthesis of compounds of structural Formula I wherein G, and H are C, J and L are N, and K is C—R 3 .
- Scheme 4 displays a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, J is N, and K and L are independently C—R 3 .
- Coupling of 4-2 with a boronic acid or boronic ester R 1 B(OR) 2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K 2 CO 3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 5 shows a method useful for the synthesis of compounds of structural Formula I wherein G, H, and J are C, K is C—R 3 , and L is N—R 3 .
- Coupling of 5-2 with a boronic acid or boronic ester R 1 B(OR) 2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K 2 CO 3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 6 shows a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, J and K are N, and L is C—R 3 .
- a base such as NaH or Cs 2 CO 3 in a solvent such as THF or DMF
- Scheme 7 depicts a method useful for the synthesis of compounds of structural Formula I wherein G, H, and J are C, K is N, and L is NR 3 .
- a catalyst such as tetrakis(triphenylphosphine)palladium
Abstract
Description
- This patent application is a divisional of U.S. patent application Ser. No. 16/309,858, filed Dec. 13, 2018, which is continuation-in-part of and claims the benefit of priority to PCT/US2017/041218, filed Jul. 7, 2017, which is a continuation-in-part of and claims the benefit of priority to U.S. Provisional Patent Application Ser. Nos. 62/361,423, filed Jul. 12, 2016 and 62/378,177, filed Aug. 22, 2016, all applications are herein incorporated by reference in their entirety and for all purposes.
- This invention was made with government support under R44 All 12097 awarded by U.S. National Institutes of Health. The government has certain rights in the invention.
- NOT APPLICABLE
- The present invention relates to the use of heterocyclic compounds for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.
- Arenaviridae comprise a diverse family of 29 (and growing) negative stranded enveloped RNA viruses. Arenaviruses are divided into two groups, Old and New World complex, based on serological, genetic and geographical data. Old World viruses are found primarily throughout South and West Africa and include the prototypic lymphocytic choriomeningitis virus (LCMV), along with Lassa (LASV), Lujo (LUJV), Mopeia (MOPV), Ippy and Mobala (MOBV) viruses. Both LASV and LUJV can cause lethal hemorrhagic fever (HF), while LCMV infection is associated with aseptic meningitis. Lassa (LASV) alone is estimated to cause over 300,000 disease cases each year in West Africa of which 15-20% of hospitalized patients die and survivors often suffer sequelae, including permanent bilateral hearing damage. The larger New World complex primarily located in the South American continent, is divided into 3 clades, A, B, and C, with clade B being important as many of the viruses in this group can cause lethal HF. Clade B HF viruses include, Junin (JUNV), Machupo (MACV), Guanarito (GTOV), Sabia (SABV) and Chapare, along with non-HF viruses such as Tacaribe (TCRV) and Amapari (AMPV). Human infection occurs through contact with the excretions of an infected rodent or by inhalation of tiny particles soiled with rodent urine or saliva (aerosol transmission). There is also evidence of human-to-human spread primarily in nosocomial settings (e.g., hospitals). Incubation period of virus is 1-2 weeks followed by fever, general malaise, weakness, sore throat, headache, cough, diarrhea, and vomiting. These general symptoms make it difficult to differentially diagnose arenavirus infection. Poor prognosis is indicated as symptoms worsen to include pleural effusions, facial edema, neurological complications and bleeding from mucosal surfaces. Current arenavirus treatment is limited to the use of ribavirin, which is only partially effective if given early and associated with significant side effects. Although a vaccine has been developed for Junin virus its usage is primarily restricted to the most at risk populations of farm workers in Argentina and there are no approved vaccines for any other arenaviruses. Although highly desirable, prophylactic vaccines may not always be effective countermeasures against rapidly emerging, antigenically distinct new virus strains and the existing vaccine development and production strategies cannot adequately respond to the diverse family of current or emergent arenaviruses. Novel broad-spectrum antiviral drugs could therefore provide a first line therapy and/or prophylactic, not only for endemic regions of arenavirus infection but also as a safeguard against potential biological warfare agents.
- Arenaviruses consist of a nucleocapsid (NP) surrounded by an envelope membrane, and the NP contains two ambisense RNA genome segments L and S that direct the synthesis of two polypeptides. The L segment encodes the RNA-dependent-RNA polymerase (RdRp) and a small Ring Finger protein Z. The S segment encodes for nucleoprotein and a glycoprotein precursor GPC that is cleaved by host proteases and undergoes post-translational modification into a mature complex composed of glycoproteins GP1 (binds host protein at the cell surface), GP2 (directs pH dependent membrane fusion and release ofgenomic material in the cytoplasm) and a stable signal peptide (SSP1). The mature glycoprotein complex (GP) is formed in the viral envelope and is responsible for mediating viral entry. The Old World arenaviruses bind to host α-dystroglycan while New World arenaviruses bind to transferrin receptor 1 for entry/endocytosis into cells. Upon binding to cell surface receptors, the virus is endocytosed and directed to acidic late endosomes whereby GP2 mediates pH dependent membrane fusion and release of genomic material into the cytoplasm for viral replication and transcription. Therefore, viral entry inhibitors (e.g., small molecules) that target virus GP complex or host factors are a potential therapeutic/prophylactic approach in treating patients infected with arenavirus infection. Because the HF arenavirus species are classified as BSL-4, alternative approaches are needed to identify viral entry inhibitors. To facilitate the identification of arenavirus entry inhibitors one may express arenavirus GP complex in nonpathogenic BSL-2 envelope viruses, to produce single round infectious pseudoviruses whose viral entry functions are determined by the heterogeneous glycoprotein of interest. One viral expression system that may be utilized is the vesicular stomatitis virus (VSV) system, whereby the envelope protein of VSV is substituted with an envelope glycoprotein from another virus, e.g., LASV, to mediate entry of the pseudotype virion. The cell entry and infectivity properties of GP pseudotype VSV viruses have been shown for multiple viruses including HIV, Hepatitis B and C, Ebola, Lassa, Hanta and others [Ogino, M., et al. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin. Diagn. Lab. Immunol. (2003) 10(1):154-60; Saha, M. N., et al. Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus. J. Virol. (2005) 79(19):12566-74; Takada, A., et al. A system for functional analysis of Ebola virus glycoprotein, Proc. Natl. Acad. Sci. (1997) 94:14764-69; Garbutt, M., et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. (2004) 78(10):5458-65]. To monitor pseudovirus infection, a reporter gene such as green fluorescent protein (GFP) or luciferase can be engineered into the pseudovirus genome, and virus infectivity in mammalian cell lines (e.g. Vero or Hek293) can be monitored using optical detection methods (e.g. plate reader) [Cote, M.; Misasi, J.; Ren, T.; Bruchez, A., Lee, K., Filone, C. M.; Hensley, L.; Li, Q.; Ory, D.; Chandran, K.; Cunningham, J., Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection, Nature (2011) 477: 344-348, Elshabrawy, H. A., et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome Coronavirus and Ebola, Hendra, and Nipah Viruses by using a novel high-throughput screening assay. J. Virol. (2014) 88: 4353-4365]. The “pseudoviruses” may therefore be used to screen chemical compound libraries to identify inhibitors of arenavirus cell entry while avoiding the complications of working with highly pathogenic BSL-4 agents. In the present invention, entry inhibitors described were identified using an arenavirus GP pseudovirus screen and selected compounds were tested against native non-HF virus TCRV to confirm activity against replicative arenavirus. Selected top compounds were then tested against native HF viruses including LASV and JUNV to confirm activity against the native highly pathogenic human (HF) arenaviruses.
- The present invention relates to the use of heterocyclic compounds for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.
- In one embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I
- or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are independently N or C;
- K and L are independently N, O, S, N—R3, or C—R3;
- and A, D, E, G, H, J, K, and L together cannot have more than 4 N;
- R1 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- each of the R3 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —C(O)NR6aR6b, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —(CH2)nC(O)OR5, —(CH2)nC(O)NR6aR6b, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR5aR5b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R4 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —C(O)NR6aR6b, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —(CH2)nC(O)OR5, —(CH2)nC(O)NR6aR6b, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R5 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R6a, R6b, and R6c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl,
- or R6a and R6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R7 group;
- R7 is independently selected from hydrogen, halogen, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, cyano, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R8, —C(O)NR9aR9b, —NR9aR9b, —S(O)mR8, —S(O)mNR9aR9b, —NR9aS(O)mR8, —(CH2)nC(O)ORB, —(CH2)nC(O)N(R9aR9b), —OC(O)R8, —NR9aC(O)R8, and —NR9aC(O)N(R9aR9b), wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, is optionally substituted with at least one R10 group;
- each of the R8 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R10 group;
- each of the R9a, R9b, and R9c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl,
- or R9a and R9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted;
- R10 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted.
- The present invention relates to the use of heterocyclic compounds for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare, and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.
- In one embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I
- or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are independently N or C;
- K and L are independently N, O, S, N—R3, or C—R3;
- and A, D, E, G, H, J, K, and L together cannot have more than 4 N;
- R1 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- each of the R3 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —C(O)NR6aR6b, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —(CH2)nC(O)OR5, —(CH2)nC(O)NR6aR6b, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR5aR5b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R4 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —C(O)NR6aR6b, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —(CH2)nC(O)OR5, —(CH2)nC(O)NR6aR6b, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R5 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R6a, R6b, and R6c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl,
- or R6a and R6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R7 group;
- R7 is independently selected from hydrogen, halogen, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, cyano, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R8, —C(O)NR9aR9b, —NR9aR9b, —S(O)mR8, —S(O)mNR9aR9b, —NR9aS(O)mR8, —(CH2)nC(O)ORB, —(CH2)nC(O)N(R9aR9b), —OC(O)R8, —NR9aC(O)R8, and —NR9aC(O)N(R9aR9b), wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, is optionally substituted with at least one R10 group;
- each of the R8 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R10 group;
- each of the R9a, R9b, and R9c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl,
- or R9a and R9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted;
- R10 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted;
- m is 0, 1, or 2;
- n is 0, 1, 2, 3, 4, 5, or 6.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are independently N or C;
- K and L are independently N, O, S, N—R3, or C—R3;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein R3 and R4 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are independently N or C—R3;
- G, H, and J are independently N or C;
- L is N, N—R3, or C—R3;
- and A, D, E, G, H, J, K, and L together cannot have more than 4 N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, R2, and R3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, R2, and R3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy, surprisingly providing improved metabolic stability in multi-species microsomal assays.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein R3 is defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and H are C;
- J and L are N;
- K is C—R3;
- R1 is selected from (C1 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, R2, and R3 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen;
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein G and H are C, J and L are N, A, D, E, and K are independently C—R3, and R1 is defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein G and H are C, A, J, and L are N, and D, E, and K are independently C—R3, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein G and H are C, D, J and L are N, and A, E, and K are independently C—R3, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein G and H are C, A, D, J, and L are N, and E and K are independently C—R3, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, and E are independently N or C—R3, G and H are C, J is N, and K and L are independently CR3, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, and E are independently N or C—R3, G and H are C, J and K are N, and L is CR3, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, and E are independently N or C—R3, G, H and J are C, K and L are independently N or NR3, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and J are C;
- H and L are N;
- K is C—R3;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen;
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, and E are independently C—R3, G and J are C, H and L are N, K is C—R3, and R1 is define as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein D and E are independently C—R3, G and J are C, A, H, and L are N, K is C—R3, and R1 is defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein D and E are independently C—R3, G and J are C, A, H, and L are N, K is C—R3, and R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A and D are independently C—R3, G and J are C, E, H, and L are N, and K is C—R3, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3:
- G and H are C;
- J, K, and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen;
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R3;
- G and H are C;
- J, K, and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R3;
- G and J are C;
- H, K, and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein (C2 to C9) heteroaryl is C-attached;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, and R1 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R2 is selected from the group consisting of
- wherein
- R4b is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, and —C(O)R5, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, A, D, E, G, H, J, K, L, R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and H are C;
- J and L are N;
- K is C—R3.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are independently C—R3;
- G and H are C;
- J and L are N.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R3;
- G and H are C;
- J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are C—H;
- G and H are C;
- J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are independently C—R3;
- G and H are C;
- J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-alkoxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are C—H;
- G and H are C;
- J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-alkoxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R3;
- G and H are C;
- J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-isopropyloxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E, and K are C—H;
- G and H are C;
- J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-isopropyloxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are independently C—R3;
- G and H are C;
- A, J and L are N.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are independently C—R3;
- G and H are C;
- A, J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are C—H;
- G and H are C;
- A, J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are independently C—R3;
- G and H are C;
- A, J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-alkoxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are C—H;
- G and H are C;
- A, J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-alkoxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are independently C—R3;
- G and H are C;
- A, J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-isopropyloxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D, E, and K are C—H:
- G and H are C;
- A, J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-isopropyloxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and H are C;
- J is N;
- K and L are independently C—R3.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are C;
- K is C—R3;
- L is N—R3.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and H are C;
- J and K are N;
- L is C—R3.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are C;
- K is N;
- L is N—R3.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and J are C;
- H and L are N;
- K is C—R3.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R3;
- G and J are C;
- H and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are C—H;
- G and J are C;
- H and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R3;
- G and J are C;
- H and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-alkoxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are C—H;
- G and J are C;
- H and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-alkoxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are independently C—R3;
- G and J are C;
- H and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-isopropyloxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, E and K are C—H;
- G and J are C;
- H and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group;
- R2 is 4-isopropyloxyphenyl.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and J are C;
- H and K are N;
- L is CR3.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- H and J are C;
- G and K are N;
- L is C—R3.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and J are C;
- H, K, and L are N.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and H are C;
- J, K, and L are N.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are C;
- K is C—R3;
- L is O.
- In another embodiment, the method comprises administering to humans, other mammals, cell culture, or biological sample an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are C;
- K is O;
- L is N.
- In another embodiment, the invention relates to compounds of Structural Formula I
- or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are independently N or C;
- K is N or C—H;
- L is N, N—R3, or C—R3;
- and A, D, E, G, H, J, K, and L together cannot have more than 4 N;
- R1 is selected from (C1 to C10) aryl and (C2 to C9) heteroaryl, and 5-indolyl, wherein
- each of the said (C1 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached;
- with the proviso that R1 is not selected from the group consisting of substituted 3-carbamoyl-2-phenyl-1-benzofuran-5-yl, substituted 1,3,4-oxadiazolyl, substituted 1,3,4-triazolyl, substituted 1,3,4-thiadiazolyl, substituted oxazoyl, substituted thiazoyl, substituted 1H-pyrazol-4-yl, substituted 1H-pyrazol-5-yl, optionally substituted 1-phenyl-1H-imidazol-5-yl, 4-{[(2-aminoethyl)amino]methyl}phenyl, (2-amino-1,3-benzoxazol)-5-yl; (2-amino-1,3-benzoxazol)-4-yl, 2-chloropyridyl-3-yl, 2-methylpyridinyl-4-yl, 2-fluoropyridyl-4-yl, 6-aminopyridyl-3-yl, 6-methoxypyridyl-3-yl, pyridyl-4-yl-N-oxide, 3,4-difluorophenyl, and substituted 1H-pyrrol-3-yl;
- R2 is selected from the group consisting of
- each of the R3 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —C(O)NR6aR6b, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —(CH2)nC(O)OR5, —(CH2)nC(O)NR6aR6b, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR5aR5b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- R4a is independently selected from halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, surprisingly providing broad spectrum activity against multiple arenavirus strains,
- and we believe that similar broad spectrum activity against multiple arenavirus strains can be observed when R4b is selected from the group consisting of
- n-propyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, cyclobutyloxy, cyclopentyloxy, (1-hydroxycyclopentan)-1-yl, hydroxyethoxy, ethoxyethoxy, isopropoxyethoxy, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, cyclobutyl, cyclopentyl, tert-butyl, propanoyl, isobutanoyl, sec-butanoyl, tert-butanoyl, cyclopropanoyl, cyclobutanoyl, and cyclopentanoyl;
- each of the R5 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R6a, R6b, and R6c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl,
- or R6a and R6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R7 group;
- R7 is independently selected from hydrogen, halogen, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, cyano, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R8, —C(O)NR9aR9b, —NR9aR9b, —S(O)mR8, —S(O)mNR9aR9b, —NR9aS(O)mR8, —(CH2)nC(O)ORB, —(CH2)nC(O)N(R9aR9b), —OC(O)R8, —NR9aC(O)R8, and —NR9aC(O)N(R9aR9b), wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, is optionally substituted with at least one R10 group;
- each of the R8 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R10 group;
- each of the R9a, R9b, and R9c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl,
- or R9a and R9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted;
- R10 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted;
- m is 0, 1, or 2;
- n is 1, 2, 3, 4, 5, or 6.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R3 is hydrogen;
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and H are C;
- J and L are N;
- K is C—H.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen;
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein G and H are C, J and L are N, K is C—H, and R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R3.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D and E are independently C—R3;
- G and H are C;
- A, J, and L are N;
- K is C—H.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A and E are independently C—R3;
- G and H are C;
- D, J, and L are N;
- K is C—H.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- E is C—R3;
- G and H are C;
- K is C—H;
- A, D, J, and L are N.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and H are C;
- J is N;
- K is C—H;
- L is C—R3.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and H are C;
- J and K are N;
- L is C—R3.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G, H, and J are C;
- K is N;
- L is N—R3.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and J are C;
- H and L are N;
- K is C—H.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein G and J are C; H and L are N, K is C—H, and R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R3.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- D and E are independently C—R3;
- A, H, and L are N;
- K is C—H;
- G and J are C.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A and D are independently C—R3;
- G and J are C;
- K is C—H;
- E, H, and L are N.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- G and J are C;
- J, K, and L are N.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein G and H are C, J, K, and L are N, and R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R3.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently C—R3,
- G and J are C;
- H, K, and L are N.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1, and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R3 is hydrogen.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein A, D, E, G, H, J, K, L, R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- R4b is isopropoxy.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- A, D, and E are independently N or C—R3;
- H and J are C;
- G and K are N;
- L is C—R3.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- A, D, and E are independently N or C—R3;
- G, H, and J are C;
- K is C—H;
- L is O.
- In another embodiment, the invention relates to compounds of Structural Formula I, wherein R1 and R2 are defined as above, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- A, D, and E are independently N or C—R3;
- G, H, and J are C;
- K is N;
- L is O.
- In another embodiment, the invention relates to compounds of Structural Formula I
- or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- A, D, E, and K are C—H;
- G and H are C;
- J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4a group,
- with the proviso that R1 is not selected from the group consisting of optionally substituted 3-carbamoyl-2-phenyl-1-benzofuran-5-yl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted 1H-pyrazol-4-yl, optionally substituted 1-phenyl-1H-pyrazol-5-yl, optionally substituted 1-phenyl-1H-imidazol-5-yl, 4-{[(2-aminoethyl)amino]methyl}phenyl, and (2-amino-1,3-benzoxazol)-5-yl;
- R2 is
- R4a is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- R4b is selected from halogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —C(O)NR6aR6b, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —(CH2)nC(O)OR5, —(CH2)nC(O)NR6aR6b, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R5 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
-
- each of the R6, R6b, and R6c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl,
- or R6a and R6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R7 group;
- R7 is independently selected from hydrogen, halogen, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, cyano, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R8, —C(O)NR9aR9b, —NR9aR9b, —S(O)mR8, —S(O)mNR9aR9b, —NR9aS(O)mR8, —(CH2)nC(O)ORB, —(CH2)nC(O)N(R9aR9b), —OC(O)R8, —NR9aC(O)R8, and —NR9aC(O)N(R9aR9b), wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, is optionally substituted with at least one R10 group;
- each of the R8 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R10 group;
- each of the R9a, R9b, and R9c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl,
- or R9a and R9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted;
- R10 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted;
- m is 0, 1, or 2;
- n is 1, 2, 3, 4, 5, or 6;
- with the proviso that the following compound is excluded:
-
- In another embodiment, the invention relates to compounds of Structural Formula I
- or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- D, E, and K are C—H:
- G and H are C;
- A, J and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4a group,
- with the proviso that R1 is not selected from the group consisting of optionally substituted 3-carbamoyl-2-phenyl-1-benzofuran-5-yl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted 1H-pyrazol-4-yl, optionally substituted 1-phenyl-1H-pyrazol-5-yl, optionally substituted 1-phenyl-1H-imidazol-5-yl, and (2-amino-1,3-benzoxazol)-5-yl;
- R2 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is optionally substituted with at least one R4b group,
- R4a is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- R4b is independently selected from halogen, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —C(O)NR6aR6b, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —(CH2)nC(O)OR5, —(CH2)nC(O)NR6aR6b, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R5 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R6a, R6b, and R6c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl,
- or R6a and R6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R7 group;
- R7 is independently selected from hydrogen, halogen, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, cyano, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R8, —C(O)NR9aR9b, —NR9aR9b, —S(O)mR8, —S(O)mNR9aR9b, —NR9aS(O)mR8, —(CH2)nC(O)ORB, —(CH2)nC(O)N(R9aR9b), —OC(O)R8, —NR9aC(O)R8, and —NR9aC(O)N(R9aR9b), wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, is optionally substituted with at least one R10 group;
- each of the R8 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R10 group;
- each of the R9a, R9b, and R9c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl,
- or R9a and R9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted;
- R10 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted;
- m is 0, 1, or 2;
- n is 1, 2, 3, 4, 5, or 6;
- with the proviso that the following compound is excluded:
- 3,5-dipyridin-2-yl-3H-imidazo[4,5-b]pyridine
- In another embodiment, the invention relates to compounds of Structural Formula I
- or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein
- A, D, E, and K are CH;
- G and J are C;
- H and L are N;
- R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, wherein
- each of the said (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4a group with the proviso that
- R1 is not selected from the group consisting of optionally substituted 3-carbamoyl-2-phenyl-1-benzofuran-5-yl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted 1H-pyrazol-4-yl, optionally substituted 1-phenyl-1H-pyrrol-2-yl, optionally substituted 1-phenyl-1H-pyrazol-5-yl, optionally substituted 1-phenyl-1H-imidazol-5-yl, 2-(4-fluoro-3-methylphenyl)pyridin-3-yl, and (2-amino-1,3-benzoxazol)-5-yl;
- R2 is
- R4a is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R5, —NR6aR6b, —S(O)mR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- R4b is selected from the group consisting of
- CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, —C(O)R5, —C(O)NR6aR6b, —NR6aR6b, —SR5, —S(O)mNR6aR6b, —NR6aS(O)mR5, —(CH2)nC(O)OR5, —(CH2)nC(O)NR6aR6b, —OC(O)R5, —NR6aC(O)R5, and —NR6cC(O)NR6aR6b, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group,
- with the proviso when
- R4b is selected from the group consisting of isopropylthio, morpholin-4-yl, thiomorpholine-1,1-dione-4-yl, and amino,
- then R1 is not selected from the group consisting of
- and with the proviso when
- R4b is selected from the group consisting of 2-hydroxyethoxy, 2-(oxan-2-yloxy)ethoxy, 2-(oxan-4-yloxy)ethoxy, and 2-(oxan-4-yloxy)ethylamino,
- then R1 is not selected from the group consisting of 1H-pyrrol-3-yl, 1H-pyrazol-1yl, 1H-imidazol-1-yl, 4-pyridin-1-yl, 1-methyl-1H-methyl-pyrazol-4-yl, and 1,3-oxazol-2-yl;
- each of the R5 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R7 group;
- each of the R6a, R6b, and R6C are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl,
- or R6a and R6b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted with at least one R7 group;
- R7 is independently selected from hydrogen, halogen, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, cyano, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl, —C(O)R8, —C(O)NR9aR9b, —NR9aR9b, —S(O)mR8, —S(O)mNR9aR9b, —NR9aS(O)mR8, —(CH2)nC(O)ORB, —(CH2)nC(O)N(R9aR9b), —OC(O)R8, —NR9aC(O)R8, and —NR9aC(O)N(R9aR9b), wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, is optionally substituted with at least one R10 group;
- each of the R8 is independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R10 group;
- each of the R9a, R9b, and R9c are independently selected from hydrogen, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, (C2 to C9) heteroaryl,
- or R9a and R9b may be taken together with the nitrogen atom to which they are attached to form a 4 to 8 membered cycloheteroalkyl ring, wherein
- said 4 to 8 membered cycloheteroalkyl ring has 1 to 3 ring heteroatoms selected from the group consisting of N, O, and S, and wherein
- the said 4 to 8 membered cycloheteroalkyl ring is optionally substituted;
- R10 is independently selected from hydrogen, halogen, cyano, OH, CF3, (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein
- each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C1 to C6) alkoxy, aryloxy, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) cycloheteroalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted.
- m is 0, 1, or 2;
- n is 1, 2, 3, 4, 5, or 6.
- In another embodiment, the invention relates to compounds, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, selected from the group consisting of the compounds described as examples A1 to A31, B1 to B15, C1 to C51, and D1 to D23 in the method of preparation section.
- One can treat Arenavirus infection by administering a pharmaceutically effective amount of a pharmaceutical composition comprising a compound selected of Structural Formula I or a compound as shown above with a pharmaceutically acceptable carrier, dilutant, or vehicle. Additionally, a therapeutically effective amount of a therapeutic agent selected from the group consisting of Ribavirin, polymerase inhibitors, T-705 (favipiravir), Triazavirin, small interfering RNAs (siRNAs), vaccines, and immunomodulators can be administered with the compound of the invention.
- As used herein, the terms “comprising” and “including” are used in their open, non-limiting sense.
- The terms “halo” and/or “halogen” refer to fluorine, chlorine, bromine or iodine.
- The term “(C1 to C6)” alkyl refers to a saturated aliphatic hydrocarbon radical including straight chain and branched chain groups of 1 to 6 carbon atoms. Examples of (C1 to C6) alkyl groups include methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and the like. The terms “Me” and “methyl,” as used herein, mean a —CH3 group. The terms “Et” and “ethyl,” as used herein, mean a —C2H5 group.
- The term “(C2 to C8) alkenyl”, as used herein, means an alkyl moiety comprising 2 to 8 carbons having at least one carbon-carbon double bond. The carbon-carbon double bond in such a group may be anywhere along the 2 to 8 carbon chain that will result in a stable compound. Such groups include both the E and Z isomers of said alkenyl moiety. Examples of such groups include, but are not limited to, ethenyl, propenyl, butenyl, allyl, and pentenyl. The term “allyl,” as used herein, means a —CH2CH═CH2 group. The term, “C(R)═C(R),” as used herein, represents a carbon-carbon double bond in which each carbon is substituted by an R group, and includes E and Z isomers.
- As used herein, the term “(C2 to C8) alkynyl” means an alkyl moiety comprising from 2 to 8 carbon atoms and having at least one carbon-carbon triple bond. The carbon-carbon triple bond in such a group may be anywhere along the 2 to 8 carbon chain that will result in a stable compound. Examples of such groups include, but are not limited to, ethyne, propyne, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 1-hexyne, 2-hexyne, and 3-hexyne.
- The term “(C1 to C8) alkoxy”, as used herein, means an O-alkyl group wherein said alkyl group contains from 1 to 8 carbon atoms and is straight, branched, or cyclic. Examples of such groups include, but are not limited to, methoxy, ethoxy, n-propyloxy, iso-propyloxy, n-butoxy, iso-butoxy, tert-butoxy, cyclopentyloxy, and cyclohexyloxy.
- The term “(C to C10) aryl”, as used herein, means a group derived from an aromatic hydrocarbon containing from 6 to 10 carbon atoms. Examples of such groups include, but are not limited to, phenyl or naphthyl. The terms “Ph” and “phenyl,” as used herein, mean a —C6H5 group. The term “benzyl,” as used herein, means a —CH2C6H5 group.
- “(C2 to C9) heteroaryl”, as used herein, means an aromatic heterocyclic group having a total of from 5 to 10 atoms in its ring, and containing from 2 to 9 carbon atoms and from one to four heteroatoms each independently selected from O, S and N, and with the proviso that the ring of said group does not contain two adjacent O atoms or two adjacent S atoms. The heterocyclic groups include benzo-fused ring systems. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The (C2 to C9) heteroaryl groups may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).
- “(C2 to C9) cycloheteroalkyl”, as used herein, means a non-aromatic, monocyclic, bicyclic, tricyclic, spirocyclic, or tetracyclic group having a total of from 4 to 13 atoms in its ring system, and containing from 2 to 9 carbon atoms and from 1 to 4 heteroatoms each independently selected from O, S and N, and with the proviso that the ring of said group does not contain two adjacent O atoms or two adjacent S atoms. Furthermore, such C2 to C9 cycloheteroalkyl groups may contain an oxo substituent at any available atom that will result in a stable compound. For example, such a group may contain an oxo atom at an available carbon or nitrogen atom. Such a group may contain more than one oxo substituent if chemically feasible. In addition, it is to be understood that when such a C2 to C9 cycloheteroalkyl group contains a sulfur atom, said sulfur atom may be oxidized with one or two oxygen atoms to afford either a sulfoxide or sulfone. An example of a 4 membered cycloheteroalkyl group is azetidinyl (derived from azetidine). An example of a 5 membered cycloheteroalkyl group is pyrrolidinyl. An example of a 6 membered cycloheteroalkyl group is piperidinyl. An example of a 9 membered cycloheteroalkyl group is indolinyl. An example of a 10 membered cycloheteroalkyl group is 4H-quinolizinyl. Further examples of such C2 to C9 cycloheteroalkyl groups include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, quinolizinyl, 3-oxopiperazinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, and 1-oxo-2,8-diazaspiro[4.5]dec-8-yl.
- The term “(C3 to C10) cycloalkyl group” means a saturated, monocyclic, fused, spirocyclic, or polycyclic ring structure having a total of from 3 to 10 carbon ring atoms. Examples of such groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, and adamantyl.
- The term “spirocyclic” as used herein has its conventional meaning, that is, any compound containing two or more rings wherein two of the rings have one ring carbon in common. The rings of a spirocyclic compound, as herein defined, independently have 3 to 20 ring atoms. Preferably, they have 3 to 10 ring atoms. Non-limiting examples of a spirocyclic compound include spiro[3.3]heptane, spiro[3.4]octane, and spiro[4.5]decane.
- The term “(C1 to C8) cycloalkenyl” means an unsaturated, monocyclic, fused, spirocyclic ring structures having a total of from 5 to 8 carbon ring atoms. Examples of such groups include, but are not limited to, cyclopentenyl, cyclohexenyl.
- The term “cyano” refers to a —C≡N group.
- An “aldehyde” group refers to a carbonyl group, where R is hydrogen.
- An “alkoxy” group refers to both an —O-alkyl and an —O-cycloalkyl group, as defined herein.
- An “alkoxycarbonyl” refers to a —C(O)OR.
- An “alkylaminoalkyl” group refers to an -alkyl-NR-alkyl group.
- An “alkylsulfonyl” group refer to a —SO2-alkyl.
- An “amino” group refers to an —NH2 or an —NRR′ group.
- An “aminoalkyl” group refers to an -alkyl-NRR′ group.
- An “aminocarbonyl” refers to a —C(O)NRR′.
- An “arylalkyl” group refers to -alkyl-aryl, where alkyl and aryl are defined herein.
- An “aryloxy” group refers to both an —O-aryl and an —O-heteroaryl group, as defined herein.
- An “aryloxycarbonyl” refers to —C(O)O-aryl.
- An “arylsulfonyl” group refers to a —SO2-aryl.
- A “C-amido” group refers to a —C(O)NRR′ group.
- A “carbonyl” group refers to a —C(O)R.
- A “C-carboxyl” group refers to a —C(O)OR group.
- A “carboxylic acid” group refers to a C-carboxyl group in which R is hydrogen.
- A “dialkylaminoalkyl” group refers to an -(alkyl)N(alkyl)2 group.
- A “halo” or “halogen” group refers to fluorine, chlorine, bromine or iodine.
- A “haloalkyl” group refers to an alkyl group substituted with one or more halogen atoms.
- A “heteroalicycloxy” group refers to a heteroalicyclic-O group with heteroalicyclic as defined herein.
- A “heteroaryloxy” group refers to a heteroaryl-O— group with heteroaryl as defined herein.
- A “hydroxy” group refers to an —OH group.
- An “N-amido” group refers to a —R′C(O)NR— group.
- An “N-carbamyl” group refers to a —ROC(O)NR— group.
- A “nitro” group refers to a —NO2 group.
- An “N-Sulfonamido” group refers to a —NR—S(O)2R group.
- An “N-thiocarbamyl” group refers to a —ROC(S)NR′— group.
- An “O-carbamyl” group refers to a —OC(O)NRR′ group.
- An “O-carboxyl” group refers to a —RC(O)O— group.
- An “O-thiocarbamyl” group refers to a —OC(S)NRR′ group.
- An “oxo” group refers to a carbonyl moiety such that alkyl substituted by oxo refers to a ketone group.
- A “perfluoroalkyl group” refers to an alkyl group where all of the hydrogen atoms have been replaced with fluorine atoms.
- A “phosphonyl” group refers to a —P(O)(OR)2 group.
- A “silyl” group refers to a —SiR3 group.
- An “S-sulfonamido” group refers to a —S(O)2NR— group.
- A “sulfinyl” group refers to a —S(O)R group.
- A “sulfonyl” group refers to a —S(O)2R group.
- A “thiocarbonyl” group refers to a —C(═S)—R group.
- A “trihalomethanecarbonyl” group refers to a Z3CC(O)— group, where Z is halogen.
- A “trihalomethanesulfonamido” group refers to a Z3CS(O)2NR— group, where Z is halogen.
- A “trihalomethanesulfonyl” group refers to a Z3CS(O)2— group, where Z is halogen.
- A “trihalomethyl” group refers to a —CZ3 group, where Z is halogen.
- The term “substituted,” means that the specified group or moiety bears one or more substituents.
- The term “unsubstituted,” means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. It is to be understood that in the compounds of the present invention when a group is said to be “unsubstituted,” or is “substituted” with fewer groups than would fill the valencies of all the atoms in the compound, the remaining valencies on such a group are filled by hydrogen. For example, if a C6 aryl group, also called “phenyl” herein, is substituted with one additional substituent, one of ordinary skill in the art would understand that such a group has 4 open positions left on carbon atoms of the C6 aryl ring (6 initial positions, minus one to which the remainder of the compound of the present invention is bonded, minus an additional substituent, to leave 4). In such cases, the remaining 4 carbon atoms are each bound to one hydrogen atom to fill their valencies. Similarly, if a C6 aryl group in the present compounds is said to be “disubstituted,” one of ordinary skill in the art would understand it to mean that the C6 aryl has 3 carbon atoms remaining that are unsubstituted. Those three unsubstituted carbon atoms are each bound to one hydrogen atom to fill their valencies.
- The term “solvate,” is used to describe a molecular complex between compounds of the present invention and solvent molecules. Examples of solvates include, but are not limited to, compounds of the invention in combination with water, isopropanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof. The term “hydrate” can be used when said solvent is water. It is specifically contemplated that in the present invention one solvent molecule can be associated with one molecule of the compounds of the present invention, such as a hydrate. Furthermore, it is specifically contemplated that in the present invention, more than one solvent molecule may be associated with one molecule of the compounds of the present invention, such as a dihydrate. Additionally, it is specifically contemplated that in the present invention less than one solvent molecule may be associated with one molecule of the compounds of the present invention, such as a hemihydrate. Furthermore, solvates of the present invention are contemplated as solvates of compounds of the present invention that retain the biological effectiveness of the non-hydrate form of the compounds.
- The term “pharmaceutically acceptable salt,” as used herein, means a salt of a compound of the present invention that retains the biological effectiveness of the free acids and bases of the specified derivative and that is not biologically or otherwise undesirable.
- The term “pharmaceutically acceptable formulation,” as used herein, means a combination of a compound of the invention, or a salt or solvate thereof, and a carrier, diluent, and/or excipient(s) that are compatible with a compound of the present invention, and is not deleterious to the recipient thereof. Pharmaceutical formulations can be prepared by procedures known to those of ordinary skill in the art. For example, the compounds of the present invention can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as povidone, sodium starch glycolate, sodium carboxymethylcellulose, agar, calcium carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate and solid polyethylene glycols. Final pharmaceutical forms may be pills, tablets, powders, lozenges, saches, cachets, or sterile packaged powders, and the like, depending on the type of excipient used.
- Additionally, it is specifically contemplated that pharmaceutically acceptable formulations of the present invention can contain more than one active ingredient. For example, such formulations may contain more than one compound according to the present invention. Alternatively, such formulations may contain one or more compounds of the present invention and one or more additional agents that reduce abnormal cell growth.
- The term “Arenavirus GP-inhibiting amount” as used herein, refers to the amount of a compound of the present invention, or a salt or solvate thereof, required to inhibit the cell entry of Arenaviruses in vivo, such as in a mammal, birds or in vitro. The amount of such compounds required to cause such inhibition can be determined without undue experimentation using methods described herein and those known to those of ordinary skill in the art.
- The term “therapeutically effective amount,” as used herein, means an amount of a compound of the present invention, or a salt thereof, that, when administered to a mammal in need of such treatment, is sufficient to effect treatment, as defined herein. Thus, a therapeutically effective amount of a compound of the present invention, or a salt thereof, is a quantity sufficient to modulate or inhibit the activity of the Arenavirus GP protein such that cell entry and replication of arenaviruses that is mediated by activity of the Arenavirus GP protein is reduced or alleviated.
- The terms “treat”, “treating”, and “treatment” with reference to arenavirus infection, in mammals, particularly a human, include: (i) preventing the disease or condition from occurring in a subject which may be predisposed to the condition, such that the treatment constitutes prophylactic treatment for the pathologic condition; (ii) modulating or inhibiting the disease or condition, i.e., arresting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or (iv) relieving and/or alleviating the disease or condition or the symptoms resulting from the disease or condition.
- Unless indicated otherwise, all references herein to the inventive compounds include references to salts, solvates, and complexes thereof, including polymorphs, stereoisomers, tautomers, and isotopically labeled versions thereof. For example, compounds of the present invention can be pharmaceutically acceptable salts and/or pharmaceutically acceptable solvates.
- The term “stereoisomers” refers to compounds that have identical chemical constitution, but differ with regard to the arrangement of their atoms or groups in space. In particular, the term “enantiomers” refers to two stereoisomers of a compound that are non-superimposable mirror images of one another. A pure enantiomer can be contaminated with up to 2% of the opposite enantiomer.
- The terms “racemic” or “racemic mixture,” as used herein, refer to a 1:1 mixture of enantiomers of a particular compound. The term “diastereomers”, on the other hand, refers to the relationship between a pair of stereoisomers that comprise two or more asymmetric centers and are not mirror images of one another. In accordance with a convention used in the art, the symbol is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure. In accordance with another convention, in some structural formulae herein the carbon atoms and their bound hydrogen atoms are not explicitly depicted, e.g.,
- represents a methyl group,
- represents an ethyl group,
- represents a cyclopentyl group, etc.
- The compounds of the present invention may have asymmetric carbon atoms. The carbon-carbon bonds of the compounds of the present invention may be depicted herein using a solid line (-), a solid wedge (), or a dotted wedge (). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g., specific enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included. For example, unless stated otherwise, it is intended that the compounds of the present invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
- Unless otherwise defined, a substituent “R” may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.
- Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the reacemate using, for example, chiral high pressure liquid chromatography (HPLC). Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art. Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture. Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art. See, e.g., “Stereochemistry of Organic Compounds” by E L Eliel (Wiley, New York, 1994), the disclosure of which is incorporated herein by reference in its entirety.
- Where a compound of the invention contains an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible. Where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism (‘tautomerism’) can occur. Examples of tautomerism include keto and enol tautomers. A single compound may exhibit more than one type of isomerism. Included within the scope of the invention are all stereoisomers, geometric isomers and tautomeric forms of the inventive compounds, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallization.
- The compounds of the present invention may be administered as prodrugs. Thus certain derivatives of compounds of Formula I, which may have little or no pharmacological activity themselves can, when administered to a mammal, be converted into a compound of Formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as “prodrugs”. Prodrugs can, for example, be produced by replacing appropriate functionalities present in the compounds of Formula I with certain moieties known to those skilled in the art. See, e.g., “Prodrugs as Novel Delivery Systems”, Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association), the disclosures of which are incorporated herein by reference in their entireties. Some examples of such prodrugs include: an ester moiety in the place of a carboxylic acid functional group; an ether moiety or an amide moiety in place of an alcohol functional group; and an amide moiety in place of a primary or secondary amino functional group. Further examples of replacement groups are known to those of skill in the art. See, e.g., “Design of Prodrugs” by H Bundgaard (Elsevier, 1985), the disclosure of which is incorporated herein by reference in its entirety. It is also possible that certain compounds of Formula I may themselves act as prodrugs of other compounds of Formula I.
- Salts of the present invention can be prepared according to methods known to those of skill in the art. Examples of salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, and methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, heptanoate, hexyne-1,6-dioate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, γ-hydroxybutyrate, iodide, isobutyrate, isothionate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, mesylate, metaphosphate, methanesulfonate, methylsulfate, monohydrogenphosphate, mucate, napsylate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phenylacetates, phenylbutyrate, phenylpropionate, phthalate, phospate/diphosphate, polygalacturonate, propanesulfonate, propionate, propiolate, pyrophosphate, pyrosulfate, salicylate, stearate, subacetate, suberate, succinate, sulfate, sulfonate, sulfite, tannate, tartrate, teoclate, tosylate, triethiodode, and valerate salts.
- The compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially equivalent amount of the selected mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon evaporation of the solvent, the desired solid salt is obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding an appropriate mineral or organic acid to the solution.
- Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
- If the inventive compound is a base, the desired salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalicacid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
- If the inventive compound is an acid, the desired salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
- In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystal or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulas.
- The invention also includes isotopically-labeled compounds of the invention, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 36Cl, fluorine, such as 18F, iodine, such as 123I and 125I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulfur, such as 35S.
- Certain isotopically-labeled compounds of the invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, (3H) and carbon-14, (14C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, 35S increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
- The compounds of the present invention may be formulated into pharmaceutical compositions as described below in any pharmaceutical form recognizable to the skilled artisan as being suitable. Pharmaceutical compositions of the invention comprise a therapeutically effective amount of at least one compound of the present invention and an inert, pharmaceutically acceptable carrier or diluent.
- To treat or prevent diseases or conditions mediated in part or whole by arenavirus infection, a pharmaceutical composition of the invention is administered in a suitable formulation prepared by combining a therapeutically effective amount (i.e., an arenavirus GP modulating, regulating, or inhibiting amount effective to achieve therapeutic efficacy) of at least one compound of the present invention (as an active ingredient) with one or more pharmaceutically suitable carriers, which may be selected, for example, from diluents, excipients and auxiliaries that facilitate processing of the active compounds into the final pharmaceutical preparations.
- The pharmaceutical carriers employed may be either solid or liquid. Exemplary solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the inventive compositions may include time-delay or time-release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like. Further additives or excipients may be added to achieve the desired formulation properties. For example, a bioavailability enhancer, such as Labrasol, Gelucire or the like, or formulator, such as CMC (carboxymethyl cellulose), PG (propyleneglycol), or PEG (polyethyleneglycol), may be added. Gelucire®, a semi-solid vehicle that protects active ingredients from light, moisture and oxidation, may be added, e.g., when preparing a capsule formulation.
- If a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or formed into a troche or lozenge. The amount of solid carrier may vary, but generally, will be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampoule or vial or non-aqueous liquid suspension. If a semi-solid carrier is used, the preparation may be in the form of hard and soft gelatin capsule formulations. The inventive compositions are prepared in unit-dosage form appropriate for the mode of administration, e.g., parenteral or oral administration.
- To obtain a stable water-soluble dose form, a salt of a compound of the present invention may be dissolved in an aqueous solution of an organic or inorganic acid, such as a 0.3 M solution of succinic acid or citric acid. If a soluble salt form is not available, the agent may be dissolved in a suitable co-solvent or combinations of co-solvents. Examples of suitable co-solvents include alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in concentrations ranging from 0 to 60% of the total volume. In an exemplary embodiment, a compound of the present invention is dissolved in DMSO and diluted with water. The composition may also be in the form of a solution of a salt form of the active ingredient in an appropriate aqueous vehicle such as water or isotonic saline or dextrose solution.
- Proper formulation is dependent upon the route of administration selected. For injection, the agents of the compounds of the present invention may be formulated into aqueous solutions, preferably in physiologically compatible buffers such as Hanks solution, Ringer's solution, or physiological saline buffer.
- For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained using a solid excipient in admixture with the active ingredient (agent), optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as crosslinked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, polyvinylpyrrolidone, Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agents.
- Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
- For administration intranasally or by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of gelatin for use in an inhaler or insufflator and the like may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit-dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- In addition to the formulations described above, the compounds of the present invention may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. A pharmaceutical carrier for hydrophobic compounds is a co-solvent system comprising benzyl alcohol, a non-polar surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be a VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the non-polar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD: 5W) contains VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. The proportions of a co-solvent system may be suitably varied without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinylpyrrolidone; and other sugars or polysaccharides may be substituted for dextrose.
- Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity due to the toxic nature of DMSO. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
- The pharmaceutical compositions also may comprise suitable solid- or gel-phase carriers or excipients. These carriers and excipients may provide marked improvement in the bioavailability of poorly soluble drugs. Examples of such carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Furthermore, additives or excipients such as Gelucire®, Capryol®, Labrafil®, Labrasol®, Lauroglycol®, Plurol®, Peceol®, Transcutol® and the like may be used.
- Further, the pharmaceutical composition may be incorporated into a skin patch for delivery of the drug directly onto the skin.
- It will be appreciated that the actual dosages of the agents of this invention will vary according to the particular agent being used, the particular composition formulated, the mode of administration, and the particular site, host, and disease being treated. Those skilled in the art using conventional dosage determination tests in view of the experimental data for a given compound may ascertain optimal dosages for a given set of conditions. For oral administration, an exemplary daily dose generally employed will be from about 0.001 to about 1000 mg/kg of body weight, with courses of treatment repeated at appropriate intervals.
- Furthermore, the pharmaceutically acceptable formulations of the present invention may contain a compound of the present invention, or a salt or solvate thereof, in an amount of about 10 mg to about 2000 mg, or from about 10 mg to about 1500 mg, or from about 10 mg to about 1000 mg, or from about 10 mg to about 750 mg, or from about 10 mg to about 500 mg, or from about 25 mg to about 500 mg, or from about 50 to about 500 mg, or from about 100 mg to about 500 mg.
- Additionally, the pharmaceutically acceptable formulations of the present invention may contain a compound of the present invention, or a salt or solvate thereof, in an amount from about 0.5 w/w % to about 95 w/w %, or from about 1 w/w % to about 95 w/w %, or from about 1 w/w % to about 75 w/w %, or from about 5 w/w % to about 75 w/w %, or from about 10 w/w % to about 75 w/w %, or from about 10 w/w % to about 50 w/w %.
- The compounds of the present invention, or salts or solvates thereof, may be administered to a mammal, such as a human, suffering from a condition or disease mediated by arenavirus, either alone or as part of a pharmaceutically acceptable formulation, once a day, twice a day, three times a day, four times a day, or even more frequently.
- The compounds of the present invention, or salts or solvates thereof, may be administered to a mammal, such as a human, suffering from a condition or disease mediated by arenavirus in combination with at least one other agent used for treatment of arenavirus selected from the group consisting of Ribavirin, viral RNA-dependent-RNA-polymerase inhibitors as shown by Ng K K, Arnold J J and Cameron C E, Structure-Function Relationships Among RNA-Dependent RNA Polymerases, Curr Top Microbiol Immunol, 2008; 320: 137-156, incorporated herein by reference in its entirety, Favipiravir, a broad-spectrum inhibitor of viral RNA-Dependent RNA Polymerases, Triazavirin, a broad-spectrum inhibitor of viral RNA-Dependent RNA Polymerases, small interfering RNAs (siRNAs) and microRNAs as shown by Carthew R W and Sontheimer E J, Origins and Mechanisms of miRNAs and siRNAs, Nature, 2009; 136: 642-655, incorporated herein by reference in its entirety, vaccines as shown by Nablel G J, Designing Tomorrow's Vaccines, NEJM, 2013; 368: 551-560, incorporated herein by reference in its entirety, and immunomodulators as shown by Patil U S, JaydeokarA V and Bandawane D D, Immunomodulators: A Pharmacological Review, Internatl J Pharmacy and Pharmaceutical Sci, 2012; 4: 30-36, incorporated herein by reference in its entirety, alone or as part of a pharmaceutically acceptable formulation, once a day, twice a day, three times a day, four times a day, or even more frequently.
- Those of ordinary skill in the art will understand that with respect to the compounds of the present invention, the particular pharmaceutical formulation, the dosage, and the number of doses given per day to a mammal requiring such treatment, are all choices within the knowledge of one of ordinary skill in the art and can be determined without undue experimentation.
- The compounds of the present invention are useful for modulating or inhibiting arenavirus GP.
- Accordingly, these compounds are useful for the prevention and/or treatment of disease states associated with arenavirus infection.
- This invention also relates to a method for the treatment of arenavirus infection including a human comprising administering to said mammal an amount of a compound of the Formula I, as defined above, or a salt or solvate thereof, that is effective in treating disease states associated with Arenavirus infection.
- In the following Preparations and Examples, “Ac” means acetyl, “Me” means methyl, “Et” means ethyl, “Ph” means phenyl, “Py” means pyridine, “BOC”, “Boc” or “boc” means N-tert-butoxycarbonyl, “Ns” means 2-Nitrophenylsulfonyl, “DCM” (CH2Cl2) means dichloromethane or methylene chloride, “dba” means dibenzylideneacetone, “DCE” means dichloroethane or ethylene chloride, “DIAD” means diisopropylazadicarboxylate, “DIPEA” or “DIEA” means diisopropyl ethyl amine, “DMA” means N,N-dimethylacetamide, “DMF” means N—N-dimethyl formamide, “DMSO” means dimethylsulfoxide, “DPPP” means 1,3-bis(diphenylphosphino)propane, “HOAc” means acetic acid, “IPA” means isopropyl alcohol, “NMP” means 1-methyl 2-pyrrolidinone, “TEA” means triethyl amine, “TFA” means trifluoroacetic acid, “DCM” means dichloromethane, “EtOAc” means ethyl acetate, “MgSO4” means magnesium sulphate, “Na2SO4” means sodium sulphate, “MeOH” means methanol, “Et2O” means diethyl ether, “EtOH” means ethanol, “H2O” means water, “HCl” means hydrochloric acid, “POCl3” means phosphorus oxychloride, “SOCl2” means thionylchloride, “K2CO3” means potassium carbonate, “THF” means tetrahydrofuran, “DBU” means 1,8-diazabicyclo[5.4.0]undec-7-ene, “LiHMDS” or “LHMDS” means lithium hexamethyldisilazide, “TBME” or “MTBE” means tert-butyl methyl ether, “LDA” means lithium diisopropylamide, “NBS” means N-bromosuccinimide, “NIS” means N-iodosuccinimide, “Xantphos” means 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, “P(Ph3)” means triphenylphosphine, “N” means Normal, “M” means molar, “mL” means millilitre, “mmol” means millimoles, “μmol” means micromoles, “eq.” means equivalent, “° C.” means degrees Celsius, “Pa” means pascals, “rt” means room temperature.
- Compounds of the present invention may be prepared using the reaction routes and synthetic schemes described below, employing the techniques available in the art using starting materials that are readily available. The preparation of certain embodiments of the present invention is described in detail in the following examples, but those of ordinary skill in the art will recognize that the preparations described may be readily adapted to prepare other embodiments of the present invention. For example, the synthesis of non-exemplified compounds according to the invention may be performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions. Alternatively, other reactions referred to herein or known in the art will be recognized as having adaptability for preparing other compounds of the invention.
- Scheme 1 shows a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, J and L are N, and K is C—R3. Compound 1-1 (X=C, Br, or I, and Y is F, C, Br, or I) can be reacted with amine R2NH2 in the presence of a base such as NaH or Cs2CO3 in a solvent such as THE or DMF to form compound 1-2. Reduction of the nitro group using a reducing agent such as Fe or SnCl2 in a solvent such as THE or methanol can provide aniline 1-3 which can be reacted with ester R3CO2R or orthoester R3C(OR)3 to form 1-4. Coupling of 1-4 with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 2 shows a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, E, J and L are N, and K is C—R3. Compound 2-1 (X=Cl, Br, or I, and Y is F, Cl, Br, or I) can be reacted with amine R2NH2 in the presence of a base such as NaH or Cs2CO3 in a solvent such as THF or DMF to form compound 2-4 which can be reacted with ester R3CO2R or orthoester R3C(OR)3 to form 2-5. Alternatively, 2-5 can be formed by reaction of compound 2-2 (X=Cl, Br, or I, and Y is F, Cl, Br, or I) on treatment with primary amide 2-3 in a presence of a palladium catalyst such as Pd(dba)3 [A. Rosenberg, J. Zhao, D. A. Clark, Org. Lett. 14, 2012, 1764-1767]. Coupling of 2-5 with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 3 depicts an alternative method useful for the synthesis of compounds of structural Formula I wherein G, and H are C, J and L are N, and K is C—R3. Compound 3-1 (X=Cl, Br, or I) can be reacted with an alkyl halide R2Z (Z=Cl, Br, or I) in the presence of a base such as NaH or Cs2CO3 in a solvent such as THE or DMF, or with an aryl halide R2Z (Z=1) in the presence of CuI, a ligand such as 1,10-phenanthroline, and a base such as K2CO3 in a solvent such as DMF [C. Baumgartner et al. Helv. Chim. Acta 90, 2007, 1043-1068] to form a mixture of isomers 3-2 and 3-3 which can be separated by column chromatography or other methods know to those skilled in the arts. Coupling of 3-3 with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 4 displays a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, J is N, and K and L are independently C—R3. Compound 4-1 (X=Cl, Br, or I) can be reacted with an alkyl halide R2Z (Z=Cl, Br, or I) in the presence of a base such as NaH or Cs2CO3 in a solvent such as THE or DMF, or with an aryl halide R2Z (Z=1) in the presence of CuI, a ligand such as 1,10-phenanthroline, and a base such as K2CO3 in a solvent such as DMF to form compound 4-2. Coupling of 4-2 with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 5 shows a method useful for the synthesis of compounds of structural Formula I wherein G, H, and J are C, K is C—R3, and L is N—R3. Compound 5-1 (X=Br) can be reacted with an aryl bromide R2Br in the presence a catalyst such as Pd(OAc)2 and a base such as K2CO3 in a solvent such as toluene [F. Bellina, F. Benelli, R. Rossi J. Org. Chem. 2008, 73, 5529-5535] to form compound 5-2. Coupling of 5-2 with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 6 shows a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, J and K are N, and L is C—R3. Compound 6-1 (X=Cl, Br, or I, and Y is F, Cl, Br, or I) can be reacted with hydrazine 6-2 in the presence of a base such as DIEA in a solvent such as THF or DMF to form hydrazone 6-3 which can cyclize to 6-5 on treatment with a base such as sodium t-butoxide with or without a catalyst such as Pd(dba)3. Alternatively, compound 6-4 can be reacted with an alkyl halide R2Z (Z=Cl, Br, or I) in the presence of a base such as NaH or Cs2CO3 in a solvent such as THF or DMF, or with an aryl halide R2Z (Z=1) in the presence of CuI, a ligand such as 1,10-phenanthroline, and a base such as K2CO3 in a solvent such as DMF to form compound 6-5. Coupling of 6-5 with a boronic acid or boronic ester R1B(OR)2 using a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene] palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 7 depicts a method useful for the synthesis of compounds of structural Formula I wherein G, H, and J are C, K is N, and L is NR3. Compound 7-1 (X=Cl, Br) can be coupled with a boronic acid or boronic ester R2B(OR)2 using a catalyst such as tetrakis(triphenylphosphine)palladium in the presence of a base such as K2CO3 in a solvent such as dioxane to form 7-2 which can react with a second boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane to provide a compound of structural Formula I.
- Scheme 8 depicts a method useful for the synthesis of compounds of structural Formula I wherein G, and J are C, H and L are N, and K is C—R3. Compound 8-1 (X=Cl, Br) can be coupled with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane to form 8-2 which can be treated with a halogenation reagent such as bromine or N-bromosuccinimide (NBS), or iodine or N-iodosuccinimide (NIS) to form compound 8-3 (Y=Br, I). Treatment of 8-3 with a boronic acid or boronic ester R2B(OR)2 using a catalyst such as tetrakis(triphenylphosphine)palladium in the presence of a base such as K2CO3 in a solvent such as dioxane can provide a compound of Structural Formula I. Alternatively, compound 8-4 (X=Cl, Br) can react with boronic acid or boronic ester R2B(OR)2 using a catalyst such as tetrakis(triphenylphosphine)palladium in the presence of a base such as K2CO3 in a solvent such as dioxane to provide compound 8-5 which can react with a second boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane to provide a compound of structural Formula I.
- Scheme 9 shows a method useful for the synthesis of compounds of structural Formula I wherein G and J are C, H and K are N, and L is C—R3. Amine 9-1 (X=Cl, Br) can be reacted with an acyl halide R2COZ (Z=Cl, Br) in the presence of a base such as DIEA to form amide 9-2 which on treatment with POCl3 can cyclize to 9-3. Treatment of 9-3 with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide a compound of structural Formula I. Alternatively, compound 9-4 can react with a boronic acid or boronic ester R1B(OR)2 using a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane to form 9-5 which then can undergo a cross-coupling reaction with an aryl halide R2Z (Z=Br, I) in a presence of a catalyst such as Pd(OAc)2 in a presence of a base such as tetrabutylammmonium acetate in a solvent such as toluene [C. Huang, A. Giokaris, V. Gevorgyan, Chem. Lett. 40, 2011, 1053-1054] to provide a compound of structural Formula I.
- Scheme 10 depicts a method useful for the synthesis of compounds of structural Formula I wherein H and J are C, G and K are N, and L is C—R3. Compound 10-1 (X=Cl, Br) can be coupled with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane to form 10-2 which can be treated with a halogenation reagent such as bromine or N-bromosuccinimide (NBS), or iodine or N-iodosuccinimide (NIS) to form compound 10-3 (Y=Br, I). Treatment of 10-3 with a boronic acid or boronic ester R2B(OR)2 using a catalyst such as tetrakis(triphenylphosphine)palladium in the presence of a base such as K2CO3 in a solvent such as dioxane can provide a compound of structural Formula I. Alternatively, compound 10-4 (X=Cl, Br) can react with boronic acid or boronic ester R2B(OR)2 using a catalyst such as tetrakis (triphenylphosphine)palladium in the presence of a base such as K2CO3 in a solvent such as dioxane to provide compound 10-5 which can react with a second boronic acid or boronic ester R1B(OR)2 using a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene] palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane to provide a compound of structural Formula I.
- Scheme 11 depicts a method useful for the synthesis of compounds of structural Formula I wherein G and J are C, and H, K, and L are N. Compound 10-1 (X=Cl, Br) can react with hydrazine to form 11-2 which upon treatment with an acyl halide or ester R2COZ (Z=Cl, Br, OR) can form acyl hydrazide 11-3. Under acidic conditions (e g. acetic acid) 11-3 can cyclize to form 11-4 which then can be coupled with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane to provide a compound of structural Formula I.
- Scheme 12 depicts a method useful for the synthesis of compounds of structural Formula I wherein G and H are C, and J, K, and L are N. Compound 12-1 (X=Cl, Br, or I, and Y is F, Cl, Br, or I) can be reacted with amine R2NH2 in the presence of a base such as NaH or K2CO3 in a solvent such as THF or DMF to form compound 12-2. Reduction of the nitro groups using a reducing agent such as Fe or SnCl2 in a solvent such as THF or methanol can provide aniline 12-3 which can be reacted with nitric acid to form 12-4. Coupling of 12-4 with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide compound of structural Formula I.
- Scheme 13 depicts a method useful for the synthesis of compounds of structural Formula I wherein G, H, and J are C, K is C—R3, and L is O. Compound 13-1 (X=Cl, Br) can react with haloketone 13-2 (Z=Cl, Br) in a presence of a base such as Cs2CO3 in a solvent such as DMF to form 13-3 which under acidic conditions using an acid such as para toluene sulfonic acid can undergo cyclodehydration to form 13-4. Coupling of 13-4 with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane can provide a compound of structural Formula I.
- Scheme 14 shows a method useful for the synthesis of compounds of structural Formula I wherein G, H, and J are C, K is O, and L is N. Compound 14-1 (X=Cl, Br) can react with nitrile 14-2 using as base such as KOH in solvent such as methanol to form 14-3 which can react with a boronic acid or boronic ester R1B(OR)2 using a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride in the presence of a base such as K2CO3 in a solvent such as dimethoxyethane to provide a compound of structural Formula I.
-
- A mixture of 4-bromo-2-fluoro-1-nitrobenzene (0.3 g, 1.36 mmol), 4-(propan-2-yloxy)aniline (0.22 g, 1.43 mmol) and K2CO3 (0.38 g, 2.73 mmol) in DMF (3 mL) was stirred at 90° C. for 5 h. Then the reaction mixture was diluted with EtOAc and washed with 5% aq. LiCl solution. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 30:1 to 20:1) to give 0.43 g (90%) of the product as orange solid. 1H NMR (500 MHz, CDCl3) δ 9.37 (s, 1H), 8.04 (d, 1H), 7.12-7.17 (m, 3H), 6.93-6.97 (m, 2H), 6.81 (dd, 1H), 4.56 (sep, 1H), 1.36 (d, 6H).
-
- To a solution of 5-bromo-2-nitro-N-[4-(propan-2-yloxy)phenyl]aniline (0.156 g, 0.44 mmol) in 2-propanol (2.2 mL) were added iron powder (0.248 g, 4.4 mmol), NH4Cl (0.237 g, 4.4 mmol) and formic acid (2.2 mL) (E. J. Hanan, B. K. Chan, A. A. Estrada, D. G. Shore and J. P. Lyssikatos, Synlett 2010, 2759-2764). The resulting reaction mixture was stirred at 80° C. for 5 h. Then the reaction mixture was diluted with 2-propanol, filtered through Celite, and the filtrate was concentrated. The resulting residue was diluted with dichloromethane and washed with saturated aq. NaHCO3 solution. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 7:3 to 1:2) to give 0.1 g (68%) of the product as pale pink solid. LC/MS m/z: 331.06 (79Br, M+H)+, 332.9 (81Br, M+H)+.
-
- The title compound was prepared from 4-bromo-2-fluoro-1-nitrobenzene and 4-methoxyaniline in the same manner as described for 5-bromo-2-nitro-N-[4-(propan-2-yloxy)phenyl]aniline.
-
- The title compound was prepared from 5-bromo-N-(4-methoxyphenyl)-2-nitroaniline in the same manner as described for 6-bromo-1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazole. LC/MS m/z: 303.15 (79Br, M+H)+, 305.12 (81Br, M+H)+.
-
- The title compound was prepared from 1-bromo-3-fluoro-2-nitrobenzene and 4-methoxyaniline in the same manner as described for 5-bromo-2-nitro-N-[4-(propan-2-yloxy)phenyl]aniline.
-
- The title compound was prepared from 3-bromo-N-(4-methoxyphenyl)-2-nitroaniline in the same manner as described for 6-bromo-1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazole. LC/MS m/z: 303.09 (79Br, M+H)+, 305.15 (81Br, M+H)+.
-
- The title compound was prepared from 4-bromo-2-fluoro-1-nitrobenzene and 2-methoxyaniline in the same manner as described for 5-bromo-2-nitro-N-[4-(propan-2-yloxy)phenyl]aniline.
-
- The title compound was prepared from 5-bromo-N-(2-methoxyphenyl)-2-nitroaniline in the same manner as described for 6-bromo-1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazole. LC/MS m/z: 302.99 (79Br, M+H)+, 304.98 (81Br, M+H)+.
-
- The title compound was prepared from 4-bromo-2-fluoro-1-nitrobenzene and 3-methoxyaniline in the same manner as described for 5-Bromo-2-nitro-N-[4-(propan-2-yloxy)phenyl]aniline.
-
- The title compound was prepared from 5-bromo-N-(3-methoxyphenyl)-2-nitroaniline in the same manner as described for 6-bromo-1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazole. LC/MS m/z: 303.08 (79Br, M+H)+, 304.93 (81Br, M+H)+.
-
- To a solution of 1-bromo-5-fluoro-2-methyl-4-nitrobenzene (200 mg, 0.85 mmol) in i-propanol (2 mL), was added 4-isopropoxyaniline (129 mg, 0.85 mmol). The resulting mixture was stirred at 120° C. for 30 min under microwave irradiation. After cooling to room temperature, the reaction was concentrated under reduced pressure and the residue was dissolved in ethanol (0.6 mL), dioxane (0.6 mL), and water (0.3 mL). To the solution was added iron (476 mg, 8.5 mmol) and NH4Cl (457 mg, 8.5 mmol). The reaction was stirred at 80° C. for 2 hr. After cooling to room temperature, the reaction was filtered through a celite pad. The filtrate was concentrated under reduced pressure and the residue was poured into water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane/EtOAc=3:1) to give 198 mg (69.2%) of the product as a white solid. LC/MS m/z: 335.13 (79Br, M+H)+, 337.19 (81Br, M+H)+, 376.28 (79Br, M+H+CH3CN)+, 378.25 (81Br, M+H+CH3CN)+.
-
- To a solution of 5-bromo-N1-(4-isopropoxyphenyl)-4-methylbenzene-1,2-diamine (50.1 mg, 0.15 mmol) in THE (1 mL), was added trimethoxymethane (18.9 mg, 0.18 mmol) followed by formic acid (100 uL). The resulting mixture was stirred at 80° C. for 2 hr. After cooling to room temperature, the reaction was poured into water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane/EtOAc=1:1) to give 42.1 mg (81.7%) of the product as a white solid. LC/MS m/z: 345.15 (79Br, M+H)+, 347.21 (81Br, M+H)+, 386.28 (79Br, M+H+CH3CN)+, 388.20 (81Br, M+H+CH3CN)+.
-
- The title compound was prepared from 4-bromo-2-fluoro-1-nitrobenzene and 1H-indol-5-amine in the same manner as described for 5-bromo-N1-(4-isopropoxyphenyl)-4-methylbenzene-1,2-diamine. LCMS m/z: 302.12 (79Br, M+H)+, 344.13 (81Br, M+H)+, 343.18 (79Br, M+H+CH3CN)+, 345.22 (81Br, M+H+CH3CN)+.
-
- The title compound was prepared from 5-bromo-N1-(1H-indol-5-yl)benzene-1,2-diamine in the same manner as described for 6-bromo-5-methyl-1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazole. LC/MS m/z: 312.04 (79Br, M+H)+, 314.03 (81Br, M+H)+, 353.09 (79Br, M+H+CH3CN)+, 355.12 (81Br, M+H+CH3CN)+.
-
- The title compound was prepared from 1-bromo-5-fluoro-2-methoxy-4-nitrobenzene and 4-(propan-2-yloxy)aniline in the same manner as described for 5-Bromo-2-nitro-N-[4-(propan-2-yloxy)phenyl]aniline.
-
- The title compound was prepared from 5-bromo-4-methoxy-2-nitro-N-[4-(propan-2-yloxy)phenyl]aniline in the same manner as described for 6-Bromo-1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazole. LC/MS m/z: 402.12 (M+H)+.
-
- To a solution of 6-bromo-1-(4-methoxyphenyl)-1H-1,3-benzodiazole (30 mg, 0.1 mmol) in 1,2-dimethoxyethane (1 mL) were added [3-(propan-2-yl)phenyl]boronic acid (32 mg, 0.2 mmol), [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (7 mg, 0.01 mmol), potassium carbonate (40 mg, 0.3 mmol) and water (0.25 mL). The resulting reaction mixture was degassed with nitrogen for 10 min, then heated to 90° C. for 5 h. Then the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 7:3 to 1:4) to give 21 mg (62%) of the product as a colorless oil. LC/MS m/z: 343.34 (M+H)+, 384.30 (M+H+CH3CN)+.
- Examples A2 to A31 were prepared in the same manner as described above for 1-(4-methoxyphenyl)-6-[3-(propan-2-yl)phenyl]-1H-1,3-benzodiazole using the appropriate bromide and commercial boronic acid or boronic acid pinacol ester performing the reaction either under conventional heating or in a microwave reactor.
-
Ex. Starting materials Product/Name Analytical Data A2 6-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole [4-(propan-2-yl)phenyl] boronic acid LC/MS m/z: 343.26 (M + H)+ 1-(4-methoxyphenyl)-6-[4- (propan-2-yl)phenyl]-1H-1,3- benzodiazole A3 6-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole (4-methoxyphenyl) boronic acid LC/MS m/z: 331.25 (M + H)+; 661.42 (2M + H)+ 1,6-bis(4-methoxyphenyl)-1H- 1,3-benzodiazole A4 6-bromo-1-(4-methoxy phenyl)-1H-1,3- benzodiazole (4-cyanophenyl) boronic acid LC/MS m/z: 326.22 (M + H)+, 367.25 (M + H + CH3CN)+ 4-[1-(4-methoxyphenyl)-1H- 1,3-benzodiazol-6-yl] benzonitrile A5 6-bromo-1-(4-methoxy phenyl)-1H-1,3- benzodiazole (2-methoxyphenyl) boronic acid LC/MS m/z: 331.22 (M + H)+ 6-(2-methoxyphenyl)-1-(4- methoxyphenyl)-1H-1,3- benzodiazole A6 6-bromo-1-(4-methoxy phenyl)-1H-1,3- benzodiazole (3-methoxyphenyl) boronic acid LC/MS m/z: 331.22 (M + H)+ 6-(3-methoxyphenyl)-1-(4- methoxyphenyl)-1H-1,3- benzodiazole A7 6-bromo-1-(4-methoxy phenyl)-1H-1,3- benzodiazole [4-(dimethylamino) phenyl]boronic acid LC/MS m/z: 344.32 (M + H)+ 4-[1-(4-methoxyphenyl)-1H- 1,3-benzodiazol-6-yl]-N,N- dimethylaniline A8 6-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole [4-(2-hydroxypropan-2- yl)phenyl]boronic acid LC/MS m/z: 359.27 (M + H)+, 400.30 (M + H + CH3CN)+ 2-{4-[1-(4-methoxyphenyl)- 1H-1,3-benzodiazol-6- yl]phenyl}propan-2-ol A9 6-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole 4,4,5,5-tetramethyl-2- [(4-methylphenyl) methyl]-1,3,2- dioxaborolane LC/MS m/z: 329.23 (M + H)+, 370.27 (M + H + CH3CN)+ 1-(4-methoxyphenyl)-6-[(4- methylphenyl)methyl]-1H-1,3- benzodiazole A10 6-bromo-1-(4- methoxyphenyl)--1,3- benzodiazole [4-(hydroxymethyl) phenyl]boronicacid LC/MS m/z: 331.27 (M + H)+ {4-[1-(4-methoxyphenyl)- 1H-1,3-benzodiazol-6- yl]phenyl}methanol A11 6-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole (4-methanesulfonyl phenyl)boronic acid LC/MS m/z: 379.19 (M + H)+, 420.16 (M + H + CH3CN)+ 6-(4-methanesulfonylphenyl)- 1-(4-methoxyphenyl)-1H-1,3- benzodiazole A12 6-bromo-1-(4-methoxy phenyl)-1H-1,3- benzodiazole 1H-indol-5-ylboronic acid LC/MS m/z: 340.27 (M + H)+, 679.38 (2M + H)+ 6-(1H-indol-5-yl)-1-(4- methoxyphenyl)- 1H-1,3-benzodiazole A13 6-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole (4-hydroxyphenyl) boronic acid LC/MS m/z: 317.23 (M + H)+ 4-[1-(4-methoxyphenyl)-1H- 1,3-benzodiazol-6-yl]phenol A14 6-bromo-1-(4-methoxy phenyl)-1H-1,3- benzodiazole (4-acetylphenyl)boronic acid LC/MS m/z: 343.13 (M + H)+ 1-{4-[1-(4-methoxyphenyl)- 1H-1,3-benzodiazol-6-yl] phenyl}ethan-1-one A15 6-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole [4-(piperidin-1- yl)phenyl]boronic acid LC/MS m/z: 384.34 (M + H)+ 1-(4-methoxyphenyl)-6-[4- (piperidin-1-yl)phenyl]-1H-1,3- benzodiazole A16 6-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole [4-(morpholin-4- yl)phenyl]boronic acid LC/MS m/z: 386.29 (M + H)+ 1-(4-methoxyphenyl)-6-[4- (morpholin-4-yl)phenyl]-1H- 1,3-benzodiazole A17 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H-1,3- benzodiazole [4-(2-hydroxypropan-2- yl)phenyl]boronic acid 1H NMR (300 MHz, CDCl3) δ 8.67 (br. s, 1H), 8.07 (d, 1H), 7.71 (d, 1H), 7.64 (s, 1H), 7.58-7.40 (m, 6H), 7.12-7.04 (m, 2H), 4.69- 4.59 (m, 1H), 3.35 (br. s, 1H), 1.61 (s, 6H), 1.40 (d, 6H). LC/MS m/z: 387.32 (M + H)+ 2-(4-{1-[4-(propan-2-yloxy) phenyl]-1H-1,3-benzodiazol- 6-yl}phenyl)propan-2-ol A18 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H-1,3- benzodiazole [4-(dimethylamino) phenyl]boronic acid 1H NMR (300 MHz, CDCl3) δ 8.10 (s, 1H), 7.88 (d, 1H), 7.59-7.48 (m, 4H), 7.42 (d, 2H), 7.05 (d, 2H), 6.84 (d, 2H), 4.62 (sep, 1H), 2.99 (s, 6H), 1.40 (d, 6H). LC/MS m/z: 372.24 (M + H)+ N,N-dimethyl-4-{1-[4-(propan- 2-yloxy)phenyl]-1H-1,3- benzodiazol-6-yl}aniline A19 4-bromo-1-(4- methoxyphenyl)-1H- 1,3-benzodiazole [4-(propan-2-yl)phenyl] boronic acid LC/MS m/z: 343.21 (M + H)+ 1-(4-methoxyphenyl)-4-[4- (propan-2-yl)phenyl]-1H-1,3- benzodiazole A20 4-bromo-1-(4-methoxy phenyl)-1H-1,3- benzodiazole [3-(propan-2-yl)phenyl] boronic acid LC/MS m/z: 343.3 (M + H)+, 685.45 (2M + H)+ 1-(4-methoxyphenyl)-4-[3- (propan-2-yl)phenyl]-1H-1,3- benzodiazole A21 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H-1,3- benzodiazole [4-(morpholin-4- yl)phenyl]boronic acid LC/MS m/z: 414.28 (M + H)+ 6-[4-(morpholin-4-yl)phenyl]- 1-[4-(propan-2-yloxy)phenyl]- 1H-1,3-benzodiazole A22 6-bromo-1-(2- methoxyphenyl)-1H- 1,3-benzodiazole [4-(2-hydroxypropan-2- yl)phenyl]boronic acid LC/MS m/z: 359.22 (M + H)+ 2-{4-[1-(2-methoxyphenyl)- 1H-1,3-benzodiazol-6- yl]phenyl}propan-2-ol A23 6-bromo-1-(3-methoxy phenyl)-1H-1,3- benzodiazole [4-(2-hydroxypropan-2- yl)phenyl]boronic acid LC/MS m/z: 359.23 (M + H)+ 2-{4-[1-(3-methoxyphenyl)- 1H-1,3-benzodiazol-6- yl]phenyl}propan-2-ol A24 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H-1,3- benzodiazole 1H-indol-5-ylboronic acid 1H NMR (300 MHz, CDCl3) δ 8.44 (br. s, 1H), 8.33 (s, 1H), 7.96 (d, 1H), 7.83 (s, 1H), 7.73-7.64 (m, 2H), 7.47-7.39 (m, 4H), 7.06 (d, 2H), 6.60-6.56 (m, 1H), 4.62 (sep, 1H), 3.66 (br. s, 1H), 1.39 (d, 6H). LC/MS m/z: 368.22 (M + H)+ 6-(1H-indol-5-yl)-1-[4- (propan-2-yloxy)phenyl]-1H- 1,3-benzodiazole A25 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H-1,3- benzodiazole (4-isopropoxyphenyl) boronic acid 1H NMR (300 MHz, CDCl3) δ 8.27 (br, 1H), 7.97 (br, 1H), 7.61 (br, 2H), 7.53 (d, 2H), 7.45 (d, 2H), 7.11 (d, 2H), 6.97 (d, 2H), 4.70- 4.5 (m, 2H), 1.43 (d, 6H), 1.38 (d, 6H). LC/MS m/z: 387.35 (M + H)+ 1,6-bis[4-(propan-2-yloxy) phenyl]-1H-1,3-benzodiazole A26 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H-1,3- benzodiazole (4-acetylphenyl)boronic acid LC/MS m/z: 371.32 (M + H)+, 412.21 (M + H + CH3CN)+ 1-(4-{1-[4-(propan-2-yloxy) phenyl]-1H-1,3-benzodiazol- 6-yl}phenyl)ethan-1-one A27 6-bromo-1-(1H-indol-5- yl)-1H-1,3- benzodiazole (4-isopropoxyphenyl) boronic acid LC/MS m/z: 368.28 (M + H)+ 1-(1H-indol-5-yl)-6-[4- (propan-2-yloxy)phenyl]-1H- 1,3-benzodiazole A28 6-bromo-1-(1H-indol-5- yl)-1H-1,3- benzodiazole (4-acetylphenyl)boronic acid LC/MS m/z: 352.25 (M + H)+ 1-{4-[1-(1H-indol-5-yl)-1H-1,3- benzodiazol-6-yl]phenyl} ethan-1-one A29 6-bromo-1-(1H-indol-5- yl)-1H-1,3- benzodiazole 1H-indol-5-ylboronic acid LC/MS m/z: 349.22 (M + H)+ 1,6-bis(1H-indol-5-yl)-1H-1,3- benzodiazole A30 6-bromo-5-methyl-1-[4- (propan-2-yloxy) phenyl]-1H-1,3- benzodiazole (4-isopropoxyphenyl) boronic acid 1H NMR (300 MHz, CDCl3) δ 8.44 (br, 1H), 8.04 (d, 1H), 7.92 (s, 1H), 7.43 (d, 2H), 7.23 (d, 2H), 7.03 (d, 2H), 6.94 (d, 2H), 4.53- 4.78 (m, 2H), 2.41 (s, 3H), 1.40 (d, 6H), 1.38 (d, 6H). LC/MS m/z: 401.29 (M + H)+ 5-methyl-1,6-bis[4-(propan-2- yloxy)phenyl]-1H-1,3- benzodiazole A31 6-bromo-5-methoxy-1- [4-(propan-2- yloxy)phenyl]-1H- 1,3-benzodiazole (4-isopropoxyphenyl) boronic acid LC/MS m/z: 417.28 (M + H)+ 5-methoxy-1,6-bis[4-(propan- 2-yloxy)phenyl]-1H-1,3- benzodiazole -
- The title compound was prepared from 2,6-dibromo-3-nitropyridine and 4-(propan-2-yloxy)aniline in the same manner as described for 5-bromo-2-nitro-N-[4-(propan-2-yloxy)phenyl]aniline.
-
- The title compound was prepared from 6-Bromo-3-nitro-N-[4-(propan-2-yloxy)phenyl]pyridin-2-amine in the same manner as described for 6-Bromo-1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazole. LC/MS m/z: 332.19 (79Br, M+H)+, 334.11 (81Br, M+H)+.
-
- To a solution of 2,4-dibromo-5-nitropyridine (200 mg, 0.71 mmol) in i-propanol (3 mL) was added 4-isopropoxyaniline (128 mg, 0.85 mmol) at room temperature. The resulting mixture was heated to 90° C. for 1 hr. After cooling to room temperature, iron was added (391 mg, 7.1 mmol), followed by NH4Cl (377 mg, 7.1 mmol), and acetic acid (3 mL). The reaction was stirred at 80° C. for 8 hr. After cooling to room temperature, the reaction was filtered through a celite pad. The filtrate was concentrated under reduced pressure and the residue was poured into water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane/EtOAc=1:1) to give 215 mg (87%) of the product as a white solid. LC/MS m/z: 332.29 (79Br, M+H)+, 334.19 (81Br, M+H)+, 373.22 (79Br, M+H+CH3CN)+, 375.19 (81Br, M+H+CH3CN)+.
-
- The title compound was prepared from 2,4-dichloro-5-nitropyrimidine and 4-isopropoxyaniline in the same manner as described for 6-bromo-1-[4-(propan-2-yloxy)phenyl]-1H-imidazo[4,5-c]pyridine. LC/MS m/z: 289.24 (M+H)+, 330.24 (M+H+CH3CN)+.
-
- The title compound was prepared from 4-bromo-2-fluoro-1-nitrobenzene and 4-isopropoxyaniline in the same manner as described for 5-bromo-N1-(4-isopropoxyphenyl)-4-methylbenzene-1,2-diamine. LCMS m/z 321.20 (79Br, M+H)+, 323.19 (81Br, M+H)+, 362.20 (79Br, M+H+CH3CN)+, 364.24(81Br, M+H+CH3CN)+.
-
- To a solution of 5-bromo-N1-(4-isopropoxyphenyl)benzene-1,2-diamine (100 mg, 0.3 mmol) in acetic acid (3 mL), was added PPh3 (81.6 mg, 0.3 mmol) followed by addition of sodium nitrite (25.8 mg, 0.36 mmol) at 0° C. The reaction was warmed to room temperature and stirred for 1 h. The reaction was poured into water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane/EtOAc=2:1) to give 98.0 mg (95%) of the product as a white solid. LC/MS m/z: 332.07 (79Br, M+H)+, 334.08 (81Br, M+H)+, 373.15 (79Br, M+H+CH3CN)+, 375.14 (81Br, M+H+CH3CN)+.
-
- The title compound was prepared from 5-bromo-N1-(4-isopropoxyphenyl)-4-methylbenzene-1,2-diamine in the same manner as described for 6-bromo-1-[4-(propan-2-yloxy)phenyl]-1H-1,2,3-benzotriazole. LC/MS m/z: 345.89 (79Br, M+H)+, 347.94 (81Br, M+H)+, 387.15 (79Br, M+H+CH3CN)+, 389.10 (81Br, M+H+CH3CN)+.
-
- To a solution of 5-bromo-3-[4-(propan-2-yloxy)phenyl]-3H-imidazo[4,5-b]pyridine (11 mg, 0.033 mmol) in 1,2-dimethoxyethane (0.4 mL) were added [4-(2-hydroxypropan-2-yl)phenyl]boronic acid (12 mg, 0.066 mmol), [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (2.4 mg, 0.0033 mmol), potassium carbonate (14 mg, 0.1 mmol) and water (0.1 mL). The resulting reaction mixture was degassed with nitrogen for 10 min, then heated to 90° C. for 5 h. Then the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 1:1 to 1:8) to give 6 mg (47%) of the product as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.49 (br. s, 1H), 8.24 (d, 1H), 8.03 (d, 2H), 7.84 (d, 1H), 7.72 (d, 2H), 7.59 (d, 2H), 7.08 (d, 2H), 4.63 (sep, 1H), 2.24 (br. s, 1H), 1.62 (s, 6H), 1.40 (d, 6H). LC/MS m/z: 388.25 (M+H)+, 429.28 (M+H+CH3CN)+.
- Examples B2 to B15 were prepared in the same manner as described above for example B1, 2-(4-{3-[4-(propan-2-yloxy)phenyl]-3H-imidazo[4,5-b]pyridin-5-yl}phenyl)propan-2-ol using the appropriate starting materials performing the reaction either under conventional heating or in a microwave reactor.
-
Ex. Starting materials Product/Name Analytical Data B2 5-bromo-3-[4-(propan- 2-yloxy)phenyl]-3H- imidazo[4,5-b]pyridine (4-isopropoxyphenyl) boronic acid 1H NMR (300 MHz, CDCl3) δ 8.61 (s, 1H), 8.30 (d, 1H), 8.08 (d, 1H), 8.02 (d, 2H), 7.73 (d, 2H), 7.13 (d, 2H), 7.01 (d, 2H), 4.70-4.61 (m, 2H), 1.44 (d, 6H), 1.39 (d, 6H). LC/MS m/z: 388.33 (M + H)+, 429.25 (M + H + CH3CN)+. 3,5-bis[4-(propan-2-yloxy) phenyl]-3H-imidazo[4,5-b] pyridine B3 5-bromo-3-[4-(propan- 2-yloxy)phenyl]-3H- imidazo[4,5-b]pyridine 1H-indol-5-ylboronic acid LC/MS m/z: 369.26 (M + H)+. 5-{3-[4-(propan-2-yloxy) phenyl]-3H-imidazo[4,5- b]pyridin-5-yl}-1H-indole B4 5-bromo-3-[4-(propan- 2-yloxy)phenyl]-3H- imidazo[4,5-b]pyridine (4-acetylphenyl) boronic acid LC/MS m/z: 372.24 (M + H)+, 413.24 (M + H + CH3CN)+ 1-(4-{3-[4-(propan-2-yloxy) phenyl]-3H-imidazo[4,5-b] pyridin-5-yl}phenyl)ethan-1- one B5 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H- imidazo[4,5-c]pyridine [4-(2-hydroxypropan- 2-yl)phenyl]boronic acid LC/MS m/z: 388.32 (M + H)+ 2-(4-{1-[4-(propan-2-yloxy) phenyl]-1H-imidazo[4,5-c] pyridin-6-yl}phenyl)propan- 2-ol B6 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H- imidazo[4,5-c]pyridine (4-isopropoxyphenyl) boronic acid LC/MS m/z: 388.27 (M + H)+ 1,6-bis[4-(propan-2-yloxy) phenyl]-1H-imidazo[4,5- c]pyridine B7 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H- imidazo[4,5-c]pyridine 1H-indol-5-ylboronic acid LC/MS m/z: 369.39 (M + H)+ 5-{1-[4-(propan-2-yloxy) phenyl]-1H-imidazo[4,5- c]pyridin-6-yl}-1H-indole B8 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H- imidazo[4,5-c]pyridine (4-acetylphenyl) boronic acid LC/MS m/z: 372.29 (M + H)+ 1-(4-{1-[4-(propan-2-yloxy) phenyl]-1H-imidazo[4,5-c] pyridin-6-yl}phenyl)ethan-1- one B9 2-chloro-9-[4-(propan- 2-yloxy)phenyl]-9H- purine [4-(2-hydroxypropan- 2-yl)phenyl]boronic acid LC/MS m/z: 389.14 (M + H)+ 2-(4-{9-[4-(propan-2-yloxy) phenyl]-9H-purin-2-yl} phenyl)propan-2-ol B10 2-chloro-9-[4-(propan- 2-yloxy)phenyl]-9H- purine (4-isopropoxyphenyl) boronic acid LC/MS m/z: 389.31 (M + H)+ 2,9-bis[4-(propan-2- yloxy)phenyl]-9H-purine B11 2-chloro-9-[4-(propan- 2-yloxy)phenyl]-9H- purine 1H-indol-5-ylboronic acid LC/MS m/z: 370.32 (M + H)+ 2-(1H-indol-5-yl)-9-[4- (propan-2-yloxy)phenyl]-9H- purine B12 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H- 1,2,3- benzotriazole (4-isopropoxyphenyl) boronic acid 1H NMR (300 MHz, CDCl3) δ 8.17 (s, 1H), 7.77 (s, 1H), 7.66 (s, 1H), 7.68 (d, 2H), 7.58 (d, 2H), 7.13 (d, 2H), 7.01 (d, 2H), 4.65-4.62 (m, 2H), 1.43 (d, 6H), 1.40 (d, 6H). LC/MS m/z: 388.22 (M + H)+, 429.27 (M + H + CH3CN)+ 1,6-bis[4-(propan-2-yloxy) phenyl]-1H-1,2,3- benzotriazole B13 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H- 1,2,3-benzotriazole 1H-indol-5-ylboronic acid 1H NMR (300 MHz, CDCl3) δ 8.35 (br, 1H), 8.20 (d, 1H), 7.93 (s, 1H), 7.87 (s, 1H), 7.79 (d, 1H), 7.72 (d, 2H), 7.52 (s, 1H), 7.29 (s, 1H), 7.13 (d, 2H), 6.66 (s, 1H), 4.63-4.80 (m, 2H), 1.45 (d, 6H). LC/MS m/z: 369.17 (M + H)+. 6-(1H-indol-5-yl)-1-[4- (propan-2-yloxy)phenyl]-1H- 1,2,3-benzotriazole B14 6-bromo-1-[4-(propan- 2-yloxy)phenyl]-1H- 1,2,3-benzotriazole (4-acetylphenyl) boronic acid 1H NMR (300 MHz, CDCl3) δ 8.18 (s, 1H), 7.77 (s,1H), 7.70 (d, 2H), 7.68 (s, 1H), 7.59 (d, 2H), 7.14 (d, 2H), 7.02 (d, 2H), 4.65-4.82 (m, 2H), 1.44 (d, 6H), 1.41 (d, 6H). LC/MS m/z: 372.26 (M + H)+, 413.31 (M + H + CH3CN)+. 1-(4-{1-[4-(propan-2-yloxy) phenyl]-1H-1,2,3-benzotri- azol-6-yl}phenyl)ethan-1-one B15 6-bromo-5-methyl-1- [4-(propan-2-yloxy) phenyl]-1H-1,2,3- benzotriazole (4-isopropoxyphenyl) boronic acid 1H NMR (300 MHz, CDCl3) δ 8.03 (br, 1H), 7.67 (d, 2H), 7.54 (s, 1H), 7.28 (d, 2H), 7.06 (d, 2H), 6.97 (d, 2H), 4.57-4.68 (m, 2H), 2.43 (s, 3H), 1.41 (d, 6H), 1.39 (d, 6H). LC/MS m/z: 401.29 (M + H)+. 5-methyl-1,6-bis[4-(propan- 2-yloxy)phenyl]-1H-1,2,3- benzotriazole -
- To a solution of 6-bromo-3-iodoimidazo[1,2-a]pyridine (0.3 g, 0.93 mmol) in dioxane (9 mL) were added (4-isopropoxyphenyl)boronic acid (0.167 g, 0.93 mmol), tetrakis(triphenylphosphine) palladium(0) (0.075 g, 0.065 mmol), sodium carbonate (0.3 g, 2.8 mmol) and water (3 mL). The resulting reaction mixture was degassed with nitrogen for 10 min, then heated to 90° C. for 5 h. Then the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 4:1 to 1:2) to give 0.26 g (84%) of the product as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.36 (s, 1H), 7.62 (s, 1H), 7.57 (d, 1H), 7.42 (d, 2H), 7.23 (d, 1H), 7.03 (d, 2H), 4.62 (sep, 1H), 1.39 (d, 6H). LC/MS m/z: 331.07 (79Br, M+H)+, 333.14 (81Br, M+H)+.
-
- To a solution of 6-bromo-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (20 mg, 0.06 mmol) in 1,2-dimethoxyethane (0.8 mL) were added [4-(2-hydroxypropan-2-yl)phenyl]boronic acid (22 mg, 0.12 mmol), [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (4.4 mg, 0.006 mmol), potassium carbonate (25 mg, 0.18 mmol) and water (0.2 mL). The resulting reaction mixture was degassed with nitrogen for 10 min, then heated to 90° C. for 5 h. Then the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 1:1 to 1:10, then pure EtOAc) to give 12 mg (52%) of the product as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 8.42 (s, 1H), 7.82 (d, 1H), 7.66 (s, 1H), 7.59 (d, 2H), 7.48-7.51 (m, 3H), 7.46 (d, 2H), 7.05 (d, 2H), 4.62-4.64 (m, 1H), 2.20-2.45 (br s, 1H), 1.62 (s, 6H), 1.40 (d, 6H). LC/MS m/z: 387.27 (M+H)+.
-
- To a solution of 6-bromo-3-iodoimidazo[1,2-a]pyridine (0.3 g, 0.93 mmol) in dioxane (9 mL) and water (3 mL) was added (4-isopropoxyphenyl)boronic acid (0.334 g, 1.86 mmol) and sodium carbonate (0.6 g, 5.6 mmol). The reaction mixture was purged with nitrogen, then Pd(dppf)Cl2 (0.05 g, 0.06 mmol) was added. The resulting reaction mixture was heated to 90° C. for 12 h, brought to room temperature and was extracted with ethyl acetate. Dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 4:1 to 1:2) to give 0.24 g (62%) of the title compound as a beige solid. 1H NMR (300 MHz, CDCl3) δ 8.37 (s, 1H), 7.70 (d, 1H), 7.64 (s, 1H), 7.49 (d, 2H), 7.44 (d, 2H), 7.41 (d, 1H), 7.05 (d, 2H), 6.97 (d, 2H), 4.56-4.67 (m, 2H), 1.40 (d, 6H), 1.37 (d, 6H). LC/MS m/z: 387.28 (M+H)+.
- Examples C3 to C26 were prepared in the same manner as described above for example C1, 2-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)propan-2-ol using 6-bromo-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine and appropriate commercial boronic acid or boronic acid pinacol ester performing the reaction either under conventional heating or in a microwave reactor.
-
Ex. Starting materials Product/Name Analytical Data C3 4-(cyclopropoxy) phenylboronic acid LC/MS m/z: 385.31 (M + H)+ 6-(4-cyclopropoxyphenyl)-3- [4-(propan-2-yloxy)phenyl] imidazo[1,2-a]pyridine C4 4-(difluoromethoxy) phenyl boronic acid LC/MS m/z: 395.22 (M + H)+ 6-[4-(difluoromethoxy) phenyl]-3-[4-(propan-2-yloxy) phenyl]imidazo[1,2- a]pyridine C5 4-(difluoromethyl) phenyl boronic acid LC/MS m/z: 379.23 (M + H)+ 6-[4-(difluoromethyl)phenyl]- 3-[4-(propan-2-yloxy)phenyl] imidazo[1,2-a]pyridine C6 4-hydroxyphenyl boronic acid LC/MS m/z: 345.27 (M + H)+ 4-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}phenol C7 4-fluorophenyl boronic acid LC/MS m/z: 347.30 (M + H)+ 6-(4-fluorophenyl)-3-[4- (propan-2-yloxy)phenyl] imidazo[1,2-a]pyridine C8 1H-indol-5-ylboronic acid LC/MS m/z: 368.28 (M + H)+ 5-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}-1H-indole C9 4-(1-hydroxycyclo butyl)phenyl boronic acid LC/MS m/z: 399.28 (M + H)+ 1-(4-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}phenyl)cyclobutan-1-ol C10 1H-indazol-5- ylboronic acid LC/MS m/z: 369.33 (M + H)+ 5-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}-1H-indazole C11 1H-indol-6-boronic acid LC/MS m/z: 368.36 (M + H)+ 6-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}-1H-indole C12 2-isopropoxypyridine- 5-boronic acid LC/MS m/z: 388.28 (M + H)+ 2-(propan-2-yloxy)-5-{3-[4- (propan-2-yloxy)phenyl] imidazo[1,2-a]pyridin-6-yl} pyridine C13 (4-acetylphenyl) boronic acid 1H NMR (300 MHz, CDCl3) δ 8.48 (s, 1H), 8.06 (d, 2H), 7.93 (d, 1H), 7.70 (s, 1H), 7.66-7.58 (m, 3H), 7.49 (d, 2H), 7.08 (d, 2H), 4.69- 4.61 (m, 1H), 2.65 (s, 3H), 1.41 (d, 6H). LC/MS m/z: 371.33 (M + H)+ 1-(4-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}phenyl)ethan-1-one C14 5-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2- yl)pyridin-2-amine LC/MS m/z: 345.32 (M + H)+ 5-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}pyridin-2-amine C15 4-(1-aminocyclo propyl)phenyl boronic acid LC/MS m/z: 384.35 (M + H)+ 1-(4-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}phenyl)cyclopropan-1- amine C16 (4-carbamoylphenyl) boronic acid LC/MS m/z: 372.23 (M + H)+ 4-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}benzamide C17 1-cyclopropyl-4- (4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2- yl)pyrazole LC/MS m/z: 359.26 (M + H)+ 1-cyclopropyl-4-{3-[4- (propan-2-yloxy)phenyl] imidazo[1,2-a]pyridin-6-yl}- 1H-pyrazole C18 4-isopropoxy-2- methylphenyl boronic acid LC/MS m/z: 401.39 (M + H)+ 6-[2-methyl-4-(propan-2- yloxy)phenyl]-3-[4-(propan-2- yloxy)phenyl]imidazo[1,2- a]pyridine C19 4-isopropoxy-3- methylphenyl boronic acid 1H NMR (300 MHz, CDCl3) δ 8.36 (s, 1H), 8.13 (d, 1H), 7.76 (d, 1H), 7.69 (s, 1H), 7.48 (d, 2H), 7.29 (s, 1H), 7.26 (d, 1H), 7.09 (d, 2H), 6.92 (d, 1H), 4.51-4.73 (m, 2H), 2.27 (s, 3H), 1.41 (d, 6H), 1.38 (d, 6H). LC/MS m/z: 401.34 (M + H)+ 6-[3-methyl-4-(propan-2- yloxy)phenyl]-3-[4-(propan-2- yloxy)phenyl]imidazo[1,2-a] pyridine C20 {4-[(propan-2-yloxy) carbonyl]phenyl} boronic acid LC/MS m/z: 415.30 (M + H)+ propan-2-yl 4-{3-[4-(propan- 2-yloxy)phenyl]imidazo[1,2-a] pyridin-6-yl}benzoate C21 [4-(tert-butoxy) phenyl]boronic acid 1H NMR (300 MHz, CDCl3) δ 8.39 (s, 1H), 7.94 (d, 1H), 7.68 (s, 1H), 7.62 (d, 1H), 7.49 (d, 2H), 7.43 (d, 2H), 7.09 (d, 2H), 7.06 (d, 2H), 4.60-4.71 (m, 1H), 1.42 (d, 6H), 1.39 (s, 9H). LC/MS m/z: 401.30 (M + H)+ 6-[4-(tert-butoxy)phenyl]-3-[4- (propan-2-yloxy)phenyl] imidazo[1,2-a]pyridine C22 1-methylindole-5- boronic acid 1H NMR (300 MHz, CDCl3) δ 8.45 (s, 1H), 7.85 (d, 1H), 7.77 (s, 1H), 7.66 (s, 1H), 7.64 (d, 1H), 7.51 (d, 2H), 7.40 (br s, 2H), 7.12 (d, 1H), 7.06 (d, 2H), 6.55 (d, 1H), 4.61- 4.69 (m, 1H), 3.84 (s, 3H), 1.41 (d, 6H). LC/MS m/z: 382.35 (M + H)+ 1-methyl-5-{3-[4-(propan-2- yloxy)phenyl]imidazo[1,2-a] pyridin-6-yl}-1H-indole C23 [2-fluoro-4-(propan-2- yloxy)phenyl]boronic acid LC/MS m/z: 405.30 (M + H)+ 6-[2-fluoro-4-(propan-2- yloxy)phenyl]-3-[4-(propan-2- yloxy)phenyl]imidazo[1,2-a] pyridine C24 [3-fluoro-4-(propan-2- yloxy)phenyl]boronic acid 1H NMR (300 MHz, CDCl3) δ 8.36 (s, 1H), 7.99 (d, 1H), 7.69 (s, 1H), 7.59 (d, 1H), 7.48 (d, 2H), 7.28 (s, 1H), 7.23 (d, 1H), 7.08 (d, 2H), 7.05 (d, 1H), 4.53-4.72 (m, 2H), 1.41 (d, 6H), 1.39 (d, 6H). LC/MS m/z: 405.26 (M + H)+ 6-[3-fluoro-4-(propan-2-yloxy) phenyl]-3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridine C25 4-(2-morpholino ethoxy)phenyl boronic acid LC/MS m/z: 458.32 (M + H)+ 4-[2-(4-{3-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin- 6-yl}phenoxy)ethyl] morpholine C26 N-(propan-2-yl)-4- (4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2- yl)aniline 1H NMR (300 MHz, CDCl3) δ 8.32 (s, 1H), 8.19 (d, 1H), 7.82 (dd, 1H), 7.66 (s, 1H), 7.45 (d, 2H), 7.31 (d, 2H), 7.07 (d, 2H), 6.65 (d, 2H), 4.69-4.59 (m, 1H), 3.73-3.60 (m, 1H), 1.40 (d, 6H), 1.23 (d, 6H). LC/MS m/z: 386.32 (M + H)+ N-(propan-2-yl)-4-{3-[4- (propan-2-yloxy)phenyl] imidazo[1,2-a]pyridin-6-yl} aniline -
- To a solution of 1-(4-bromophenyl)cyclopropan-1-ol (90 mg, 0.42 mmol) in DCM (1.5 mL) cooled to 0° C. was added imidazole (57 mg, 0.84 mmol), followed by TBDMSCl (76 mg, 0.5 mmol). The reaction mixture was brought to rt gradually and stirred for 2 h. Then DCM (10 mL) was added and the reaction mixture was washed with water. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was dissolved in DCM and passed through a short pad of silica gel eluting with DCM. Then volatiles were removed in vacuo to give 0.14 g (quantitative yield) of the product as a colorless oil, which was used in the next step.
-
- To a degassed mixture of [1-(4-bromophenyl)cyclopropoxy](tert-butyl)dimethylsilane (0.14 g, 0.42 mmol), bis(pinacolato)diboron (0.16 g, 0.63 mmol) and potassium acetate (0.13 g, 1.3 mmol) in anhydrous dioxane (1.6 mL) was added bis(triphenylphosphine)palladium(II) dichloride (0.03 g, 0.042 mmol). The resulting reaction mixture was stirred under N2 atmosphere at 90° C. for 3 h. Then the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on SiO2 (hexanes/EtOAc8:1) to give 0.11 g (69%) of the product as a colorless oil which solidified upon standing. 1H NMR (300 MHz, CDCl3) δ 7.75 (d, 2H), 7.31 (d, 2H), 1.35 (s, 12H), 1.23-1.17 (m, 2H), 1.04-0.99 (m, 2H), 0.89 (s, 9H), 0.00 (s, 6H).
-
- The title compound was prepared from 3-(4-bromophenyl)oxetan-3-olin the same manner as described above for [1-(4-bromophenyl)cyclopropoxy](tert-butyl)dimethylsilane.
-
- The title compound was prepared from {[3-(4-bromophenyl)oxetan-3-yl]oxy}(tert-butyl)dimethylsilanein the same manner as described above for tert-butyldimethyl{1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropoxy}silane. 1H NMR (300 MHz, CDCl3) δ 7.87 (d, 2H), 7.62 (d, 2H), 5.00 (d, 2H), 4.84 (d, 2H), 1.37 (s, 12H), 0.96 (s, 9H), 0.00 (s, 6H).
-
- The title compound was prepared from tert-butyl 3-(4-bromophenyl)-3-hydroxyazetidine-1-carboxylate in the same manner as described above for [1-(4-bromophenyl)cyclopropoxy](tert-butyl)dimethylsilane.
-
- The title compound was prepared from tert-butyl 3-(4-bromophenyl)-3-[(tert-butyldimethylsilyl)oxy]azetidine-1-carboxylate in the same manner as described above for tert-butyldimethyl{1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropoxy}silane.
-
- The title compound was prepared from 6-bromo-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine and tert-butyldimethyl{1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropoxy}silane in the same manner as described above for 2-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)propan-2-ol (Example C1). LC/MS m/z: 499.36 (M+H)+.
-
- To a solution of 6-(4-{1-[(tert-butyldimethylsilyl)oxy]cyclopropyl}phenyl)-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (12 mg, 0.024 mmol) in THE (0.5 mL) was added TBAF.3H2O (20 mg, 0.063 mmol). The reaction mixture was stirred at rt for 2 h, then concentrated in vacuo. The residue was dissolved in EtOAc and washed with water. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 1:1 to 1:10, then pure EtOAc) to give 5.6 mg (60%) of the title compound as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.39 (s, 1H), 8.02 (d, 1H), 7.69-7.63 (m, 2H), 7.46-7.36 (m, 6H), 7.06 (d, 2H), 4.63 (sep, 1H), 3.31 (br. s, 1H), 1.39 (d, 6H), 1.37-1.33 (m, 2H), 1.09-1.05 (m, 2H). LC/MS m/z: 385.29 (M+H)+.
-
- The title compound was prepared from 6-bromo-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine and tert-butyldimethyl({3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]oxetan-3-yl}oxy)silane in the same manner as described above for 2-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)propan-2-ol (Example C1). LC/MS m/z: 515.38 (M+H)+.
-
- The title compound was prepared from 6-(4-{3-[(tert-butyldimethylsilyl)oxy]oxetan-3-yl}phenyl)-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine in the same manner as described above for 1-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)cyclopropan-1-ol. LC/MS m/z: 401.31 (M+H)+.
-
- The title compound was prepared from 6-bromo-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine and tert-butyl 3-[(tert-butyldimethylsilyl)oxy]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]azetidine-1-carboxylate in the same manner as described above for 2-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-ylphenyl)propan-2-ol (Example C1). LC/MS m/z: 614.42 (M+H)+.
-
- To a solution of tert-butyl 3-[(tert-butyldimethylsilyl)oxy]-3-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)azetidine-1-carboxylate (29 mg, 0.047 mmol) in DCM (1 mL) was added trifluoroacetic acid (0.25 mL). The reaction mixture was stirred at rt overnight. Then, solvent was evaporated, and the residue was dissolved in DCM and washed with saturated aq. NaHCO3 solution. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo to give 20 mg (83%) of the product as a colorless oil, which was used in the next step without further purification. LC/MS m/z: 514.44 (M+H)+.
-
- The title compound was prepared from 3-[(tert-butyldimethylsilyl)oxy]-3-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)azetidine in the same manner as described above for 1-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)cyclopropan-1-ol. LC/MS m/z: 400.41 (M+H)+.
-
- 3-bromo-6-iodoimidazo[1,2-a]pyridine (100 mg, 0.3 mmol) was added to a microwave reactor vial followed by 4-isopropoxyphenyl boronic acid (62 mg, 0.34 mmol), tetrakis(triphenylphosphine) palladium(0) (34 mg, 0.03 mmol), sodium carbonate (94 mg, 0.9 mmol), 3 mL of 1,4-dioxane, and 1 mL of water. The mixture was capped tightly and degassed by bubbling nitrogen through the septum for 5 minutes. The resulting solution was heated to 90° C. for 15 minutes in a microwave reactor and allowed to cool. The mixture was then diluted with ethyl acetate, washed with water (2×) and brine (1×), dried over sodium sulfate, and evaporated. The crude oil was purified by flash chromatography on silica (1:1 hexanes:ethyl acetate, isocratic) to provide the title compound (82 mg) as a light yellow oil that slowly solidified. LC/MS m/z: 331.24 (79Br, M+H)+, 333.28(81Br, M+H)+.
-
- To a solution of 3-bromo-6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (20 mg, 0.06 mmol) in 2 mL THF:Water 3:1 was added 4-cyclopropylboronic acid (12 mg, 0.072 mmol), potassium carbonate (5 mg, 0.18 mmol), and Pd(dppf)Cl2 dichloromethane complex (5 mg, 0.006 mmol). The mixture was capped tightly and degassed by bubbling nitrogen through the septum for 5 minutes. The resulting solution was heated to 100° C. for 15 minutes in a microwave reactor and allowed to cool. The mixture was then diluted with ethyl acetate, washed with water (2×) and brine (1×), dried over sodium sulfate, and evaporated. The crude oil was purified by flash chromatography on silica (3:7 hexanes:ethyl acetate, isocratic) to provide 13 mg of the title compound as a light yellow oil. LC/MS m/z: 369.26 (M+H)+
- Examples C31 to C43 were prepared in the same manner as described above for example C30, 3-(4-cyclopropylphenyl)-6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine, using 3-bromo-6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine, the appropriate commercial boronic acid or boronic acid pinacol ester, and the appropriate catalyst (Method A: Pd(PPh3)4; Method B: Pd(dppf)Cl2.DCM; Method C: Pd(dba)2 (0.1 eq.)/PCy3 (0.15 eq.))
-
Meth- Starting Ex. od materials Product/Name Analytical Data C31 A (4-cyclopropoxy phenyl)boronic acid 1H NMR (300 MHz, CDCl3) δ ppm 8.39 (s, 1H), 8.08 (d, 1H), 7.72 (d, 2H), 7.56-7.39 (m, 5H), 7.25 (s, 1H), 7.00 (d, 2H), 4.62 (sep, 1H), 3.88-3.80 (m, 1H), 1.38 (d, 6H), 0.87 (br:s, 4H). LC/MS m/z: 385.31 (M + H)+ 3-(4-cyclopropoxy phenyl)-6- [4-(propan-2-yloxy)phenyl] imidazo[1,2-a]pyridine C32 A (4-(tert-butoxy) phenyl)boronic acid 1H NMR (300 MHz, CDCl3) δ ppm 8.41 (s, 1H), 8.02 (d, 1H), 7.72 (s, 1H), 7.66 (d, 1H), 7.47 (dd, 4H), 7.19 (d, 2H), 7.00 (d, 2H), 4.62 (sept, 1H), 1.46 (s, 9H), 1.39 (d, 6H). LC/MS m/z: 401.35 (M + H)+ 3-[4-(tert-butoxy)phenyl]-6-[4- (propan-2-yloxy)phenyl] imidazo[1,2-a]pyridine C33 A (4-(cyclopropyl methoxy)phenyl) boronic acid 1H NMR (300 MHz, CDCl3) δ ppm 8.37 (s, 1H), 8.05 (d, 1H), 7.73- 7.66 (m, 2H), 7.47 (dd, 4H), 7.11 (d, 2H), 6.99 (d, 2H), 4.62 (sept, 1H), 3.91 (d, 2H), 1.39 (d, 6H), 0.77-0.66 (m, 2H), 0.46-0.37 (m, 2H). LC/MS m/z: 399.31 (M + H)+ 3-[4-(cyclopropylmethoxy) phenyl]-6-[4-(propan-2-yloxy) phenyl]imidazo[1,2a]pyridine C34 A (2,3-dihydro benzofuran-5-yl) boronic acid LC/MS m/z: 371.35 (M + H)+ 3-(2,3-dihydro-1-benzofuran-5- yl)-6-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridine C35 A (3-isopropoxy phenyl)boronic acid LC/MS m/z: 387.34 (M + H)+, 428.47 (M + H + CH3CN)+ 3-[3-(propan-2-yloxy)phenyl]- 6-[4-(propan-2-yloxy)phenyl] imidazo[1,2-a]pyridine C36 B (4- (difluoromethyl) phenyl)boronic acid LC/MS m/z: 379.31 (M + H)+, 420.51 (M + H + CH3CN)+ 3-[4-(difluoromethyl)phenyl]-6- [4-(propan-2-yloxy)phenyl] imidazo[1,2-a]pyridine C37 A (6-isopropoxy pyridin-3- yl)boronic acid LC/MS m/z: 388.32 (M + H)+, 429.34 (M + H + CH3CN)+ 2-(propan-2-yloxy)-5-{6-[4- (propan-2-yloxy)phenyl] imidazo[1,2-a]pyridin-3- yl}pyridine C38 B (4-(2-hydroxy propan-2-yl phenyl)boronic acid LC/MS m/z: 387.28 (M + H)+, 428.55 (M + H + CH3CN)+ 2-(4-{6-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin-3- yl}phenyl)propan-2-ol C39 B 1H-indol-5- ylboronic acid LC/MS m/z: 368.24 (M + H)+ 5-{6-[4-(propan-2yloxy)phenyl] imidazo[1,2-a]pyridin-3-yl}-1H- indole C40 C (4-(difluoro methoxy)phenyl) boronic acid LC/MS m/z: 395.26 (M + H)+, 436.22 (M + H + CH3CN)+ 3-[4-(difluoromethoxy)phenyl]- 6-[4-(propan-2-yloxy)phenyl] imidazo[1,2a]pyridine C41 A (4-acetylphenyl) boronic acid LC/MS m/z: 371.28 (M + H)+ 1-(4-{6-[4-(propan-2-yloxy) phenyl]imidazo[1,2-a]pyridin-3- yl}phenyl)ethan-1-one C42 B [4-(2-methoxy ethoxy)phenyl] boronic acid LC/MS m/z: 403.31 (M + H)+ 3-[4-(2-methoxyethoxy) phenyl]-6-[4-(propan-2- yloxy)phenyl]imidazo[1,2- a]pyridine C43 B 4-(2-morpholino ethoxy)phenyl boronic acid LC/MS m/z: 458.10 (M + H)+ 4-[2-(4-{6-[4-(propan-2- yloxy)phenyl]imidazo[1,2- a]pyridin-3-yl}phenoxy) ethyl]morpholine -
- The title compound was prepared from 3-bromo-6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine and tert-butyldimethyl{1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropoxy}silane in the same manner as described above for 3-(4-cyclopropylphenyl)-6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C30). LC/MS m/z: 499.33 (M+H)+.
-
- The title compound was prepared from 3-(4-{1-[(tert-butyldimethylsilyl)oxy]cyclopropyl}phenyl)-6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine in the same manner as described above for 1-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)cyclopropan-1-ol. 1H NMR (300 MHz, CDCl3) δ 8.43-8.37 (m, 2H), 7.97 (d, 1H), 7.63 (s, 1H), 7.55-7.48 (m, 4H), 7.41 (d, 2H), 6.99 (d, 2H), 4.60 (sep, 1H), 1.96 (br. s, 1H), 1.47-1.42 (m, 2H), 1.36 (d, 6H), 1.17-1.13 (m, 2H). LC/MS m/z: 385.35 (M+H)+.
-
- The title compound was prepared from 3-bromo-6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine and [4-(ethoxycarbonyl)phenyl]boronic acid in the same manner as described above for 3-(4-cyclopropylphenyl)-6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C30). LC/MS m/z: 401.31 (M+H)+.
-
- To a solution of ethyl 4-{6-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-3-yl}benzoate (9.7 mg, 0.024 mmol) in a mixture of MeOH/THF (1:1) (0.5 mL) was added 2N NaOH (0.25 mL). The reaction mixture was stirred at rt for 4 h, then concentrated in vacuo. The residue was acidified with 1 N HCl, and then purified by preparative HPLC to afford 2 mg (22%) of the product as a white solid. LC/MS m/z: 373.20 (M+H)+.
-
- The title compound was prepared from 6-bromo-3-iodoimidazo[1,2-a]pyridine and 4-(cyclopropoxy)phenylboronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). LC/MS m/z: 383.33 (M+H)+.
-
- The title compound was prepared from 6-bromo-3-iodoimidazo[1,2-a]pyridine and 4-(1-hydroxycyclobutyl)phenylboronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). LC/MS m/z: 411.34 (M+H)+.
-
- To a solution of 6-bromo-7-methylimidazo[1,2-a]pyridine (100 mg, 0.47 mmol) in CH2Cl2 (1 mL), was added 1-lodopyrrolidine-2,5-dione (84 mg, 0.47 mmol) and MeOH (0.1 mL). The resulting mixture was stirred at room temperature for 2 h. The reaction was poured into water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane/EtOAc=1:1) to give 122 mg (77%) of the product as a white solid. LC/MS m/z: 337.00 (M+H)+.
- The title compound was prepared from 6-bromo-3-iodo-7-methylimidazo[1,2-a]pyridine and [4-(propan-2-yloxy)phenyl]boronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). LC/MS m/z: 401.33 (M+H)+.
-
- The title compound was prepared from 6-bromo-7-methoxyimidazo[1,2-a]pyridine in the same manner as described above for 6-bromo-3-iodo-7-methylimidazo[1,2-a]pyridine (Example C48, step 1). LC/MS m/z: 394.01(M+H+CH3CN)+.
-
- The title compound was prepared from 6-bromo-3-iodo-7-methoxyimidazo[1,2-a]pyridine and [4-(propan-2-yloxy)phenyl]boronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). 1H NMR (300 MHz, CDCl3) δ 8.06 (s, 1H), 7.68 (s, 1H), 7.53 (s, 1H), 7.41 (d, 2H), 7.34 (d, 2H), 7.06 (d, 2H), 6.96 (d, 2H), 4.54-4.68 (m, 2H), 4.05 (s, 3H), 1.39 (d, 6H), 1.37 (d, 6H). LC/MS m/z: 417.27 (M+H)+.
-
- The title compound was prepared from 6-bromo-8-methylimidazo[1,2-a]pyridine in the same manner as described above for 6-bromo-3-iodo-7-methylimidazo[1,2-a]pyridine (Example C48, step 1). LC/MS m/z: 337.05 (79Br, M+H)+, 339.04 (81Br, M+H)+, 378.22 (79Br, M+H+CH3CN)+, 380.00 (81Br, M+H+CH3CN)+.
-
- The title compound was prepared from 6-bromo-3-iodo-8-methylimidazo[1,2-a]pyridine and [4-(propan-2-yloxy)phenyl]boronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). LC/MS m/z: 401.33 (M+H)+.
-
- The title compound was prepared from 6-bromo-7-methylimidazo[1,2-a]pyridine in the same manner as described above for 6-bromo-3-iodo-8-methylimidazo[1,2-a]pyridine (Example C50, step 1). LC/MS m/z: 337.00(M+H)+.
-
- The title compound was prepared from 6-bromo-3-iodo-7-methoxyimidazo[1,2-a]pyridine and [4-(propan-2-yloxy)phenyl]boronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). 1H NMR (300 MHz, CDCl3) δ 8.14 (d, 1H), 7.63 (s, 1H), 7.56 (d, 1H), 7.37 (d, 2H), 7.18 (d, 2H), 6.97 (d, 2H), 6.94 (d, 2H), 4.53-4.69 (m, 2H), 2.19 (s, 3H), 1.39 (d, 6H), 1.37 (d, 6H). LC/MS m/z: 401.29 (M+H)+.
-
- To a solution of 6-bromo-1H-indazole (10 mg, 0.04 mmol) in DMF (1 mL), were added 1-iodo-4-isopropoxybenzene (10 mg, 0.06 mmol), (1S,2S)—N1,N2-dimethylcyclohexane-1,2-diamine (0.8 mg, 0.084 mmol), copper(I) iodide (0.25 mg, 0.042 mmol), and Cs2CO3 (32.5 mg, 0.10 mmol). The resulting mixture was stirred at 120° C. for 2 hr under microwave irradiation. After cooling to room temperature, the reaction was filtered through a celite pad. The filtrate was concentrated under reduced pressure and the residue was poured into water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane/EtOAc=1:1) to give 7.5 mg (45.2%) of the product as a colorless oil. LC/MS m/z: 331.13 (79Br, M+H)+, 333.14 (81Br, M+H)+, 374.23 (79Br, M+H+CH3CN)+, 376.22 (81Br, M+H+CH3CN)+.
-
- To a solution of 6-bromo-1-(4-isopropoxyphenyl)-1H-indazole (10 mg, 0.03 mmol) in dioxane (1.0 mL) and water (0.3 mL) was added (4-isopropoxyphenyl)boronic acid (6.5 mg, 1.2 eq.) and sodium carbonate (10.4 mg, 2.5 eq.). The reaction mixture was purged with nitrogen, then Pd(dppf)Cl2 (2.2 mg, 0.1 eq.) was added. The resulting reaction mixture was heated to 110° C. for 0.5 h under microwave irradiation. After cooling the reaction was poured into water and extracted with ethyl acetate. Dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc=1:2) to give 7.2 mg (65%) of the title compound as an oil. LC/MS m/z: 387.34 (M+H)+.
-
- The title compound was prepared from 6-bromo-1-(4-isopropoxyphenyl)-1H-indazole and (1H-indol-5-yl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 368.27 (M+H)+.
-
- The title compound was prepared from 6-bromo-1-(4-isopropoxyphenyl)-1H-indazole and (4-acetylphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 371.30 (M+H)+, 413.24 (M+H+CH3CN)+.
-
- The title compound was prepared from 6-bromo-1H-indole and 1-iodo-4-isopropoxybenzene in the same manner as described above for 6-bromo-1-(4-isopropoxyphenyl)-1H-indazole (Example D1, Step 1). LC/MS m/z: 330.12 (79Br, M+H)+, 332.14 (81Br, M+H)+
-
- The title compound was prepared from 6-bromo-1-(4-isopropoxyphenyl)-1H-indole and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 386.33 (M+H)+.
-
- The title compound was prepared from 6-bromo-1-(4-isopropoxyphenyl)-1H-indole and (1H-indol-5-yl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 386.33 (M+H)+.
-
- To a solution of 6-(4-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine (10 mg, 0.039 mmol) in CH2Cl2 (0.5 mL), was added 1-bromopyrrolidine-2,5-dione (14.1 mg, 0.80 mmol) and MeOH (0.05 mL). The resulting mixture was stirred at room temperature for 2 hr. The reaction was poured into water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc) to give 7.2 mg (56%) of the product as a white solid. LC/MS m/z: 342.08 (79Br, M+H)+, 344.14 (81Br, M+H)+, 373.13 (79Br, M+H+CH3CN)+, 375.22 (81Br, M+H+CH3CN)+.
-
- The title compound was prepared from 6-bromo-3-(4-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 388.83 (M+H)+.
-
- The title compound was prepared from 3-bromo-6-(4-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine and (1H-indol-5-yl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 369.27 (M+H)+.
-
- To a solution of 2-bromo-1-(4-isopropoxyphenyl)ethan-1-one (100 mg, 0.39 mmol) in DMF (5 mL), were added 4-bromophenol (67.2 mg, 0.39 mmol) and Cs2CO3 (252 mg, 0.78 mmol) at room temperature. The resulting mixture was stirred at 40° C. for 1 hr. After cooling to room temperature, the reaction was filtered with a through pad. The filtrate was poured into water and extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was dissolved in toluene (5 mL) and then treated with trifluoromethylsulfonic acid (23.3 mg, 0.16 mmol) with 1 g of SiO2. The resulting mixture was heated to 105° C. for 5 hr. After cooling, the reaction was filtered through a celite pad. The filtrate was washed with water and the organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 (hexane/EtOAc=5:1) to afford 102 mg of the title compound (82 mg, 63.4%) as a colorless oil.
-
- The title compound was prepared from 5-bromo-3-(4-isopropoxyphenyl)benzofuran and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole.
-
- The title compound was prepared from 5-bromo-3-(4-isopropoxyphenyl)benzofuran and (1H-indol-5-yl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole.
-
- The title compound was prepared from 6-chloro-3-iodoimidazo[1,2-b]pyridazine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 6-bromo-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine. LC/MS m/z: 288.13 (35C1, M+H)+, 290.15 (37Cl, M+H)+.
-
- The title compound was prepared from 6-chloro-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-b]pyridazine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 388.25 (M+H)+.
-
- To a solution of tert-butyl 5-bromo-3-iodo-1H-indazole-1-carboxylate (30 mg, 0.071 mmol) in dioxane (0.5 mL) were added (4-isopropoxyphenyl)boronic acid (25 mg, 0.14 mmol), [1,1′-bis(diphenylphosphino) ferrocene]dichloropalladium(II) complex with dichloromethane (5.8 mg, 0.0071 mmol), potassium carbonate (30 mg, 0.22 mmol) and water (0.125 mL). The resulting reaction mixture was degassed with nitrogen for 10 min, heated to 100° C. for 10 min in a microwave reactor, then heated to 120° C. for additional 15 min. Then, the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was dissolved in DCM (1 mL) and TFA (0.25 mL) was added dropwise. The reaction mixture was stirred at rt for 3 h, then concentrated in vacuo. The residue was purified by preparative HPLC to afford 7 mg (26%) of the product as a yellow solid. LC/MS m/z: 387.28 (M+H)+, 773.52 (2M+H)+.
-
- The title compound was prepared from 6-bromoimidazo[1,2-a]pyrazine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 254.54 (M+H)+.
-
- The title compound was prepared from 6-(4-isopropoxyphenyl)imidazo[1,2-a]pyrazine in the same manner as described above for 3-bromo-6-(4-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine (Example D6, Step 1). LC/MS m/z: 342.19 (79Br, M+H)+, 344.17 (81Br, M+H)+, 373.16 (79Br, M+H+CH3CN)+, 375.14 (81Br, M+H+CH3CN)+.
-
- The title compound was prepared from 3-bromo-6-(4-isopropoxyphenyl)imidazo[1,2-a]pyrazine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 388.26 (M+H)+, 429.31 (M+H+CH3CN)+.
-
- The title compound was prepared from 3-bromo-6-(4-isopropoxyphenyl)imidazo[1,2-a]pyrazine and (1H-indol-5-yl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 369.27 (M+H)+.
-
- The title compound was prepared from 3-bromo-6-(4-isopropoxyphenyl)imidazo[1,2-a]pyrazine and (4-acetylphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 369.27 (M+H)+, 413.35 (M+H+CH3CN)+.
-
- The title compound was prepared from 6-(4-isopropoxyphenyl)imidazo[1,2-a]pyrimidine in the same manner as described above for 3-bromo-6-(4-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine (Example D6, Step 1). LC/MS m/z: 332.16 (79Br, M+H)+, 334.15 (81Br, M+H)+.
-
- The title compound was prepared from 6-bromo-3-(4-isopropoxyphenyl)imidazo[1,2-a]pyrimidine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 388.28 (M+H)+.
-
- The title compound was prepared from 3-bromo-6-(4-isopropoxyphenyl)imidazo[1,2-a]pyrimidine and (1H-indol-5-yl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole as a colorless oil. LC/MS m/z: 369.31 (M+H)+.
-
- The title compound was prepared from 6-bromoimidazo[1,5-a]pyridine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 253.22 (M+H)+.
-
- The title compound was prepared from 6-(4-isopropoxyphenyl)imidazo[1,5-a]pyridine in the same manner as described above for 6-bromo-3-iodo-7-methylimidazo[1,2-a]pyridine (Example C48, step 1). LC/MS m/z: 379.16 (M+H)+, 420.13 (M+H+CH3CN)+.
-
- The title compound was prepared from 3-iodo-6-(4-isopropoxyphenyl)imidazo[1,5-a]pyridine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole as a colorless oil. LC/MS m/z: 387.39 (M+H)+.
-
- To a vigorously stirred solution of KOH (0.64 g, 11.4 mmol) in MeOH (1.3 mL) cooled to 0° C. was added 2-[4-(propan-2-yloxy)phenyl]acetonitrile (0.1 g, 0.57 mmol). After the solution was complete, a solution of 1-bromo-4-nitrobenzene (0.115 g, 0.57 mmol) in a mixture of THE (0.5 mL) and MeOH (1 mL) was added dropwise. The reaction mixture was brought to r.t. gradually and stirred overnight, then concentrated in vacuo. The residue was dissolved in EtOAc and washed with water. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 9:1 to 4:1) to give 36 mg (19%) of the product as yellow solid. LC/MS m/z: 331.92 (79Br, M+H)+, 333.97 (81Br, M+H)+.
-
- The title compound was prepared from 5-bromo-3-[4-(propan-2-yloxy)phenyl]-2,1-benzoxazole and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 1,6-bis[4-(propan-2-yloxy)phenyl]-1H-indazole. LC/MS m/z: 388.21 (M+H)+, 775.52 (2M+H)+.
-
- The title compound was prepared from 7-bromoimidazo[1,5-a]pyridine in the same manner as described above for 6-bromo-3-iodo-7-methylimidazo[1,2-a]pyridine (Example C48, step 1). LC/MS m/z: 322.56 (79Br, M+H)+, 324.93 (81Br, M+H)+, 364.01 (79Br, M+H+CH3CN)+, 366.05 (81Br, M+H+CH3CN)+.
- Step 2: 1,7-bis[4-(propan-2-yloxy)phenyl]imidazo[1,5-a]pyridine
- The title compound was prepared from 7-bromo-1-iodoimidazo[1,5-a]pyridine and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). LC/MS m/z: 387.30 (M+H)+.
-
- The title compound was prepared from ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate in the same manner as described above for 3-bromo-6-(4-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine (Example D6, Step 1). LC/MS m/z: 346.95 (79Br, M+H)+, 348.97 (81Br, M+H)+.
-
- The title compound was prepared from ethyl 3,6-dibromoimidazo[1,2-a]pyridine-2-carboxylate and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). LC/MS m/z: 459.27 (M+H)+.
-
- To a solution of ethyl 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine-2-carboxylate (30 mg, 0.065 mmol) in a mixture of EtOH/THF (1:1) (1 mL) was added 2N NaOH (0.5 mL). The reaction mixture was stirred at rt for 4 h, then concentrated in vacuo. The residue was acidified with 1 N HCl, and then purified by preparative HPLC to afford 19.6 mg (70%) of the product as a white solid. LC/MS m/z: 431.25 (M+H)+.
-
- To a solution of 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine-2-carboxylic acid (16 mg, 0.037 mmol) in DMF (0.5 mL) cooled to 10° C. were added Et3N (11 mg, 0.11 mmol) and HATU (21 mg, 0.055 mmol). The reaction mixture was stirred at rt for 0.5 h, and then NH4Cl (8 mg, 0.15 mmol) was added. The reaction mixture was stirred at rt overnight, then diluted with DCM. The organic phase was washed with saturated NaHCO3 solution and water. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC to afford 6 mg (37%) of the product as a white solid. LC/MS m/z: 430.28 (M+H)+.
-
- To a mixture of 6-bromoimidazo[1,2-a]pyridine-2-carbaldehyde (0.1 g, 0.44 mmol), hydroxylamine hydrochloride (34 mg, 0.49 mmol), and Et3N (49 mg, 0.49 mmol) in DMF (0.5 mL) was added propylphosphonic anhydride solution in DMF (50 wt. %, 0.29 mL, 0.49 mmol). The reaction mixture was stirred at 100° C. for 3 h. Then, the reaction mixture was cooled to rt, diluted with EtOAc and washed with saturated NaHCO3 solution and water. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexanes/EtOAc from 7:3 to 1:1) to give 35 mg (35%) of the product as a white solid. LC/MS m/z: 222.08 (79Br, M+H)+, 224.13 (81Br, M+H)+.
-
- The title compound was prepared from 6-bromoimidazo[1,2-a]pyridine-2-carbonitrile in the same manner as described above for 3-bromo-6-(4-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine (Example D6, Step 1). LC/MS m/z: 340.92 (79Br, M+CH3CN+H)+, 342.97 (81Br, M+CH3CN+H)+.
-
- The title compound was prepared from 3,6-dibromoimidazo[1,2-a]pyridine-2-carbonitrile and (4-isopropoxyphenyl)boronic acid in the same manner as described above for 3,6-bis[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine (Example C2). LC/MS m/z: 412.21 (M+H)+.
- Utilizing a VSV pseudotype system expressing arenavirus glycoproteins (pseudotyped viruses here to referred to as LASV-p, MACV-p, JUNV-p, GTOV-p and TCRV-p) and the Renilla luciferase reporter gene, heterocyclic compounds were screened to identify individual compounds that inhibit infectivity of the pseudotyped viruses but not the native VSV virus expressing the VSV glycoprotein. VSV viruses expressing the VSV glycoprotein or pseudotyped with LASV, MACV, JUNV, GTOV and TCRV glycoproteins (LASV-p, MACV-p, JUNV-p, GTOV-p and TCRV-p) were generated in cultured HEK-293T cells (ATCC CRL-3216), which were grown in 10 cm dishes in DMEM supplemented with 10% FBS, 1×Pen-Strep, non-essential amino acids and L-glutamine. When cells reached approximately 80% confluency, they were transfected with a mixture of 15 μg of the pCAGGS plasmid encoding the desired glycoprotein and 45 μl of PEI (polyethylenimine) transfection reagent (PEI MAX, Polysciences Inc., #24765). The cells were incubated with the solution for 5 hours at 37° C. at 5% CO2 then washed and the mixture replaced with supplemented DMEM and incubated at 37° C. at 5% CO2 for approximately 16-18 hours. Subsequently cells were infected with approximately 50 μl of VSV reporter virus whereby the VSV glycoprotein was replaced with a luciferase reporter gene. The cells were infected for 1 hour, then washed 1× with PBS and incubated in supplemented media. 24 hours post-infection, supernatant was collected, clarified by centrifugation and filtration through a 0.45 um filter, aliquoted and stored at −80° C. Both VSV-Luciferase and arenavirus glycoprotein pseudotypes were titrated for luminescence activity in Vero cells as described in the Luciferase assay protocol (below). Vero cells (ATCC: CCL-81) were grown in clear 384 well plates (3000 cells/well) in supplemented DMEM media. After incubating overnight at 37° C. and 5% CO2, cells were treated with compounds at desired concentrations and pseudotyped virus in assay media. Assay media consisted of 50% Opti-MEM, 50% DMEM, with 1% FBS, Pen-Strep, non-essential amino acids and L-glutamine. Each of the viral supernatants generated was diluted (from 1:100 to 1:2000) to give similar luminescence signal/background values of ≥200. Final DMSO concentration in the compound testing wells was kept ≤1% and control wells were treated with assay media and 1% DMSO. Cells were incubated for 24 hours at 37° C. and 5% CO2. The compound-virus mixture was aspirated off the cells 24 hours post-infection and washed 1× with PBS. Cells were then lysed using 20 μl of lysis buffer from a Luciferase kit diluted according to manufacturer's instructions. After incubating for approximately 20 minutes, 5 μl of cell lysate was transferred to an opaque white plate, and mixed with 12.5 μl of Coelenterazine diluted in buffer. This mixture was incubated at room temperature for 10 minutes on a plate shaker and then the luminescence was read using a plate reader (Beckman Coulter DTX 880 multimode detector with an emission of 535 nm). Luminescence signals were obtained for compound-containing and control wells to determine % activity (inhibition of luciferase signal) for each compound.
- Surprisingly, it was found that certain R2 groups such as
- wherein
- R4b is selected from the group consisting of
- isopropoxy, cyclopropoxy, tert-butoxy, cyclopropylmethoxy, (2-hydroxypropan)-2-yl, (1-hydroxycyclopropan)-1-yl, (1-hydroxycyclobutan)-1-yl, difluoromethoxy, methoxyethoxy, difluoromethyl, cyclopropyl, and acetyl, can provide broad spectrum activity across multiple arenavirus strains.
- Selected compounds were tested against native replicating Tacaribe (TCRV) virus (TRVL-11573, BEI Resources) using an ELISA-based assay. Vero cells (ATCC: CCL-81) were grown in a 96-well format (5000 cells/well) in supplemented DMEM media. After overnight incubation, cells were treated with TCRV and compounds at desired concentrations, in DMEM media with 1% FBS and supplements. Final DMSO concentration in the compound testing wells was kept ≤1% and control wells were treated with TCRV or media and 1% DMSO. After 5 days of incubation at 37° C. in 5% CO2, cells were fixed with 2% paraformaldehyde for 45 minutes and then washed with PBS. Subsequently the cells were permeabilized with 0.25% triton-X, then TCRV was detected using ELISA with the following protocol. Monoclonal Anti-Junin Virus antibody (BEI #NR 41860), which cross reacts with TCRV nucleoprotein, was used to stain cells. After washing, cells were treated with biotin conjugated secondary antibody and subsequently, streptavidin conjugated horseradish peroxidase. TMB substrate was added to the wells, and the reaction was stopped using 2M sulfuric acid. The absorbance was read using a plate reader (Beckman Coulter DTX 880 multimode detector with an emission of 450 nm). OD readings were obtained for compound-containing and control wells to determine % activity for each compound.
- Compounds active in the pseudotype assays were also evaluated for cytotoxicity over a period of 3 days. Compounds were serially diluted and added to Vero cells (4000 cells/well) with final DMSO concentration maintained at 1% in growth media consisting of minimal essential media (MEM) with 1% FBS. The plates were incubated at 37° C. for 3 days, and then dead cells were removed by washing with Phosphate buffered saline (PBS). CPE was assessed by staining cells with neutral red dye for 1 hour and then de-staining with a solution of 50% ethanol/1% acetic acid solution. Absorbances were read at 540 nm and 690 nm on a Spectramax Plus 384 spectrophotometer. Data were analyzed as (540 nm-690 nm) and then compared to untreated controls to obtain % cell survival.
- Confluent or near-confluent cell culture monolayers in 12-well disposable cell culture plates were prepared. Cells were maintained in MEM or DMEM supplemented with 10% FBS. For antiviral assays the same medium was used but with FBS reduced to 2% or less and supplemented with 1% penicillin/streptomycin. The test compounds were prepared at seven half log 10 final concentrations, (01-10 μM) in 2×MEM or 2×DMEM. Test compounds and positive control compounds (favipiravir or ribavirin) were run in parallel in biological triplicates. The assay was initiated by first removing growth media from the 12-well plates of cells, which was challenged with compound at a given concentration and 0.01 MOI of virus or about 50 to 100 plaque forming units (pfu). Cells were incubated for 60 min: 100 μL inoculum/well, at 37° C., 5% CO2 with constant gentle rocking. Virus inoculum was removed, cells washed and overlaid with either 1% agarose or 1% methylcellulose diluted 1:1 with 2×MEM and supplemented with 2% FBS and 1% penicillin/streptomycin and along with the corresponding drug concentration. Cells were incubated at 37° C. with 5% CO2 for 5 days. The overlay was then removed and plates stained with 0.05% crystal violet in 10% buffered formalin for approximately twenty minutes at room temperature. The plates were washed, dried and the number of plaques counted. The number of plaques in each set of compound dilution was converted to a percentage relative to the untreated virus control. The 50% effective (EC50, virus-inhibitory) concentrations were then calculated by linear regression analysis. The quotient of CC50 divided by EC50 gives the selectivity index (SI) value. Compounds showing SI values ≥10 were considered active.
- Confluent or near-confluent cell culture monolayers in 96-well disposable microplates were prepared and maintained in MEM or DMEM supplemented with FBS, which was reduced to 2% or less for antiviral testing supplemented with 50 μg/ml gentamicin. The test compound was prepared at four log 10 final concentrations. Four compounds were tested per microplate with five microwells per dilution: three for infected cultures and two for uninfected toxicity cultures. Controls for the experiment consist of six microwells that were infected (virus controls) and six that were untreated (cell controls). The virus control and cell control wells were on every microplate. In parallel, a known active drug ribavirin was tested as a positive control using the same method as applied for test compounds. The assay was initiated by first removing growth media from the 96-well plates of cells and the test compound was applied in 0.1 ml volume to wells at 2× concentration. Virus, normally at ≤100 50% cell culture infectious doses (CClD50) in 0.1 ml volume, were placed in those wells designated for virus infection. Medium devoid of virus was placed in toxicity control wells and cell control wells. Virus control wells were treated similarly with virus. Plates were incubated at 37° C. with 5% CO2 until maximum CPE (cytopathic effect or cell death) was observed in virus control wells. The plates were then stained with 0.011% neutral red for approximately two hours at 37° C. in a 5% CO2 incubator. The neutral red medium was removed by complete aspiration, and the cells rinsed 1× with phosphate buffered solution (PBS) to remove residual dye. The PBS was removed and the incorporated neutral red was eluted with 50% Sorensen's citrate buffer/50% ethanol for 30 minutes. Neutral red dye penetrates into living cells, thus, the more intense the red color, the larger the number of viable cells present in the wells. The dye content in each well was quantified using a 96-well spectrophotometer at 540 nm wavelength. The dye content in each set of wells was converted to a percentage of dye present in untreated control wells using a Microsoft Excel computer-based spreadsheet. The 90% effective (EC9o, virus-inhibitory) concentrations and 50% cytotoxic (CC50, cell-inhibitory) concentrations were calculated by linear regression analysis. The quotient of CC50 divided by EC90 gives the selectivity index (SI90) value. Compounds showing SI values ≥10 were considered active.
- In addition to the ability of compounds to demonstrate broad inhibitory activity against arenaviruses in vitro, compounds must also have certain drug-like properties for them to be used to inhibit arenaviruses and provide methods of treatment for arenavirus infection in mammals in vivo. Such compounds may exhibit drug-like properties including but not limited to chemical stability against metabolic degradation by liver microsomal CYP p450 enzymes, cell permeability and oral bioavailability (if the drug is to delivered orally) and lack of inhibition of the hERG ion channel, which is associated with cardiac safety [Kerns, E. H. Li, D. Drug-like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization, (2008) Academic Press, Burlington Mass.]. To characterize drug-like properties of the chemical series example compounds were evaluated for metabolic stability in human, mouse, guinea pig, monkey, rat, mouse, and dog liver microsome assays (Table 3), and for inhibition of the hERG ion channel (Table 4). Compounds exhibiting >60% remaining of parent indicate attractive chemical stability. The demonstration of good microsomal stability in human and nonhuman species facilitates the ability to test and optimize compounds in preclinical animal studies.
- A reaction premixture was set up, containing 1 uM compound of interest, 1 mg/mL liver microsomes of desired species, 2.1 mM MgCl2 and 0.1 M sodium phosphate buffer, pH 7.4. This premixture was incubated at 37° C. for 30 minutes with gentle agitation to allow the compound to be completely dissolved in the mixture. Then freshly made NADPH solution in 0.1 M sodium phosphate buffer was added at a concentration of 2 mM to start the reaction. A ‘Time 0’ sample (30 uL) was taken out immediately after addition of NADPH and added to 140 uL cold acetonitrile containing 1 uM of pre-decided internal standard. The rest of the reaction mixture was incubated at 37° C. for the remaining time period. Test compounds were left in the reaction mixture for 60 minutes before ‘Time 60’ sample was added to acetonitrile with internal standard. The control compound (Verapamil for human, monkey and dog LM, Lidocaine for Guinea pig LM, and diphenhydramine for rat and mouse LM) was incubated in reaction mixture for 15 minutes before ‘Time 15’ samples were collected and added to cold acetonitrile with internal standard. The samples were then spun in a centrifuge for 10 minutes at 4000 rpm, supernatant was collected and mixed with equal parts distilled water. These were then analyzed on a Varian 500-MS. Surprisingly, when R4b was isopropoxy, better microsomal stability was observed across multiple species tested.
- hERG Channel Assay
- Drugs belonging to different classes have been shown to be associated with QT prolongation and in some cases serious ventricular arrhythmias. The most common mechanism for these adverse events is the inhibition of one or more cardiac potassium channels, in particular hERG. This channel is important for cardiac myocyte repolarization and is a common target for drugs that prolong the QT interval. Test articles in this study were therefore, characterized to determine their ability to inhibit the hERG channel. Ion channel activity was measured using a stably transfected Chinese Hamster Ovary (CHO) cell line expressing the hERG mRNA. The pharmacology of this cloned channel expressed in the CHO cell line is very similar to that observed in native tissue. Cells were cultured in DMEM/F12 containing 10% FBS, 1% penicillin/streptomycin and 500 μg/ml G418. Before testing, cells were harvested using Accumax (Innovative Cell Technologies). For electrophysiological recordings, the following solutions were used: External solution: 2 mM CaCl2; 2 mM MgCl2; 4 mM KCl; 150 mM NaCl; 10 mM Glucose; 10 mM HEPES; 305-315 mOsm; pH 7.4 (adjusted with 5M NaOH); Internal solution: 140 mM KCl; 10 mM MgCl2; 6 mM EGTA; 5 mM HEPES-Na; 5 mM ATP-Mg; 295-305 mOsm; pH 7.25 (adjusted with 1 M KOH). Whole cell recordings were performed using PX 7000 A (Axon Instruments) with AVIVA's SealChip™ technology. Cells were voltage clamped at a holding potential of −80 mV. The hERG current was then activated by a depolarizing step to −50 mV for 300 ns. This first step at −50 mV was used as a baseline for measuring peak amplitude of the tail current. Next, a voltage step to +20 mV was applied for 5 s to activate the channels. Finally, a step back to −50 mV for 5 s removed activation and the deactivating tail current was recorded. External solution containing 0.1% DMSO (vehicle) was applied to the cells to establish a baseline. After allowing the current to stabilize for 3 to 10 min, test articles were applied. Test article solutions were added to cells in 4 separate additions. Cells were kept in test solution until effect of the test article reached steady state, to a maximum of 12 min. Next, 1 μM cisapride (positive control) was added. Finally, washout with External Solution was performed until the recovery current reached steady state. Data analysis was performed using DataXpress (Axon Instruments), Clampfit (Axon Instruments) and Origin (OriginLab Corporation) software.
-
TABLE 1 Examples. Example compounds and their observed inhibitory activities against the indicated pseudotyped viruses (LASV-p, MACV-p, JUNV-p, TCRV-p, GTOV-p, VSV-p) or in cellular cytotoxicity assays; shown are EC50 for LASV-p, MACV-p, JUNV-p, TCRV-p, and GTOV-p, and VSV-p CC50 for cytotoxicity; nd: not determined LASV-p MACV-p JUNV-p TCRV-p GTOV-p VSV-p CC50 Ex. EC50 (nM) EC50 (nM) EC50 (nM) EC50 (nM) EC50 (nM) EC50 (nM) (nM) A1 31.7 >100 >100 >100 nd nd 12,890 A2 6.6 >100 >100 >100 nd nd 25,580 A3 7.6 >25 >25 >25 nd nd <300 A4 >25 >25 >25 >25 nd nd <300 A5 >25 >25 >25 >25 nd nd <300 A6 >25 >25 >25 >25 nd nd 9,720 A7 8.9 17.0 1.8 >25 nd 980 3,960 A8 6.4 22.3 3.98 21.7 nd >1,000 9,540 A9 >100 nd nd nd nd nd nd A10 21.8 >25 >25 >25 nd nd 4,560 A11 >25 >25 >25 >25 nd nd nd A12 0.81 >25 19.3 21.4 nd 800 200 A13 5.0 >25 >25 >25 nd nd 1,270 A14 7.4 >25 >25 >25 nd nd 1,950 A15 14.7 24.95 2.23 29.6 nd nd 12,940 A16 17.2 >25 15.29 >25 nd >1,000 >100,000 A17 1.1 0.2 0.2 0.6 0.52 >1,000 5,810 A18 1.08 2.27 1.55 12.50 0.07 >1,000 14,000 A19 >100 nd nd nd nd nd nd A20 >100 nd nd nd nd nd nd A21 3.07 14.4 3.5 >25 nd nd 5,220 A22 >25 >25 >25 >25 nd nd nd A23 >25 >25 >25 >25 nd nd nd A24 0.91 3.7 1.7 15.9 0.3 nd 71,320 A25 1.61 7.1 4.9 28.0 0.2 nd 12,190 A26 0.59 0.70 0.81 1.45 0.73 nd 7,520 A27 0.60 0.38 0.39 2.57 nd nd 3,860 A28 11.0 >25 7.29 >25 nd nd nd A29 0.53 11.07 6.96 15.23 nd nd nd A30 0.53 0.21 0.03 0.07 0.21 5.31 3,670 A31 2.6 0.9 0.18 0.7 nd nd 3,790 B1 1.61 7.09 4.95 27.99 0.88 >1,000 12,190 B2 0.41 0.935 0.21 5.53 0.07 >10,000 4,140 B3 1.01 10.27 1.79 27.73 nd nd >100,000 B4 0.956 18.63 4.31 14.95 nd nd 19,740 B5 >25 >25 13.38 >25 nd nd nd B6 17.76 14.28 3.35 18.83 nd nd nd B7 8.18 24.08 16.19 >25 nd nd 13,900 B8 >25 >25 >25 >25 nd nd nd B9 19.72 29.7 11.88 >25 nd nd 27,700 B10 11.0 19.6 3.1 >25 nd nd 4,680 B11 6.4 25.0 25.0 >25 nd nd 24,200 B12 0.88 1.04 0.26 5.21 0.04 5,490 >100,000 B13 1.53 5.58 1.805 20.38 1.24 5,360 6,620 B14 1.055 15.43 1.36 >25 nd nd 7,390 B15 0.95 0.25 0.02 0.37 0.18 >10,000 >100,000 C1 0.59 0.7 0.82 1.45 0.08 >1,000 7,520 C2 0.6 0.38 0.4 2.57 0.14 >1,000 3,860 C3 7.25 2.7 1.17 10.57 0.31 >10,000 6,160 C4 4.35 23.94 4.62 29.88 nd nd 4,560 C5 4.1 31.4 9.09 >25 nd nd 4,690 C6 2.7 18.59 7.02 >25 nd nd 10,510 C7 >25 >25 >25 >25 nd nd 4,810 C8 2.03 1.7 1.08 9.44 0.21 8,120 31,130 C9 1.15 0.71 0.45 1.7 0.27 5,810 3,970 C10 4.61 28.93 19.04 >25 nd nd >100 C11 2.83 10.04 3.21 18.44 0.86 3,090 25,240 C12 6.07 3.12 1.32 7.76 0.44 5,060 4,020 C13 0.3 1.22 0.62 2.95 0.29 1,880 5,090 C14 >25 >25 >25 >25 nd nd nd C15 7.97 13.46 2.85 7.6 0.58 5,060 nd C16 >25 >25 >25 >25 nd nd nd C17 13.37 28.8 6.38 >25 nd nd 23,880 C18 18.13 0.59 0.305 2.68 nd nd 3,980 C19 2.9 0.23 0.195 1.83 0.2 9.86 8,200 C20 4.98 6.82 1.43 5.12 0.15 >10,000 3,750 C21 0.51 0.16 0.115 >25 0.2 >10,000 3,980 C22 2.33 0.335 0.415 4.94 0.45 nd 24,390 C23 >25 >25 >25 >25 nd nd nd C24 4.58 0.875 0.416 3.91 0.15 9,810 4,180 C25 >25 >25 25 >25 nd nd nd C26 0.56 0.2 0.1 0.2 0.27 4,530 3,540 C27 0.66 0.68 0.51 0.58 0.24 >10,000 5,280 C28 17.27 >25 14.86 >25 nd nd >100,000 C29 >25.0 >25 >25 >25 nd nd nd C30 1.02 1.08 0.82 3.83 0.05 6,960 3,980 C31 1.35 2.09 0.65 2.65 0.76 >10,000 >10,000 C32 0.4 0.11 0.06 0.06 0.2 4,840 4,840 C33 1.3 5.31 2.3 6.57 0.91 4,770 4,770 C34 4.73 25.14 3.68 16.52 nd nd nd C35 14.46 28.2 13.05 >25 nd nd nd C36 8.18 >25 23.19 >25 nd nd nd C37 3.34 2.36 0.38 >25 0.25 9,950 nd C38 0.84 0.34 0.2 1.77 0.2 7,390 95,870 C39 8.41 2.67 0.73 9.86 nd nd >100,000 C40 3.83 5.85 0.97 22.64 1.35 6,170 4,110 C41 0.67 13.96 1.6 >25 nd nd 8,650 C42 3.08 23.08 2.6 11.67 nd nd 5,360 C43 >25 >25 >25 >25 nd nd nd C44 0.23 0.32 0.07 0.135 nd nd >100 C45 >25 >25 >25 >25 nd nd nd C46 7.23 8.47 4.42 22.52 1.26 4,550 4,610 C47 1.8 0.5 0.55 1.17 0.44 4,340 7,860 C48 0.38 0.41 0.165 0.2 nd nd 4,710 C49 8.02 0.86 0.16 1.1 nd nd 5,270 C50 15.48 6.56 4.65 >25 nd nd 3,810 C51 0.31 0.13 0.15 0.37 0.21 nd 4,190 D1 >25 >25 13.98 >25 nd nd nd D2 7.99 22.46 17.78 >25 nd nd 4,340 D3 7.04 15.5 20.25 >25 nd nd 15,900 D4 >25 16.94 8.1 >25 nd nd nd D5 12.47 >25 27.81 >25 nd nd 5.870 D6 9.6 2.56 1.005 15.45 0.53 6,420 4,410 D7 4.1 >25 18.04 26.33 nd nd 1,870 D8 >25 >25 >25 >25 nd nd nd D9 >25 >25 >25 >25 nd nd nd D10 1.5 14.755 0.95 >25 nd 9,360 7,720 D11 10.5 >25 3.22 >25 nd nd 5,210 D12 2.95 16.37 2.605 20.68 0.93 6,980 8,510 D13 12.34 12.0 3.2911 10.35 nd nd >100,000 D14 6.77 25.0 13.53 20.25 nd nd 13,030 D15 1.24 1.65 0.34 3.57 1.04 >10,000 6,230 D16 5.37 19.1 1.05 19.85 3.52 nd 7,530 D17 >25 >25 >25 >25 nd nd nd D18 >25 >25 5.58 >25 Nd nd >100,000 D19 >25 >25 >25 >25 nd nd 7,540 D20 >25 >25 >25 >25 nd nd nd D21 >25 >25 >25 >25 nd nd nd D22 >25 >25 >25 >25 nd nd 49,520 D23 27.35 >25 3.78 >25 nd nd >100,000 -
TABLE 2 Inhibition of Native Arenaviruses. Example compounds and their observed inhibitory activities and selectivity index values (SI) in replicative LASV, JUNV, TCRV, and LCMV inhibitory activity assays LASV JUNV TCRV LCMV EC50 EC50 EC50 EC90 Ex. uM SI uM SI uM SI50 uM SI90 A17 0.06 249 0.115 82 0.023 609 0.71 12 A24 0.06 527 0.56 53 0.010 7100 0.56 18 C1 0.025 921 0.055 352 0.003 2500 0.82 37 C2 0.015 1200 0.035 509 0.002 1950 0.44 22 -
TABLE 3 Multi-species Microsomal Stability. Percent parent compound remaining at 60 minutes in liver microsomes Ex. Human Guinea Monkey Rat Mouse Dog A17 69 62 7 86 44 nd A24 63 0 nd 32 nd nd A30 95 99 20 100 100 100 A31 93 100 40 nd nd nd B2 100 81 68 85 100 93 B12 100 93 98 100 99 92 B15 100 100 5 100 100 100 C1 76 42 16 77 22 nd C2 82 77 53 nd 103 nd C51 100 95 21 75 92 82 -
TABLE 4 hERG Channel Assay Ex. Dose (uM) hERG % Inhibition A30 3 <10 A31 3 <10 B2 3 <10 B12 3 17 B15 3 <10 C1 3 55 C2 3 89 C51 3 49 - To determine if the compound series demonstrates oral exposure, an oral pharmacokinetic (PK) study was done with example compounds (A17, C2) in guinea pigs. 3 guinea pigs per compound were dosed at 10 mg/kg via oral gavage and blood samples taken at times 0, 1, 2, 4, 8, 12 and 24 hr. Bioanalysis was done on a LC-MS/MS (Water Acquity-UPLC/API4000 mass spectrometer). Both compounds demonstrated oral exposure in guinea pigs with half-lives between 4 and 6 hours.
-
TABLE 5 Pharmacokinetic (PK) data in guinea pig Example Cmax (ng/mL) Tmax (hr) T ½ (hr) A17 639.3 1 4-6 C2 156.0 1 4-6
Claims (34)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/726,096 US20220281825A1 (en) | 2016-07-12 | 2022-04-21 | Heterocyclic compounds for the treatment of arenavirus infection |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662361423P | 2016-07-12 | 2016-07-12 | |
US201662378177P | 2016-08-22 | 2016-08-22 | |
PCT/US2017/041218 WO2018013430A2 (en) | 2016-07-12 | 2017-07-07 | Heterocyclic compounds for the treatment of arenavirus infection |
US201816309858A | 2018-12-13 | 2018-12-13 | |
US17/726,096 US20220281825A1 (en) | 2016-07-12 | 2022-04-21 | Heterocyclic compounds for the treatment of arenavirus infection |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/309,858 Division US11352328B2 (en) | 2016-07-12 | 2017-07-07 | Heterocyclic compounds for the treatment of arenavirus |
PCT/US2017/041218 Division WO2018013430A2 (en) | 2016-07-12 | 2017-07-07 | Heterocyclic compounds for the treatment of arenavirus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220281825A1 true US20220281825A1 (en) | 2022-09-08 |
Family
ID=60953313
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/309,858 Active US11352328B2 (en) | 2016-07-12 | 2017-07-07 | Heterocyclic compounds for the treatment of arenavirus |
US17/726,096 Pending US20220281825A1 (en) | 2016-07-12 | 2022-04-21 | Heterocyclic compounds for the treatment of arenavirus infection |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/309,858 Active US11352328B2 (en) | 2016-07-12 | 2017-07-07 | Heterocyclic compounds for the treatment of arenavirus |
Country Status (2)
Country | Link |
---|---|
US (2) | US11352328B2 (en) |
WO (1) | WO2018013430A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3548033B1 (en) | 2016-11-28 | 2024-04-10 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11731966B2 (en) * | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
MX2020012838A (en) | 2018-05-30 | 2021-07-16 | Praxis Prec Medicines Inc | Ion channel modulators. |
US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
JPWO2020071550A1 (en) * | 2018-10-04 | 2021-09-24 | 京都薬品工業株式会社 | CDK8 Inhibitors and Their Applications |
AR117228A1 (en) * | 2018-12-06 | 2021-07-21 | Arisan Therapeutics | DERIVATIVES OF PYRAZOLE [1,2-a] PYRIDINE, 1H-BENZO [d] [1,2,3] TRIAZOL, IMIDAZOPYRIMIDINE AND BENZIMIDAZOLE FOR USE IN THE TREATMENT OF ARENAVIRUS INFECTION |
EP3917932A4 (en) | 2019-01-30 | 2022-09-28 | Avista Pharma Solutions, Inc. | Chemical compounds |
EP3917935A4 (en) | 2019-01-30 | 2022-11-16 | Avista Pharma Solutions, Inc. | Synthetic process and novel intermediates |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
WO2022108849A1 (en) * | 2020-11-17 | 2022-05-27 | Arisan Therapeutics Inc. | Heterocyclic compounds as therapeutic agents |
CN113307773A (en) * | 2021-06-17 | 2021-08-27 | 上海毕得医药科技股份有限公司 | 6-bromo-3-methoxy-1-phenyl-1H-indazole and synthetic method and application thereof |
CN115403516B (en) * | 2021-08-03 | 2024-01-26 | 河南省儿童医院郑州儿童医院 | Aromatic heterocyclic compound containing 3,4, 5-trisubstituted benzene ring, pharmaceutical composition, preparation method and application thereof |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4143152A (en) | 1977-12-19 | 1979-03-06 | Riker Laboratories, Inc. | Anti-microbial (2-nitro-3-phenyl benzofuranyl)-phenylalkanoic acids and derivatives |
US4153721A (en) | 1977-12-19 | 1979-05-08 | Riker Laboratories, Inc. | Derivatives of 2-nitrobenzofuran |
US4526896A (en) | 1978-12-26 | 1985-07-02 | Riker Laboratories, Inc. | Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof |
US5369086A (en) | 1993-04-28 | 1994-11-29 | Zeneca Limited | N-benzotriazoles |
US5523277A (en) | 1995-02-10 | 1996-06-04 | American Cyanamid Company | 6-heterocyclyl-1-(substituted phenyl)benzotriazole herbicidal agents |
DE60003899T2 (en) | 1999-03-11 | 2004-05-27 | Neurogen Corp., Branford | ARYL-ANNELLATED DISUBSTITUTED PYRIDINE: NK3 RECEPTOR LIGANDS |
US6498165B1 (en) | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
JP4025468B2 (en) | 1999-07-29 | 2007-12-19 | 三井化学株式会社 | Organic electroluminescence device |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
YU54202A (en) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation |
ATE300540T1 (en) | 2000-04-27 | 2005-08-15 | Yamanouchi Pharma Co Ltd | IMIDAZOPYRIDINE DERIVATIVES |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
EP1382603B1 (en) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
JP4541695B2 (en) | 2001-06-15 | 2010-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | 5- (2-Aminopyrimidin-4-yl) benzisoxazole as a protein kinase inhibitor |
EP1427707A1 (en) | 2001-09-19 | 2004-06-16 | Pharmacia Corporation | Substituted indazole compounds for the treatment of inflammation |
CA2478338A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
US7259179B2 (en) | 2002-05-23 | 2007-08-21 | Cytopia Research Pty Ltd | Kinase inhibitors |
AU2003290734A1 (en) | 2002-11-27 | 2004-06-23 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
EP1581526B1 (en) | 2002-12-18 | 2009-03-11 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
US7867629B2 (en) | 2003-01-10 | 2011-01-11 | Idemitsu Kosan Co., Ltd. | Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
AU2004293035A1 (en) | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc | Methods of treating diseases and disorders by targeting multiple kinases |
EP1689739B1 (en) | 2003-12-03 | 2016-03-30 | YM BioSciences Australia Pty Ltd | Azole-based kinase inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
GB0400895D0 (en) | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
WO2006024666A1 (en) | 2004-09-03 | 2006-03-09 | Applied Research Systems Ars Holding N.V. | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
MX2007004551A (en) | 2004-10-18 | 2007-05-23 | Amgen Inc | Thiadiazole compounds and methods of use. |
US7446210B2 (en) | 2004-10-26 | 2008-11-04 | Janssen Pharmaceutica N.V. | Factor Xa compounds |
AR051596A1 (en) | 2004-10-26 | 2007-01-24 | Irm Llc | CONDENSED HETEROCICLIC COMPOUNDS NITROGENATED AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FOOD DISORDERS |
WO2006058007A2 (en) | 2004-11-23 | 2006-06-01 | Celgene Corporation | Jnk inhibitors for treatment of cns injury |
JP4804480B2 (en) | 2005-01-26 | 2011-11-02 | シェーリング コーポレイション | 3- (Indazol-5-yl)-(1,2,4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer |
US20070004777A1 (en) | 2005-03-23 | 2007-01-04 | Bhagwat Shripad S | Methods for treating or preventing acute myelogenous leukemia |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
MX2007012393A (en) | 2005-04-05 | 2008-02-22 | Pharmacopeia Inc | Purine and imidazopyridine derivatives for immunosuppression. |
JP2009502734A (en) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Fused heterocycles as Lck inhibitors |
ES2340321T3 (en) | 2005-09-27 | 2010-06-01 | F.Hoffmann-La Roche Ag | OXADIAZOLILPIRAZOLO-PIRIMIDINAS, AS ANGLGIST OF MGLUR2. |
PE20070978A1 (en) | 2006-02-14 | 2007-11-15 | Novartis Ag | HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks) |
WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
AP2267A (en) | 2006-03-02 | 2011-08-02 | Siga Technologies Inc | Antiviral drugs for treatment of arenavirus infection. |
US7977365B2 (en) | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
US8097617B2 (en) | 2006-03-31 | 2012-01-17 | Novartis Ag | Organic compounds |
CA2648809A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of cdc7 |
WO2007123953A2 (en) | 2006-04-19 | 2007-11-01 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
WO2008016123A1 (en) | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
EP2471529A3 (en) | 2006-09-05 | 2012-10-10 | Emory University | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof |
EP2068869A4 (en) | 2006-10-06 | 2011-05-25 | Abbott Lab | Novel imidazothiazoles and imidazoxazoles |
CA2667960A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Imidazopyridazines as pi3k lipid kinase inhibitors |
US20120058997A1 (en) | 2006-11-06 | 2012-03-08 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
MX2009006706A (en) | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Bicyclic heterocyclic compounds as fgfr inhibitors. |
CN101622001A (en) | 2007-01-26 | 2010-01-06 | Irm责任有限公司 | The purine compound and the compositions that are used for the treatment of plasmodium related diseases as inhibitors of kinases |
DK2133332T3 (en) | 2007-04-11 | 2013-09-30 | Kissei Pharmaceutical | (AZA) DERIVATIVE DERIVATIVES AND THEIR USE FOR MEDICAL PURPOSES |
EP2155753A1 (en) | 2007-05-09 | 2010-02-24 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
AR067326A1 (en) | 2007-05-11 | 2009-10-07 | Novartis Ag | IMIDAZOPIRIDINES AND PIRROLO -PIRIMIDINES REPLACED AS INHIBITORS OF LIPIDO KINASE |
EP2187883A2 (en) | 2007-08-10 | 2010-05-26 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
US20120004222A1 (en) | 2007-08-21 | 2012-01-05 | Zhicai Wu | Cb2 receptor ligands for the treatment of pain |
CA2698075C (en) | 2007-08-27 | 2016-04-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
ES2393430T3 (en) | 2007-10-17 | 2012-12-21 | Novartis Ag | Imidazo [1,2-A] -pyridine derivatives useful as ALK inhibitors |
EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | Pyridosulfonamide derivatives as pi3 kinase inhibitors |
GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
DE102008017590A1 (en) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
WO2009133127A1 (en) | 2008-04-30 | 2009-11-05 | Merck Serono S.A. | Fused bicyclic compounds and use thereof as pi3k inhibitors |
WO2009157196A1 (en) | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | Amide compound |
CA2728098A1 (en) | 2008-07-17 | 2010-01-21 | Asahi Kasei Pharma Corporation | Pyrazole-containing tricyclic compounds as_antagonits of an ep1 receptor |
WO2010012745A2 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
CA2736472A1 (en) | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyrine or pyrazine derivatives for treating hcv |
PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
CN102395585A (en) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | Heteroaryls and their use as pi3k inhibitors |
CA2752603C (en) | 2009-02-18 | 2016-04-05 | Bayer Pharma Aktiengesellschaft | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof |
US8729074B2 (en) | 2009-03-20 | 2014-05-20 | Amgen Inc. | Inhibitors of PI3 kinase |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
CA2760778A1 (en) | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
SI2464645T1 (en) | 2009-07-27 | 2017-10-30 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
CN105078978A (en) | 2009-08-17 | 2015-11-25 | 因特利凯公司 | Heterocyclic compounds and uses thereof |
WO2011041713A2 (en) * | 2009-10-02 | 2011-04-07 | Glaxosmithkline Llc | Piperazinyl antiviral agents |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
KR20110049217A (en) | 2009-11-04 | 2011-05-12 | 다우어드밴스드디스플레이머티리얼 유한회사 | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
ES2531109T3 (en) | 2009-12-30 | 2015-03-10 | Arqule Inc | Imidazopyridinyl-aminopyridine compounds |
CN102947302A (en) | 2010-02-18 | 2013-02-27 | 西班牙国家癌症研究中心 | Triazolo [4, 5 - b] pyridin derivatives |
WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
EP2560962B1 (en) | 2010-04-22 | 2015-05-20 | Janssen Pharmaceutica NV | Indazole compounds useful as ketohexokinase inhibitors |
KR20130065632A (en) | 2010-04-28 | 2013-06-19 | 다이이찌 산쿄 가부시키가이샤 | [5,6]heterocyclic compound |
EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | Positive allosteric modulators of mglur2 |
ES2552841T3 (en) | 2010-07-12 | 2015-12-02 | Bayer Intellectual Property Gmbh | Imidazo [1,2-a] pyrimidines and substituted -pyridines |
JP2013530250A (en) | 2010-07-13 | 2013-07-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Bicyclic pyrimidine compounds |
CN103384670B (en) | 2010-07-28 | 2016-05-25 | 拜耳知识产权有限责任公司 | Imidazo [1, the 2-b] pyridazine replacing |
US9458463B2 (en) | 2010-09-03 | 2016-10-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for treatment of diabetes by a small molecule inhibitor for GRK5 |
TWI541243B (en) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | Substituted imidazopyridazines |
WO2012065297A1 (en) | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
EP2649065A1 (en) | 2010-12-09 | 2013-10-16 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
AR085397A1 (en) | 2011-02-23 | 2013-09-25 | Intellikine Inc | COMBINATION OF QUINASA INHIBITORS AND THEIR USES |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
CN102675286B (en) | 2011-03-07 | 2015-08-19 | 中国科学院上海药物研究所 | One class indazole compounds and preparation method thereof, purposes and pharmaceutical composition |
MX2013010771A (en) | 2011-03-22 | 2014-01-31 | Amgen Inc | Azole compounds as pim inhibitors. |
WO2012131501A1 (en) | 2011-03-28 | 2012-10-04 | Glenmark Pharmaceuticals S.A. | Substituted benzimidazole compounds as cot kinase inhibitors |
ES2571741T3 (en) | 2011-03-31 | 2016-05-26 | Bayer Ip Gmbh | Substituted benzimidazoles as Mps-1 kinase inhibitors |
JP5951750B2 (en) | 2011-04-06 | 2016-07-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Substituted imidazopyridines and intermediates thereof |
RU2598840C2 (en) | 2011-05-19 | 2016-09-27 | Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii | Novel compounds |
WO2012174312A2 (en) | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
JP6046710B2 (en) | 2011-06-24 | 2016-12-21 | アーキュール,インコーポレイティド | Substituted imidazopyridinyl-aminopyridine compounds |
US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
KR101274986B1 (en) | 2011-07-27 | 2013-06-17 | 한국과학기술원 | Imidazopyridine derivatives, PI3K and/or mTOR inhibiting composition and composition used in diseases linked to PI3K and/or mTOR comprising the same |
LT2751083T (en) | 2011-08-31 | 2018-03-26 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
EP3659599B1 (en) | 2011-10-19 | 2022-12-21 | Signal Pharmaceuticals, LLC | 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for use in the treatment of glioblastoma multiforme |
WO2013071264A1 (en) | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2013078254A1 (en) | 2011-11-22 | 2013-05-30 | Array Biopharma Inc. | Bicyclic heteroaryl derivatives as kinase inhibitors |
MX359989B (en) | 2012-02-17 | 2018-10-18 | Siga Tech Inc | Antiviral drugs for treatment of arenavirus infection. |
WO2013134336A2 (en) | 2012-03-09 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
JP2015515469A (en) | 2012-03-28 | 2015-05-28 | シンタ ファーマシューティカルズ コーポレーション | Triazole derivatives as HSP90 inhibitors |
US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
JP5917774B2 (en) | 2012-07-26 | 2016-05-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Benzisoxazole modulator of neurogenesis |
WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
CA2882525A1 (en) | 2012-10-01 | 2014-04-10 | F. Hoffman-La Roche Ag | Benzimidazoles as cns active agents |
JP2016504268A (en) | 2012-10-04 | 2016-02-12 | オヤジェン インコーポレイテッドOyaGen, Inc. | Small molecules as anti-HIV agents that disrupt self-association of VIF and methods of use thereof |
KR20150072412A (en) | 2012-10-05 | 2015-06-29 | 리겔 파마슈티칼스, 인크. | Gdf-8 inhibitors |
WO2014080241A1 (en) | 2012-11-21 | 2014-05-30 | Piramal Enterprises Limited | Imidazopyridine compounds and uses thereof |
KR101735975B1 (en) | 2012-11-29 | 2017-05-15 | 에프. 호프만-라 로슈 아게 | Imidazopyridine derivatives |
EP2964230A4 (en) | 2013-03-07 | 2016-10-26 | Califia Bio Inc | Mixed lineage kinase inhibitors and method of treatments |
US20160089371A1 (en) | 2013-03-15 | 2016-03-31 | Intellikine, Llc | Combination of Kinase Inhibitors and Uses Thereof |
JP2016113366A (en) | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | 1,2,4-triazine-6-carboxamide derivative with acetamide group |
EP2818472A1 (en) | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators |
AU2014291142B2 (en) | 2013-07-17 | 2018-10-11 | Otsuka Pharmaceutical Co., Ltd. | Cyanotriazole compounds |
TW201512173A (en) | 2013-08-22 | 2015-04-01 | Hoffmann La Roche | Alkynyl alcohols and methods of use |
AR097543A1 (en) | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPOUNDS BASED ON IMIDAZO [1,2-b] PIRIDAZINE, COMPOSITIONS THAT INCLUDE THEM AND THEIR METHODS OF USE |
CN104672240A (en) | 2013-12-26 | 2015-06-03 | 北京鼎材科技有限公司 | Carbazole type derivative and application thereof in organic electroluminescent device |
CN104672231A (en) | 2013-12-26 | 2015-06-03 | 北京鼎材科技有限公司 | Carbazole type derivative containing imidazopyridine group and application of carbazole type derivative |
MX367267B (en) | 2014-03-24 | 2019-08-12 | Arqule Inc | Process of preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl- 3h-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine. |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
EP3129367B1 (en) | 2014-04-08 | 2019-09-04 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as tgf-beta inhibitors |
US20170050939A1 (en) | 2014-04-21 | 2017-02-23 | Mayo Foundation For Medical Education And Research | Small molecule inhibitors of g protein coupled receptor 6 kinase polypeptides |
TW201613872A (en) | 2014-07-18 | 2016-04-16 | Biogen Ma Inc | IRAK4 inhibiting agents |
US10954240B2 (en) | 2014-09-03 | 2021-03-23 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
RU2019142694A (en) | 2014-09-05 | 2020-02-26 | Аркьюл, Инк. | COMPOSITIONS AND METHODS WHICH CAN BE USED FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2016044585A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
ES2749679T3 (en) | 2014-10-22 | 2020-03-23 | Bristol Myers Squibb Co | Substituted pyrrolotriazine amine compounds as PI3k inhibitors |
WO2016089977A1 (en) | 2014-12-03 | 2016-06-09 | Celgene Corporation | Substituted indazole compounds, compositions thereof, and methods of treatment therewith |
US20160168140A1 (en) | 2014-12-12 | 2016-06-16 | Synereca Pharmaceuticals | Heterocyclic compounds as antibiotic potentiators |
KR102412146B1 (en) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | Sodium channel blockers |
JP6642567B2 (en) | 2015-03-06 | 2020-02-05 | コニカミノルタ株式会社 | Organic electroluminescent element, method of manufacturing organic electroluminescent element, and organic electroluminescent element material |
WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP6761805B2 (en) | 2015-08-12 | 2020-09-30 | 持田製薬株式会社 | Isothiazole derivative |
KR102111576B1 (en) | 2015-08-20 | 2020-05-20 | 주식회사 엘엠에스 | Novel compound and light-emitting diode containing the same |
MX2018002631A (en) | 2015-09-03 | 2019-02-07 | Univ Arizona | Small molecule inhibitors of dyrk1a and uses thereof. |
AU2016321218A1 (en) | 2015-09-09 | 2018-03-29 | Warren C. Lau | Methods, compositions, and uses of novel fyn kinase inhibitors |
-
2017
- 2017-07-07 WO PCT/US2017/041218 patent/WO2018013430A2/en active Application Filing
- 2017-07-07 US US16/309,858 patent/US11352328B2/en active Active
-
2022
- 2022-04-21 US US17/726,096 patent/US20220281825A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190308938A1 (en) | 2019-10-10 |
WO2018013430A3 (en) | 2018-02-22 |
US11352328B2 (en) | 2022-06-07 |
WO2018013430A2 (en) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11352328B2 (en) | Heterocyclic compounds for the treatment of arenavirus | |
AU2018331172B2 (en) | Influenza virus replication inhibitor and use thereof | |
EP3535262B1 (en) | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
EP3189038B1 (en) | Inhibitors of lysine specific demethylase-1 | |
CN112940010B (en) | Substituted polycyclic pyridone derivatives and prodrugs thereof | |
CN109748915B (en) | Inhibitors of influenza virus replication and methods of use and uses thereof | |
RU2712196C2 (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives applicable in therapy | |
AU2017202759A1 (en) | Nitrogen-containing aromatic heterocyclic compound | |
TW200911810A (en) | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | |
RU2770363C2 (en) | Heteroaromatic compounds suitable in therapy | |
CA2935658C (en) | Pyrazolo[1,5-a]pyrimidin-7-amine derivatives useful in therapy | |
US20200017514A1 (en) | Adamantane derivatives for the treatment of filovirus infection | |
TW202035412A (en) | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections | |
JP2014122161A (en) | Pyrazole compounds | |
AU2016335043A1 (en) | Compounds for treatment of cancer and epigenetics | |
TWI508968B (en) | Compounds for treating respiratory syncytial virus infections | |
JP2018138609A (en) | Naphthyridinedione derivatives | |
CN103249733A (en) | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | |
CN110117285B (en) | Inhibitors of influenza virus replication and uses thereof | |
CA2669886A1 (en) | Compounds useful as protein kinase inhibitors | |
US20210244721A1 (en) | Small molecule enterovirus inhibitors and uses thereof | |
CN110446711B (en) | Inhibitors of influenza virus replication and uses thereof | |
JP7385467B2 (en) | hypoxanthine compound | |
US20220193038A1 (en) | Compounds for the treatment of arenavirus infection | |
Zhang et al. | Discovery and optimization of thieno [3, 2-d] pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:ARISAN THERAPEUTICS INC;REEL/FRAME:064475/0998 Effective date: 20230606 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |